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Inflammation is thought to play a driving role in an expanding number of vascular and cerebral 
pathologies. Sulforaphane (SFN) is a naturally occurring isothiocyanate which has previously been 
shown to harbour anti-inflammatory properties in several immune cell types. In this work, intra vital 
microscopy was used to visualise the cellular interactions within the cerebral microvasculature 
stimulated downstream of an inflammatory challenge, namely intraperitoneal injection of LPS (0.1-
4mg/kg). This resulted in a time, not dose, dependent stimulation of leukocyte-endothelial 
interactions; the number of rolling cells significantly increased, cells exhibited a slow rolling velocity 
and the number of adherent cells significantly increased versus sham or vehicle treated animals. SFN 
pre-treatment at 50mg/kg 24hr prior to LPS challenge (0.5mg/kg), increased the number of cells rolling 
through the cerebral microvasculature, significantly increased the speed at which they were rolling 
versus LPS treated animals and decreased the number of cells that were adherent to the pial vessel 
walls. These alterations were not associated with alterations in systemic cytokine levels (IL12p70, IL-
6, TNFα, IL-10, IFNγ, MCP-1) or nuclear Nrf2 expression within the cerebral cortex. LPS (1µg/ml) 
increased IL-1β release from isolated human neutrophils which also showed no alteration following 
SFN incubation (0.1-25µM). Investigation into the effects of SFN revealed that SFN significantly altered 
the ability of platelets to aggregation in response to several agonists (thrombin, collagen and ADP), 
and that this response was not associated with the intracellular Ca2+ movement or induction of LDH 
release. This work highlights the ability of SFN to alter inflammatory cell interactions within the 
cerebral microvasculature in vivo, and also indicates the inhibitory effect of SFN on isolated platelet 
function ex vivo. 
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1. Inflammation 
1.1. A brief overview 
Inflammation is a critical response integral to our ability to survive tissue damage following either 
infection or sterile tissue injury. As mammals, we have developed a highly orchestrated cellular 
response aimed at removing the invading pathogen or damaged host cells and repairing the injured 
tissue. This life preserving response, termed the inflammatory response, involves an array circulating 
immune and vascular cells, as well as those making up the parenchyma of the damaged tissue itself1. 
Under normal conditions this response is highly controlled in both a temporal and spatial manner 
through an active resolution of the inflammatory response involving removal of the initial immune 
effectors, in part, via their ability to produce anti-inflammatory mediators2. In this way, inflammation 
and the innate immune response provide a crucial life preserving function. However, in certain 
circumstances the delicate balance of the inflammatory response involving specific coordinated 
immune cell activation, effector function and resolution does not occur. Loss of temporal or spatial 
inflammatory resolution results in over activation or chronic recruitment of immune cells within the 
tissue, thus amplifying, rather than clearing tissue damage. It is known that this aberrant immune cell 
activation is present in many pathologies, both centrally and peripherally. This includes sterile 
inflammatory responses such as the ischaemia reperfusion injury present in myocardial infarction (MI) 
and stroke, and also following bacterial infection, as is the case in sepsis 3-5. The main aim of this thesis 
was to investigate the potential anti-inflammatory effects of SFN, and how these effects were related 
to alterations in cellular interactions and their ability to respond to physiological stimuli. 
 
1.2.  Sulforaphane 
SFN is a naturally occurring isothiocyanate, so called due to the nitrogen-carbon-sulphur (N=C=S) 
moiety to which is owes its reactivity. Sulforaphane is released via the breakdown of its precursor 
glucosinolate, glucoraphanin. In nature, glucoraphanin is the most abundant glucosinolate in broccoli, 
explaining the high concentration of SFN that can be made bioavailable following glucophanins 
hydrolysis by the enzyme, myrosinase6. In a healthy plant glucoraphanin and myrosinase are spatially 
separated, however, following the breakdown of the plants structure, as would be the case following 
insect/fungal attack; as well as food preparation and mastication during human consumption of 
broccoli, glucoraphanin is exposed to myrosinase and the breakdown product SFN is released. SFN 
then acts as part of the plants defence system. 
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It appears that mammals have evolved to utilise this function for themselves. As well as having genes 
that are responsive to the presence of SFN (discussed later, see Figure 1.1), mammals also have the 
ability to further maximise the release of SFN through the presence of microbiota in the gut which 
contain myrosinase activity7. This allows glucosinolates that pass through the digestive to be broken 
down to increase the yield of SFN which can then enter the host system. The bioavailability of SFN in 
broccoli has also been shown to be affected by the transportation, storage from harvesting, and 
method of preparation, as well as presence of gut bacteria8-10.  
 
Pharmacokinetic studies suggest that SFN is absorbed rapidly with first order kinetics depending on 
the dosing regime and the form of ingestion7,11. SFN metabolites are then generally excreted within 
24h, however, its pharmacodynamic effects are ongoing due to cellular uptake11. Teaming the 
knowledge that SFN is a key molecule in the defence system of plants with the fact that mammals 
have adapted to maximise its release, and therefore the uptake of SFN, presents an interesting 
question as to whether SFN can positively affect aspects of mammalian physiology.  
1.2.1. Molecular effects of SFN 
Indeed SFN has been shown to be absorbed across the jejenum barrier, enter the blood stream and 
accumulate in cells via attachment to glutathione. The mainstay of SFN’s effects are currently thought 
to be via gene induction. Alteration of the transcription factor Nuclear factor (erythroid-derived 2)-
like 2 (Nrf2), and the homeostatic systems in place to maintain its cellular levels and location, are 
central to the current dogma of SFN’s anti-inflammatory actions6.  This transcription factor, along with 
the antioxidant response element (ARE) it binds, represents an important cellular defence mechanism 
against host and environment oxidants (see Figure 1.1). The importance of the Nrf2:ARE system is 
highlighted in its conservation across animal species, having been previously observed in zebra fish12. 
 
SFN has been proposed to bind several cysteine residues with Nrf2’s binding domain with cellular 
repressor Kelch-like ECH-associated protein (KEAP1)13,14. Under normal physiological conditions, Nrf2 
is bound to the cytosolic actin bound protein KEAP1. This interaction brings Nrf2 into a complex with 
the ubiquitin ligase CUL3, leading to continual breakdown via the 26S proteosome15,16. On top of this 
BACH1 binds the ARE, to inhibit the interaction between Nrf2 and the ARE, and therefore decrease 
the production of anti-oxidant genes associated with their interaction17. This system maintains a basal 
level of Nrf2 and the genes it activates. Absence of KEAP1 leads to increased nuclear Nrf2 levels 
highlighting its role in maintaining low level expression of Nrf2 and also, its spatial constriction18. Early 
studies noted the high expression of cysteine residues within KEAP1, suggesting it as likely candidate 
to sense an oxidative cellular environment, and therefore its likely role in an anti-oxidant pathway13. 
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In line with this, BACH1 has also been shown to harbour several reactive cysteine molecules, thereby 
also making it a target for electrophilic/pro-oxidant attack17.  
 
The N=C=S moiety of SFN provides an electrophilic component to the molecule which enables it to 
interact with positive ionic centres and form covalent bonds with cellular proteins. Most commonly, 
these centres are thiol (–SH) groups such as those found in cysteine residues. At these sites, SFN forms 
reversible bonds with the –SH containing proteins, altering their conformation and/or way that they 
interact with their target proteins19. In the presence of an oxidative stressor or indeed SFN, bonds 
formed at cysteine thiol groups lead to the dissociation of Nrf2 from KEAP1 (and BACH-1 from the 
ARE), allowing Nrf2 to translocation from the cells cytosol into the nucleus20. Once within the nucleus, 






Figure 1.1: Effect of SFN on Nrf2 cellular localisation 
Schematic representation of the effects of SFN on Nrf2 in a nucleated cell (Gillespie, unpublished) 
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The ARE is a 5’ enhancer region found upstream of a battery of enzymes whose induction protects the 
cell from subsequent oxidative damage. These inducible genes can be grouped according to their 
function; for example, anti-oxidant regenerating enzymes, oxidant metabolising enzymes and direct 
anti-oxidants22. The central role that the induction of Nrf2 and the resultant production of these anti-
oxidant enzymes plays has been elucidated in several inflammatory models and knock out animal 
models. Loss of Nrf2 results in both a reduction of basal levels of Nrf2 regulated enzymes, as well as 
causing an interruption of their upregulation following SFN treatment22. The fact that some enzymes 
are still upregulated following SFN treatment in the absence of Nrf2 does, however, suggest that SFN 
may act elsewhere to alter gene regulation or that these genes may also be under the control of other 
transcription factors. SFN’s ability to induce Nrf2 regulated genes has been shown in various tissues 
including the vasculature, heart, lungs, liver and brain following oral, dietary, topical and intra-
peritoneal administration; thus highlighting its bioavailability and pharmacodynamic ability via various 
routes23-26. The key enzymes upregulated downstream of SFN and other Nrf2 activators include HO-1, 
NQO-1, and enzymes involved in the maintenance of total and reduced glutathione levels. The 
dynamics of the induction of these genes varies between tissues and also the enzymes themselves.  
 
1.2.2. Phase II detoxification and anti-oxidant enzymes 
Heme oxygenase (HO-1): is an evolutionary conserved protein that breaks down heme to release 
iron, biliverdin and CO. This decreases the production of free radicals through the catabolism of heme, 
as well as providing anti-inflammatory effects via bilirubin and CO. Pharmacological and physiological 
alterations in HO-1 expression alone has been shown to alter the outcome of various inflammatory 
models; whereby its upregulation is associated with protection against inflammatory challenges, and 
reciprocally, a loss of its function or downregulation leads to increased susceptibility or worsened 
outcome to inflammation (reviewed by 27). Induction of HO-1 by SFN in several cell studies of glial cells 
has been shown to peak within 24hr post treatment, and is in line with an increased survival to various 
inflammatory stimuli such as oxygen glucose deprivation, hemin challenge and LPS28-30. The need for 
the presence of Nrf2 for these effects is confirmed by the reduction in HO-1 upregulation following 
Nrf2 knock down using siRNA 29.  
 
NAD(P)H:quinone oxidoreductase (NQO-1) is an oxidant metabolising enzyme which aids to 
maintain the intracellular redox balance through elimination of ‘quinone’ molecules via reduction 
reactions, and in so doing decreases the formation of highly reactive free radical products with which 
these molecules are associated. Following SFN treatment, the upregulation of NQO1 mRNA and 
protein has been shown to be dose and time dependent in a variety of cell types; and furthermore, 
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this upregulation has been shown to persist longer than other Nrf2 controlled enzymes such as HO-
129,31,32.   
 
The glutathione system. The importance of the glutathione system in maintaining cellular 
homeostasis and protecting cellular components from oxidant damage is highlighted by the number 
of genes involved specifically in this system. These include: glutathione synthetase, which generates 
glutathione from γ-glutamylcysteine and glycine; glutamate cysteine ligase, a rate limiting enzyme 
composed of two subunits central to synthesis of glutathione; glutathione reductase, an enzyme vital 
to maintenance of the cellular pool of reduced glutathione, glutathione-s-transferase, an enzyme 
involved in conjugation; and glutathione peroxidase, which is involved in reduction of lipid and 
hydrogen peroxides33. The fact that so many enzymes are involved in the synthesis of the glutathione 
system highlights the importance of its cellular regulation. Moreover, the ability of SFN to induce these 
enzymes in an Nrf2 dependent manner suggest the applicability of SFN to protect the cellular 
glutathione content and maintain the favourable balance of reduced versus oxidised glutathione in 
order to protect the cell22.  As is seen following the knockout of other phase II detoxification enzymes, 
animal models lacking enzymes involved glutathione production show increased susceptibility to 
oxidative challenge34. 
 
Therefore, the ability of SFN to alter Nrf2, which controls the expression of these aforementioned 
detoxification and anti-oxidant genes presents an attractive property of the phytochemical to provide 
potential cellular protection against the known pro-oxidant environment to which cells are exposed 
to during inflammation. 
1.2.3. Effects of SFN in models of pathology and innate immune cells 
Of interest to this work, SFN’s effects have been investigated in a plethora of both central and 
peripheral inflammatory models. The ability of SFN to affect, as well as cross, the BBB alone is a major 
finding since, the later, has previously represented a real downfall of several previous agents that have 
shown promise for targeting inflammatory condition within the brain24,35.  
 
In vitro findings have shown the ability of SFN to alter the inflammatory phenotype of many cells of 
the innate immune system including neutrophils, platelets and macrophages that are known to 
provide first line defence protection following infection and injury36,37. Furthermore, SFN has also been 
shown to provide protection to cells fulfilling as barrier like function; such as endothelial cells, lining 
the blood vessels, and epithelial cells, covering the exterior surfaces of the body and also the gut 
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mucosa38. Likewise, glial cells and immune effectors within the brain have also been shown to be 
responsive to SFN treatment30,39. 
 
In support of these data, the ability of SFN to alter whole organism responses to inflammatory 
pathologies has also been shown. Several pathologies known to be pre-dispose neuro-inflammatory 
pathologies, such as stroke, have been shown to be altered via SFN treatment; these include 
atherosclerosis, endothelial dysfunction and peripheral immune cell activation25,40. Furthermore, the 
damage caused downstream of neuro-inflammatory conditions have also been shown to be 
ameliorated by SFN41,42. This highlights the ability of SFN as a potential prophylactic treatment of ‘at 
risk’ groups both for protection against the development of key underlying co-morbidities seen in 
neuro-inflammatory  conditions and the possible ensuing inflammation itself. Furthermore, the 
protection afforded in central neuropathologies indicates other beneficial effects associated SFN 
treatment; these include maintenance of the BBB via its tight junction, a decrease in the pro-
inflammatory phenotype of activated microglial cells, protection against oedema formation and 
increased phase II detoxification enzyme mRNA and protein in multiple glia cells35,40,42). Beneficial 
effects following exposure to SFN have also been shown in several epidemiological studies and early 
clinical trial work (See Table 1.1). 
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into the effects following 
ingestion of fresh broccoli 
sprouts vs. broccoli powder 
pill devoid of myrosinase 
 
Sprouts: 40 g broccoli sprouts 
which was equivalent to 
150µmol glucoraphanin  
 
Pill: 6 BroccoMax® pill which was 
equivalent to approx. 3 g of freeze 
dried broccoli sprouts and 
contained 121 µmol glucoraphanin  
SFN metabolites post sprout ingestion 
peaked within 3hr and were cleared by 
24hr. Following BroccoMax ingestion 
plasma levels peaked at 6hr and were 
significantly lower than those seen with 
sprout ingestion. 
Outcome was not affected by 
glutathione-S-transferase genotype 
 
Highlights the need for the 
presence of myrosinase (as 
in sprouts) for optimal SFN 
bioavailability 
Hanlon 
et al,  
200944 
Determine the effect of 
repeated broccoli shake 
intake on SFN bioavailability 
 
300ml of broccoli homogenate 
was ingested on 10 consecutive 
morning; dose was equivalent to 
0.32 µmol/kg 
 
Repeated ingested of broccoli 
homogenate did not alter 
pharmacokinetic profiles.  
Cmax  ≈ 12 ng/ml plasma 
Tmax ~ 1.2hr 
 
SFN is rapidly absorbed but 
repeated dosing does not 
alter plasma levels 





Investigation into the ability 
of orally administered SFN 
to increase ARE associated 
enzymes 
 
Broccoli sprout homogenate (BSH) 
ranging from 25 – 200g equivalent 
to >6µmol glucosinolates/gram or 
0.283 μmol/ml BSH with 25g fresh 
sprouts = 45g BSH. Therefore, 
200g gives rise to 102µmol SFN. 
 
Doses of 100-200g of BSH were capable 
of increasing phase II enzyme expression 
in nasal lavage cells. 
Data highlighted 60% bioavailability.  
Dose response was present 
with 200g BSH significantly 





Effect of Brocco sprout 
consumption of peripheral 
blood mononuclear cell 
(PBMC) histone 
deaceteylase activity (HDAC) 
 
Consumption of 68g of 
BroccoSprouts ≈ 105 mg SFN 
HDAC activity was significantly inhibit at 
3h posts consumption and appeared 
lowered at 6h. Levels returned to 
baseline at 24h. 
Delivery of SFN via 
Broccosprout consumption 
sufficient to reduce HDAC 




Examine the effect of 
ingestion of broccosprout 
homogenate on breast 
tissue SFN metabolites 
Consumption of a 20ml filtered 
broccoli sprout drink containing 
200µmol SFN, ≈50min prior to 
surgery 
Breast removal occurred ≈93-103 min 
post dosage. SFN metabolites were 
readily found in removed tissue 
Presence of SFN metabolites 
in breast tissue highlight 
bioavailability in this tissue 
following oral admin 
Table 1.1: Pharmacodynamic and pharmacokinetic effects of SFN containing ingestants gained from pilot studies 
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1.3.  Innate immune effectors and pathogen detection 
As eluded to above, the key early effectors of the inflammatory response belong to the innate immune 
system and also those cells such as endothelial and epithelial cells which are exposed to the external 
environment and circulating pathogens respectively. Innate immune cells include cells of myeloid 
lineage, such as macrophages and neutrophils, which are well placed to form a first line defence 
system due to their omnipresence within body wide tissue parenchyma and within the vasculature 
circulation. Furthermore, their ability to move in and out of tissues allows them to constantly survey 
tissue and rapidly respond to any damage or foreign matter.  
 
In order to rapidly detect tissue damage , cells of the innate immune system express a set of highly 
conversed pathogen recognition receptors (PRRs) named the toll like receptors (TLRs)47. These allow 
rapid detection of non-self, through conserved molecular patterns called pathogen associated 
molecular patterns (PAMPs), and also host produced danger associated molecular patterns (DAMPS) 
such as high mobility group proteins and heat shock proteins  (although some say the role of HSP’s as 
DAMPs are contentious)48,49. The homology and conservation of these receptors indicates the crucial 
role they play in the host defence system.  To date, these TLRs compromise a family of at least 11 
receptors, which detect both intra and extracellular prokaryotic and eukaryotic micro-organisms and 
are host specific50. The fact that these receptors do not require de novo protein synthesis or clonal 
expansion allows swift activation of immune cell effector function on encountering these conserved 
PAMPs allowing the immune system to quickly initiate the perpetrators removal. Interaction with 
these receptors leads to activation of downstream signalling pathways ultimately activating gene 
transcription and alteration of inflammatory gene expression50. The role of these groups of receptors, 
namely TLR4, will be relevant to this project due to their central role in detection of lipopolysaccharide 
and their expression on both leukocytes and platelets, two cell types whose biological activities will 
be investigated within. 
1.3.1. Toll like receptor 4 (TLR4) 
Due to this central role mentioned in the detection of lipopolysaccharide (LPS), the downstream 
effects of TLR4 activation is of importance to this work. The road to the discovery of TLR4 as the 
solitary transmembrane receptor for the detection of LPS spanned over 30 years at the end of the last 
millennia, where the work of several groups converged at this finding.  
 
Several groups had been working on the Toll and it was known that the gene cassette, of which Toll 
was part of, played a key developmental role during Drosophila embryogenesis51-53. Importantly, it 
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was becoming clear that there were corresponding homologs to these genes in mammals that played 
a key role in cell signalling downstream of cytokine activation. This gene cassette belonged to the Rel 
transcription factor family, which was known to be held in the cytoplasm, translocate to the nucleus 
to bind key DNA promoters and be activated by stimulation of a transmembrane receptor with 
homology to IL1R; furthermore, it was homologous to the Toll receptor51,53-55. Subsequently, Lemaitre 
et al, found that these genes were induced in Drosophila following bacterial challenge52.  
 
Using simple mammalian experiments, other groups had noticed the genetic variation associated with 
response to LPS injection in a few different mouse strains56. It was known that the Lps gene was 
associated with alteration of the response to LPS challenge, however, it wasn’t until work by Poltorak 
et al., using a genetic approach to show that the C3H/Hej and the C57BL/10ScCr mice strains had 
defective LPS responses due to allelic variation (causing missense and null expression) of a gene that 
linked to the Tlr gene that the transmembrane receptor was made apparent57. In support of this, 
clinical data of a patient with a defective response to gram negative bacteria provided support for this 
data in a human setting58.  
 
Several key molecular players in the LPS detection pathway had been previously shown. The ability of 
LPS binding protein (LBP) to bind lipid A, and in effect, concentrate LPS within the plasma had been 
published59. It had also been shown that CD14 played a role in LPS detection, as mice defective for this 
receptor had a greatly increased resistance to LPS challenge60. Equally, it was known that this receptor 
lacked a cytoplasmic tail and was; therefore, likely to act as a co-receptor rather than via transmitting 
signals across the membrane to the cell cytoplasm61.  
 
Together these formative studies combined to provide the cellular signalling pathways involved in LPS 
detection from the cell surface receptor, TLR4, to the gene upregulation that we now appreciate in 
response to gram negative bacteria (See Figure 1.2).      




Figure 1.2: Intracellular LPS induced TLR4 signalling cascade 
Diagrammatic representation of the intracellular signalling cascades stimulated downstream of TLR4 
activation in the presence of LPS. Adapted from Lu et al, 200862 (Gillespie, unpublished). 
 
Since elucidation of this pathway, the use of LPS as a stimulant of the host innate immune response 
has provided the scientific community with a highly useful tool; both to ascertain the role of multiple 
signalling pathways during the inflammatory response and to investigate possible therapeutic agents. 
The role of TLR4 has also been highlighted as a key player during the inflammatory response outside 
of microbial recognition for example in pathologies involving ischaemia-reperfusion injury such as MI 
and stroke 63-65. With reference to the brain, removal of TLR4 signalling by physiological knock out has 
been seen to ameliorate several of the inflammatory mediators, tissue damage markers and 
neurological outcomes associated with stroke pathology supporting the role for mal effects following 
its activation66. In line with this, it was been seen that patients with higher TLR4 expression on 
peripheral blood cells following ischemic stroke showed a poorer prognosis with elevated 
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inflammatory markers (TNFα,IL-1β, IL-6, ICAM1) and larger infarct development67. Together, these 
findings highlight the role of TLR4 signalling in the activation of pro-inflammatory signalling cascades 
following exposure of the host to both endogenous and exogenous PAMPs and DAMPs. 
1.4.  Immune cells 
1.4.1. Neutrophils 
Neutrophils are cells of the myeloid lineage that are derived from the same precursor haematopoietic 
stem cell lineage that produces monocytes and macrophages. They are produced within the bone 
marrow, and are constantly released into the circulation to maintain a circulating level of 2.5-
7.5x103/µl (in man vs. 3-12x104/µl in mice); however, their release is rapidly increased in response to 
infection68. Like macrophages, neutrophils are phagocytic cells that circulate in the blood and can be 
recruited into tissues by various mediators (discussed below). They form the front line defence of the 
immune system and are the most numerous circulating cell of the immune system, accounting for 
approximately 50% of circulating leukocytes (in man vs. 10-40% of white blood cell population in 
mouse). Neutrophils have a lifespan of approximately 6hr once released from the bone marrow; yet, 
during inflammatory conditions their lifespan is significantly extended69-71. Neutrophils are cleared, 
either within the tissue which they carried out their phagocytic role, or within the bone marrow, liver 
or spleen72. 
 
Central to their phagocytic and antimicrobial function are the cytosolic granules and secretory vesicles 
that neutrophils harbour. Not only do these cytosolic reservoirs contain the neutrophils potent 
effector mediators, but they also serve as a pool of membrane receptors. Controlled release of these 
cytosolic stores serves to regulate neutrophilic effector function such as their recruitment to the 
inflamed tissue by allowing stimulant induced transmigration from the blood vessel into the tissue 
(see below). Timely release of these granules is paramount since their contents are highly destructive 
both to invading pathogens and to host tissues. 
 
Primary or azurophillic granules are high in myeloperoxidase (MPO), a marker that is often used to 
suggest neutrophilic infiltration of tissues73. MPO also plays an important role in the creation of 
cytotoxic oxidants via interactions with the products of NADPH oxidase. Alpha defensins and serine 
proteases are also important component of azurophillic granules and play an important role in the 
killing of internalised bacteria74. These granules are mainly involved in intracellular killing following 
engulfment of bacteria, and are not readily released75.  
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Secondary or specific granules contain important adhesion molecules and receptor, several of which 
are involved in leukocyte-platelet-endothelial cell interactions, such as CD11b/CD18 and urokinase 
plasminogen activator (uPA) and its receptor (R), uPAR76. These two granule subsets have overlapping 
features in their peroxidase negative nature, and ability to release CD11b/CD18 (indicating its 
importance). Secondary granules also have a rich antimicrobial capacity, which differentiates them 
from tertiary (gelatinase) granule. Tertiary granules have a much greater tendency to be exocytosed, 
whereby they release several matrix degrading components aiding neutrophil recruit into and through 
the tissue77,78. 
 
The fourth ,and smallest, granules are the secretory vesicles which have an endocytic phenotype and 
are released early following neutrophil activation75. Detection of microbial products and pro-
inflammatory cytokines induce their release79. This leads to upregulation of cell surface receptors for 
initiation of the inflammatory cell recruitment and further detection of bacteria products, for example 
CD14 to aid LPS detection80. In doing so, these granules adorn the neutrophil surface with several key 
proteins to increase microbial detection and enhance leukocyte-endothelial interactions without the 
exteriorisation of cytotoxic components harboured in other granules. 
 
Finally, and most recently appreciated, is the ability of neutrophils to produce neutrophil extracellular 
traps (NETs). These NETs are externalised DNA fibres composed of externalised chromatin fragments 
harbouring cytosolic antimicrobial products81. They deliver the final wave of the neutrophil’s arsenal 
to impede microbial invasion. NETs provide benefits in several ways; firstly, they form a physical 
barrier to capture invading pathogens and quell their dissemination; secondly, they localise 
bactericidal components released from the aforementioned mentioned granules thereby protecting 
surrounding tissue from their cytotoxic effects, and concentrating them to increase the attack on the 
pathogen81,82.  It is also worth mentioning that stimulation of the LPS:TLR4 pathway has also been 
shown to cause release of NETs, and that this can occur rapidly (within mins) and therefore, not act 
solely as a finale82. The crucial role that they play has been highlighted in simple, elegant experiments 
using DNAse to remove their function, leading to a dramatic decrease in bacterial killing81. These NETs 
can also be released via interaction with activated platelets leading to a significant increase in the total 
area of NET production82. NET production does not however, play a purely beneficial role in the 
resolution of bacterial infection. Release of NETs within the vasculature has also been seen to provide 
a scaffold for platelet adhesion and activation, and thereby potentially promote vascular occlusion82. 
This highlights yet another facet of inflammatory cell activation with the potential for a dichotomous 
outcome.  
Page | 24  
 
 
Also of great importance to the physiological function of neutrophils is their ability to produce and 
respond to a plethora of cytokines and chemokines in their extracellular milieu. Production of hallmark 
pro-inflammatory cytokines including tumor necrosis factor α (TNFα), interleukin (IL-)1, IL-6 and 
interferon-γ (IFNγ) are stimulated over varying time points following neutrophil stimulation 
downstream of several cell surface receptors such as the TLRs. Their production is associated with 
various pro-inflammatory transcription factors such as NFĸB, p38 and ERK38,47. These cytokines act to 
recruit further recruitment circulating immune cells, both additional neutrophils and other leukocytes 
such as monocytes. Various therapeutic agents that intercept these pathways either, at the initiating 
receptors, downstream kinases or transcription factors initiating their further expression, have shown 
therapeutic potential for decreasing the inflammatory response in an experimental setting. Many, 
however, appear to have little or no positive effect within the clinic potentially indicating the necessity 
of each cytokine in directing the developing immune response to inflammatory stimuli83,84. Stimulation 
of neutrophils also leads to the production of mediators, for example IL-10, which have anti-
inflammatory effects. IL-10’s effects are transmitted via STAT3 and knock out of this pathway leads to 
pathogenic release of pro-inflammatory cytokine release and vastly increased mortality rates 
following exposure to LPS85. Increasing knowledge of the role of cytokines within the immune 
response highlights the complex nature of both their temporal response and their interactions with 
one another in orchestrating both progression and resolution of inflammation. 
1.4.2. Endothelial cells 
The healthy endothelium exists as a confluent monolayer lining the inner surface of the vasculature, 
and thus, has an intimate association with circulating blood and its constituents. Under normal 
physiology and optimal flow conditions there is little interaction between the endothelium and cells 
circulating within the blood. The flow patterns within laminar sections of the vasculature mean that 
the majority of cell types are located within the central stream of the blood flow and therefore are 
not in contact with the vessel wall. To aid this, the healthy endothelium is a highly metabolically active 
interface. It is constantly producing a plethora of vasoactive compounds that act in a paracrine and 
autocrine fashion (e.g. nitric oxide (NO), prostacyclin and ADPase) on the endothelium itself, as well 
as both the cells within the vasculature and mural cells of the vessel wall86-88. Likewise, these cells are 
also able to release numerous mediators, such as NO and TNFα, that in turn alter endothelia function 
and therefore the physiology of the vasculature89,90. These vasoactive products include chemical 
messengers such as nitric oxide (NO) and prostaglandins, as well as molecules involved in the clotting 
cascade such as plasminogen activators1,91. Not only does production of these factors prevent 
leukocytes from interacting with the vasculature surface, it also maintains an anti-thrombotic 
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environment within the vessel91. Production of NO leads to anti-aggregatory effects on platelets which 
is supported further via release of heparin and tissue plasminogen activator which respectively have 
anticoagulant and fibrinolytic effects92. Together, the milieu of these bioactive factors serves to 
maintain a healthy interface between cells of the blood compartment and those of the vasculature. 
 
Endothelial cells also contain several transcription factors that are known to be associated with 
athero-protection within the vasculature, such as Nrf2 and Klf2, which are increased in the presence 
of laminar flow leading to shear stress at the endothelial surface25,93. Likewise, shear stress also alters 
the function of certain pro-inflammatory transcription factors, for example NFĸB94. Alteration of these 
transcription factors in line with flow is a relatively newly discovered phenomena but highlights how 
pathologies causing turbulent flow, such as atherosclerosis, can act to enhance inflammatory 
environments at vascular sites already at risk of inflammatory damage25. Conversely, laminar flow and 
induction of these cytoprotective enzymes  is associated with decreased in inflammatory markers at 
the apical surface of the endothelium, and protects against endothelial dysfunction and the 
recruitment of inflammatory cells. Hence, these transcription factors not only protect the vasculature 
itself, but also the surrounding tissues. Recent evidence supports the ability of therapeutic 
intervention with agents such as SFN to mimic these effects and upregulate the induction of these 
anti-inflammatory transcription factors decreasing inflammatory cytokine/chemokine release, 
decreasing adhesion molecule expression and thereby altering leukocyte-platelet-endothelial 
interactions25,26.  
 
It is known that endothelial dysfunction is closely linked to the development of many cardio- and 
cerebro-vascular pathologies, as well as those initiated following bacterial infection95-97. Hence, 
therapeutic intervention that improves, or inhibits degradation of, endothelial function is an attractive 
target in reducing risk factors for the development of these diseases. Endothelial dysfunction not only 
leads to a decrease in the anti-inflammatory and anti-platelet factors mentioned above, but it also 
increases production of factors (e.g. TNFα, ICAM1) that actively promote leukocyte and platelet-
endothelial interactions92. Loss of vasoactive mediators can also lead to alterations in flow so that cells 
are no longer held within the central stream of the blood flow, leading to a greater chance of 
interaction with the dysfunctional endothelium96. This also leads to a dysregulation of the earlier 
mentioned transcription factors, whose expression are intrinsically linked with shear associated flow 
dynamics25,93. Subsequently increased expression of adhesion molecules, such as ICAM1 and E-selectin 
thereby promotes recruitment of both platelets and leukocytes across the endothelium and into 
surrounding tissues25,93,98.  
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1.4.3. Platelets  
Platelets, once considered a rather inert sub-cellular fragment, are now thought of as a cell type in 
their own right with a wide array of biological functions. They are small, anucleated cells released from 
myeloid derived cells called megakaryocytes which are predominantly found in the bone marrow. 
Platelets are released through a process of budding off the megakaryocyte. Upon release, the mature 
platelet is approximately 2µM in diameter and discoidal in shape in their inactivate form. Their release, 
from megakaryocytes within the bone marrow into the circulation, makes them well placed to rapidly 
react in response to many physiological stimuli within the vasculature. They circulate within the 
vasculature for 8 – 10 days after which they are removed from the circulation by the spleen. Their 
normal concentration within the circulation is 2.5-7.5x105/µl (in man vs.3-10 x105/µl in mice).   
 
Platelets have a rather unusual form in that they are composed of an open canalicular system. This 
represents an extended network throughout the platelet cell body that significantly increases their 
surface area to volume ratio and therefore aids their role in reacting rapidly to thrombogenic factors 
within the vasculature; both via providing a greater surface to uptake circulating products and by 
increasing the area capable of releasing secreted products from the platelet99. Platelets also have 
another characteristic ultrastructure known as the dense tubular system. This is thought to be derived 
from the megakaryocytic endoplasmic reticulum, and serves to regulate the platelets intracellular Ca2+ 
levels100.  
 
Another key structural feature of platelets are the alpha, dense and lysosomal granules. Alpha 
granules are the most abundant (10% platelet volume), and contain an array bioactive substances101. 
Some of the key bioactive substances they include can be grouped into; cell surface adhesion 
molecules such as P-selectin, vWF and other glycoproteins; growth factors including platelet derived 
growth factor, vascular endothelial growth factor and other factors involved in the coagulation 
cascade102. Dense granules are less numerous than there alpha counterparts (3-8 per platelet). They 
contain the largest intra-platelet ADP (50%) and calcium (60-70%) stores; as well as serotonin, 
pyrophosphates and non-metabolic ADP103-105. Finally, lysosomal granules are speculated to be 
remnants of the Golgi body collected from the megakaryocyte. These structures contain hydrolase 
enzymes which are released upon platelet activation and play a role in vascular repair106. Release of 
the contents from all of these granules has effects not only on other platelets but also other cells in 
the vicinity such as leukocytes and endothelial cells, in order to begin repair the vascular damage and 
promote effect wound healing. 
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1.4.3.1. Haemostasis 
The haemostatic response by platelets can be broken down in four key stages; platelet adherence, 
activation, aggregation and clot retraction. The aim of this series of events is to repair the damage to 
the vessel wall, whilst maintaining its patency (see Figure 1.3).  
 
Under normal physiological conditions the primary initiator of platelet activation is exposure of 
collagen in the subendothelial matrix following damage to the wall of the vasculature. Adherence of 
platelets to collagen via GPVI and α2β1 receptors induces outside-in signalling, changing the platelet 
from its resting discoidal phenotype to an activated ‘amoeboid’ like appearance107,108. Alongside this 
induction of shape change, platelets also rapidly degranulate – releasing the constituents from the 
earlier mentioned granules, such as ADP, as well as newly formed mediators such as thromboxane105. 
This allows an amplification of the response, recruiting and activating further platelets in the 
circulation. At this stage, several more cell surface receptors become activated. ADP released from α-
granules interacts with the purinergic receptors P2Y1 and P2Y12 to further activate and provoke shape 
change in subsequently recruited platelets109,110. The P2Y1 receptor is thought to primarily activate 
shape change and the primary wave of platelet aggregation, since KO mice for this receptor showed 
increased bleeding time and a decreased sensitivity to ADP stimulated aggregation and thrombi 
formation109. The P2Y12 receptor on the other hand has been recognised to be responsible for 
secondary wave aggregation due to granule secretion, thromboxane production and also inside-out 
activation of the fibrinogen receptor110-112. Furthermore, vWF, released from α-granules, is expressed 
at the platelet cell surface and bound to collagen, and due to its multimeric structure, serves as a 
further substrate for successive platelet recruitment via the GPIb/V/IX complex113,114. In addition, 
expression of both P-selectin and PSGL-1 allows platelets to roll along the endothelium and further 
interact with other platelets, as well as leukocytes115. Thrombin, released as a product of the 
coagulation cascade, further activates recruited platelets via the PAR1 and PAR4 receptors, as well as 
breaking down fibrin to release fibrinogen116. This acts to stabilise the forming clot and cross links the 
aggregated platelets via αIIbβ3 receptor117. This recruitment of platelets to the sites of vascular 
damage in some ways mirrors the leukocyte adhesion cascade which will be discussed later (Section 
1.5). Not only does platelet recruitment use similar families of receptors, such as the immunoglobins 
(GPVI receptor) and integrins (α2β1), but activation of outside in signalling, as known to occur in 
leukocytes, is also involved in further platelet activation.  Early platelet rolling, allows this ‘outside in’ 
signalling phenomena to prime platelets, for example via increasing integrin affinity, leading to 
subsequent stable adhesion of the platelets a process that is also key to the leukocyte adhesion 
cascade. 
  





Figure 1.3: Platelet adhesion cascade  
Overview of the platelet adhesion cascade following damage to the vascular endothelium. Adapted from Brass, Understanding and Evaluating Platelet 
Function118. (Gillespie, unpublished) 
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1.4.3.2. Thrombosis 
Where haemostasis represents a vital and lifesaving physiological function of platelets, thrombosis 
represents the flip side of the coin whereby pathological activation of platelets is inappropriate and 
potentially life threatening. The inability of platelets to differentiate between vasculature damaged 
by injury, and exposure of pro-aggregatory sub endothelial molecules associated with pathologies 
such as atherosclerosis, leads to pathological platelet activation and issues with vascular occlusion and 
potential tissue infarction. 
 
Thrombus formation has been shown to vary depending on the blood vessel in which it occurs. 
Thrombi found within higher pressure blood vessels of the atrial system, e.g. aorta, are referred to as 
‘white’ and have a relatively higher leukocyte contents; whereas, thrombi formed within lower 
pressure vessels such as the venous system and the cardiac atria, are referred to as ‘red’ clots, due to 
their high erythrocyte and fibrin119. The disparity in properties of these clots is of clinical interest for 
optimal therapeutic intervention119.  
 
1.4.3.3. Platelet cellular interactions 
Activation of platelets is associated with phenotypic alteration: morphological change, alteration in 
cell surface receptor expression and release of chemotactic products. Expression of P-selectin is 
needed in order to allow platelets to adhere and form a stable clot following activation120. This 
increased expression of cell surface adhesion molecules, such as P-selectin released from intracellular 
Weibel-Palade bodies, promotes interactions between platelets and activated leukocytes and 
endothelial cells121,122. These interactions also allow platelets to act as a bridge to recruit circulating 
leukocytes to the sites of vascular damage123. Indeed, leukocytes circulating in the vasculature 
associated with platelets are seen to have increased adhesion molecule expression, supporting the 
view that platelets enhance the likelihood of leukocyte-endothelial interactions124. Additionally, 
platelets that are adhered to the vascular endothelium release several pro-inflammatory mediators 
including IL-1, CD40L and CCL-5 which further potentiate recruitment of circulating leukocytes via 
activation of the endothelium125-127. Furthermore, stable platelet aggregates adhered to fibrillar 
collagen have been shown to capable of capturing passing leukocytes107. Of further interest, it is 
becoming apparent that platelets do not just play a role in aiding leukocyte responses within the 
vasculature. Emigrated platelets have been found within inflamed tissues, raising the possibility that 
they further function to guide leukocytes within the inflamed tissues; possibly through production of 
further inflammatory cues or mediators128. This could be one possible reason when platelet depletion 
has previously been shown to decrease leukocyte transmigration129.  
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By inhibiting platelet-leukocyte interactions several groups have shown these interactions play a role 
in driving vascular inflammatory responses. Following peripheral immune stimulation, leukocytes 
have been seen to roll along cerebral pial venules ‘paved’ with platelets130. Reducing platelet 
activation and decreasing platelet-leukocyte interactions via therapeutic aspirin, led to a decrease in 
leukocytes interacting with the cerebral microvasculature130. This finding emphasises the effect 
platelets have on leukocyte-endothelial interactions, and highlights the inhibition of these interactions 
as an attractive therapeutic target. Similar results have also been found in other inflammatory 
conditions, both centrally and in the periphery, whereby platelet and leukocyte interactions are 
dependent on adhesion molecule expression and inhibiting these interactions dampens the ensuing 
inflammatory response124,131. In support of this, appropriate widespread use of antiplatelet and 
anticoagulant medicines within the clinic makes apparent the marked benefit that inhibiting platelet 
activation can have for the therapeutic benefit to patients at risk of inflammatory vascular 
occlusion119,132. This has the added benefit that reducing platelet activation lessens leukocyte 
activation and therefore further decreases inflammatory risks within patients133,134. 
 
When appropriate spatial and temporal control of this response are in place, platelet activation during 
haemostasis is a crucial event for the maintenance of blood vessel integrity. However; the benefits of 
these platelet targeted medicines highlight the devastating effect that inappropriately activated 
platelets can cause in several vasculopathies (e.g. atherosclerosis, MI and stroke)134-137. Investigating 
the ability of SFN to affect there physiological responses will therefore form an interesting adjunct to 
the in vivo leukocyte-endothelial interaction work conducted in this thesis.   
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1.5.  Leaving the vasculature 
As alluded to above, it is a crucial function of normal physiology and the developing inflammatory 
response that leukocytes are able to emigrate from the vascular compartment, cross the basement 
membrane and enter into inflamed tissues (see Figure 1.4). This is a key phenomenon underlying the 
onset of inflammation; visualisation of this phenomena using IVM will therefore be used as one of the 
main parameters to investigate the effects of SFN on leukocyte-endothelial interactions during the 
inflammatory response within the cerebral microvasculature. The importance of these intravascular 
cellular interactions are highlighted by patients suffering from leukocyte adhesion deficiency 
syndrome, a group of clinically related diseases whereby patients’ neutrophils have an inability to 
transmigrate into tissues leading to problems such as leucocytosis, recurrent bacterial infections and 
delayed wound healing138.   
 
The ability of leukocytes to enter in to tissues has been appreciated for nearly 200 years, and work by 
early pathologists such as Duchrochet, Addison, Elrich and Metchnikov exemplify this139. Cohnheim 
was one of the first pathologists known to actively observe leukocytes emigrating from the blood into 
the tissue of the frogs tongue using an early form of intra-vital microscopy139. Since then, the cells, 
adhesion molecules and inter- and intra-cellular pathways involved in the leukocyte recruitment 
cascade has vastly evolved. A wealth of novel technologies has aided our understanding; from the use 
of genetically engineered mice to improvements in the microscopes and software we use. Together, 
these technologies have allowed us to expand upon the previous phases of leukocyte-endothelial 
interactions termed rolling, adherence and transmigration to a multistep cascade with a much greater 
complex series of events and stages involved. IVM has been a key technology in our developing 
understanding of leukocyte-endothelial interactions during inflammation, and will therefore be used 
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Figure 1.4: Leukocyte adhesion cascade. 
Diagrammatic interpretation of a pial vessel showing the absence of cellular interactions in a healthy, uninflamed venule (left segment) versus the hallmark 
leukocyte adhesion cascade associated within an activated, inflamed venule (right). (Gillespie, unpublished).  
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Initial interactions require that both leukocytes and endothelial cells express a family of receptors 
known as selectins (See Table 1.2). Selectins are single chain glycoproteins with a transmembrane 
domain and intracellular cytoplasmic tail. Leukocytes (L-selectin) ubiquitously express selectins, 
however, under normal physiology endothelial selectins (E and P-selectin) are stored in intracellular 
α-granules of platelets and Weibel-Palade bodies within endothelial cells79,101. Following an 
inflammatory stimuli, endothelial cells and tissue resident macrophages release classic pro-
inflammatory cytokines such as TNFα, IL-1β and IL-6. These released cytokines bind receptors on the 
endothelial cell surface causing the release of cytoplasmic granules leading to a sequential 
upregulation of cell surface selectins.  All selectins bind the ligand P-selectin glycoprotein ligand 1 
(PSGL-1) which in expressed by leukocytes, platelets and endothelial cells allowing cells to undergo 
both hetero and homotypic cellular interactions140. It appears that these interactions are important, 
and that the binding of platelets to both endothelial cells and leukocytes can promote leukocyte 
recruitment into the inflamed tissue. For optimal selectin-PSGL-1 binding to occur, PSGL-1 must be 
appropriately glycosylated141. Activated leukocytes localise selectins to microvilli tips in order to 
improve initial presentation to endothelial cells and therefore promote cellular interactions142,143.  
 
Formation of these selectin based bonds are reversible and allow the initial tethering of leukocytes 
along the apical border of the inflamed endothelium. This rolling also allows exposure of the leukocyte 
to further chemokines, e.g. CXCL1, that are displayed on the surface of the endothelium on the 
glycocalyx. Chemokines are small proteins of approximately 8-10kDa, released by various cell types, 
that bind to cell surface receptors and can induce cellular movement along their concentration 
gradient144 . The glycocalyx serves to trap and present chemokines to interacting leukocytes, creating 
a higher local concentration at the inflamed site and thereby supporting leukocyte-endothelial 
interactions145. This local environment acts to further increase both the affinity and avidity of selectin 
bonds and prime for the subsequent slow rolling and adhesion phase of the leukocyte recruitment 
cascade. Binding of selectins and chemokine receptors activates intracellular kinases such as Src and 
Syk triggering a network of downstream signalling mediators (PLCγ, PI3K, and p38 MAPK); this leads 
to cytoskeletal rearrangement and priming of the next family of leukocyte-endothelial mediators, the 
integrins146-148.   
 
Integrin ligand specificity is dictated by the specific pairing of various members of the α and β subunits 
which pair to make a functional integrin molecule. Particular to neutrophils, and this next phase of 
leukocyte-endothelial interactions, are the β2 integrins (namely LFA1 and Mac1 for neutrophils) and 
their ligands ICAM1, and ICAM2 of the immunoglobulin superfamily ((Ig) see Table 1.1). Under non-
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inflamed conditions β2 integrins are held in a low affinity state with their extracellular domain in a 
bent conformation that allows only weak interactions with rolling leukocytes149. Furthermore, the 
expression of ICAM1 is low during normal physiological conditions, meaning there is little chance of 
Ig:β2 interactions. Upregulation of ICAM1 expression has been shown to occur as early as 4hr in 
presence of inflammatory cytokines such as TNFα, supporting greater interaction of ICAM1 and β2 
integrins150. This is further supported by the earlier mentioned activation of inside-out signalling via 
chemokine receptors151. A role of PLC, GTPases and cytoplasmic proteins that interact within actin-
binding proteins have all been suggested to have a role in this inside-out signalling event1. This 
signalling alters the conformation of the β2 integrins in several ways. Firstly, reorganisation of 
intracellular cytoskeleton and/or ligand binding, allows a spatial separation of the α and β chains of 
the integrins152. This is necessary to allow extension of their conformation. Secondly, combining this 
with breaking of salt bridges between the intracellular tails ‘unwinds’ the extracellular domain, thus, 
exposing the β-propeller head of the α chain and straightening of the β2 chain152,153. The sum of these 
changes leads to exposure of an ICAM1 binding site with much higher binding affinity, mostly 
mediated by LFA1. Members of the cytoskeletal proteins that associate with actin, such as Talin and 
Kindlins, then rearrange to support this new extended confirmation, and link the integrin tails to the 
cells cytoskeleton154. These changes markedly slow the speed at which the leukocyte rolls along the 
vascular endothelium, leading to slow rolling and arrest. While it has been suggested that LFA1 
mediates the beginning of leukocyte adhesion within the inflamed vessel, it seems that Mac-1 is more 
predominant in the intravascular crawling that proceeds transmigration out of the vessel155,156. The 
process of intraluminal crawling also allows the leukocyte to move along the inner surface of the vessel 
in order to find optimal sites of transmigration.  
 
These cell adhesion molecule mediated leukocyte-endothelial interactions can be visualised using IVM 
and later analysed off line whereby cell numbers can be counted and the speed at which leukocytes 
are rolling down the endothelium can be calculated as a measure of the developing or ongoing 
inflammatory response. High levels of cellular adhesion are thought to highlight the presence of 
greater strength in leukocyte-endothelial interactions and therefore the presence of a more inflamed 
environment. 
 
Once adhered, leukocytes may then emigrate via either a transcellular (through the endothelial cell) 
or paracellular route (between endothelial cells) out of the vessel. Although less well appreciated until 
recent years, it appears that the transcellular route of transmigration may account for up to one fifth 
of transmigrating cells in certain conditions156. When moving between endothelial cells, leukocytes 
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use some adhesion molecules similar to those used at the apical surface of the endothelial cell, for 
example LFA1 and Mac1 (neutrophil) interact with JAMA-C (endothelial cell); as well as other 
homotypic  interactions between CD99 and PECAM1157. Clustering of ICAM1 leads to the formation of 
focal microdomains named endothelial adhesive platforms158. These are supported and reinforced by 
further recruitment of actinins to ICAM1 cytosolic tails159,160. Intracellular signalling associated with 
ICAM1 binding at endothelial cell junctions leads to phosphorylation of another junctional protein, VE-
Cadherin, which destabilises endothelial homotypic interactions further permitting leukocyte passage 
between the cells161,162. This phenomena can be visualised in certain tissues such as the mesentery 
and cremaster muscle, but is more difficult in tissues such as the brain due to the depth and nature of 
the tissue.  
 
Once leukocytes have breached the endothelial cell monolayer, they must then cross the basement 
membrane (BM) and associated pericytes that are located within it. It has been seen that within the 
BM there are areas of less dense expression of BM matrix protein expression termed low expression 
regions (LERs). These LERs are associated with inter-pericytes spaces, suggestive of interplay between 
the pericytes and formation of the BM in the extravascular microenvironment163.  It is thought that 
these are used by leukocytes, neutrophils in particular, to aid their passage through the BM. This may 
explain why leukocytes have been visualised crawling along the abluminal surface of the vasculature; 
firstly, ‘deciding’ whether to enter the tissue before potentially re-entering the vessel, and secondly, 
‘searching’ for permissive sites at which to cross the BM164. Indeed, abluminal leukocytes have been 
visualised crawling marked distances along pericytes before crossing at LER sites90. Interestingly, 
neutrophils are seen to use similar adhesion molecules to crawl along pericytes as those used on the 
luminal surface of the vascular wall. Both ICAM1 and Mac1 are upregulated following inflammatory 
stimuli, and blocking these hinders neutrophil-pericyte interactions89,90. Neutrophils have also been 
shown to use degradative enzymes, released from intracellular granules, in order to penetrate through 
the BM. This is supported by the presence of laminin positive neutrophils in the post BM tissue, and 
also inhibition of BM penetration following treatment with a of neutrophil elastase inhibitor165.  Of 
interest, it has also been shown that leukocyte migration is not a uni-directional event. It is possible 
for leukocytes to exit the vessel, survey the abluminal environment and then cross back through the 
endothelium164.   
 
Once within the tissue, leukocytes migrate along chemokine gradients released by resident cells; IL-8 
is one of the major chemotactic agents used by neutrophils166. Alterations in the phenotype of 
neutrophils within the tissue reduce further recruitment of leukocytes. This includes activation of 
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suppressor of cytokine signalling (SOCS)3 to prevent on-going pro-inflammatory gene induction by 
factors such as signal transducer and activator of transcription (STAT)3. The importance of this has 
been highlighted by knockout of SOCS3 leading to generation of neutrophils with a hyperactive 
phenotypes167. Also, more recently the role of microRNA induced in association with inflammatory 
stimuli such as LPS has highlighted their role in negative feedback of inflammatory mediators such as 
NFkB168,169. This resolution of inflammation concomitant with tissue damage is vital to the temporal 
regulation of the inflammatory response. 
   








Cellular location Role Consequence of 
KO/blockade 
Selectin P-selectin CD62P PSGL-1 Platelets 
Endothelium 
 
Luminal/Apical Initial L-E, P-E and P-L 
interactions. Cell 
activation. 
Reduced cell rolling170 
 






Luminal/Apical Initial L-E and P-E 
interactions. Cell 
activation. 
Additive effects when 
knocked with P-selectin, less 
marked effects on leukocyte 
rolling extravasation alone171 
 L-selectin CD62L PSGL-1 Leukocytes 
 
Microvillli tips Initial L-E, L-L and P-L 
interactions. Cell 
activation. 
Decreased cell rolling and 
extravasation172,173 





Cell surface  Initial L-E, P-E and P-L 
interactions. Cell 
activation. 
Protection from thrombus 
formation174 
 ESL-1  Selectins Endothelium Cell surface  ? 
Ig Super 
Family 
ICAM-1 CD54 Integrins Endothelium 
 
Luminal/Apical Reduced velocity rolling, 
firm adhesion and cell 
activation 
Reduced leukocyte 
extravasation and resistance 
to LPS challenge175 
 ICAM-2 
 
CD102 Integrins Endothelium 
 
Junctional Paracellular cell migration Similar adherence to WT. 
Reduced transmigration in 




CD31 PECAM-1 Endothelium 
Neutrophil 
 
Junctional Paracellular cell migration Similar adherence to WT. 
Reduced transmigration in 
response to IL1β. Leukocytes 
accumulate between EC’s 
and BM. 178 Again, model 
dependent176 




















Junctional Paracellular cell migration Reduced leukocyte 
transmigration in a stimulus 
dependent manner179 






Junctional Paracellular cell migration ? 




Junctional Transcellular/ Paracellular 
cell migration 
Disrupts transendothelial 
migration, increases no. of 











Reduced velocity rolling, 
firm adhesion and cell 
activation 
Cell migration 













Reduced velocity rolling, 
firm adhesion, cell 
activation and paracellular 
cell migration 




Table 1.2: Overview of adhesion molecules 
Table reviewing current adhesion molecules known to participate in the leukocyte adhesion cascade (Gillespie, unpublished)  
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1.6.  Immune effectors within the brain 
Inflammation within the brain is central to several neurodegenerative diseases, and furthermore, it is 
now appreciated that activation of the peripheral immune system can also stimulate inflammatory 
responses within the brain. Although the brain is still classed by many as an ‘immuno-privileged’ site 
(due to the barrier function of the blood brain barrier (BBB)), our understanding of the effects of 
immune cell activation both at the BBB and within the brain parenchyma has greatly developed over 
the last half a century.  
1.6.1. Microglia 
Although still an area of contention, knowledge of the microglial as the resident immune cell of the 
brain has helped understand their role they play in both surveillance of the brain parenchyma and in 
response to the injured brain. Derived from myeloid progenitors early in the development of the brain, 
microglia are the only resident immune cell found solely in the CNS181,182. It is worth noting that 
monocytic cells can be recruited from the periphery to the CNS and act almost identically to resident 
microglia, making it difficult to discriminate between the two.  
 
Microglia display many receptors similar to those seen on peripheral immune cells such as MHC, TLRs 
and cytokine/chemokine/complement receptors 183.   Under ‘resting’ conditions, they have a dynamic 
and highly motile phenotype, constantly surveying the brain parenchyma through the extension of 
their ramified cell bodies184,185. This allows a vast area of the brain to be constantly monitored 
(estimates suggest the whole brain parenchyma could be covered within a few hr186), and continual 
removal of cellular debris to be achieved. Following activation, microglia undergo rapid phenotypic 
changes, withdrawing their highly ramified processes to become amoeboid like cells with the ability 
to migrate through brain tissue to sites of damage. Once at the site of damage, they are able to act in 
a phagocytic manner, ingesting damaged tissue and releasing cytokines, chemokines and growth 
factors to recruit further microglia and peripheral immune cells183,186. For this reason, activated 
microglia are highly indicative of an inflammatory reaction within the brain.  
1.6.2. Astrocytes 
Astrocytes are the most numerous glial cell with in the brain, accounting for approximately 50% of the 
non-neuronal cell population187. They have important functions in ionic, osmotic and neurotransmitter 
homeostasis with the brain parenchyma, as well as a supportive role to other cell types with in the 
brain, namely neuronal cells. This is achieved in part by the astrocytes role in the ‘neurovascular unit’; 
whereby, astrocytes aid not only the development but also maintenance of a functional BBB188,189. 
Likewise, their ability to regulate glutamate levels, as well as their critical role in the metabolism of 
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glutathione and its precursors, are of paramount importance for the survival of neuronal cells. In the 
absence of astrocytes, neuronal cells are exquisitely more sensitive to the cytotoxic effects of 
glutamate due to the ability of astrocytes to remove glutamate from their microenvironment 190. 
 
Additionally, astrocytes play a significant role in maintaining the redox environment within the brain. 
For an organ with such a high metabolic demand (20% of the body’s O2 consumption vs. 2% of its 
weight), it is important that the generation of reactive oxygen species (ROS) as a by-product of 
respiration is tightly controlled. The ability of neuronal cells to generate glutathione, a tripeptide 
essential for the protection against oxidative challenges within the brain, is markedly decreased in the 
absence of astrocytes191-193. This is at least in part due their ability to release essential glutathione 
precursors to the neuronal cell population. They also play a similar protective antioxidant role through 
their participation in ascorbate cycling194. On top of these functions, like microglia, they are capable 
of producing a plethora of both pro and anti-inflammatory, and vasoactive, molecules in response to 
various stimuli. The ability of astrocytes to alter local cerebral blood flow in response to neuronal 
activity has also been suggested, although, this response may be much more complex than previously 
appreciated195,196.  
1.6.3. Neurones 
Neurones are the ‘communicator’ within the brain. They control nearly all bodily functions, and rely, 
in some way, on other brain cells to support their function. They predominantly reside within the grey 
matter of the brain and it is the pathological alteration of their function, and the associated 
devastating effects that these can have, which drives the bulk of neurotherapeutic research. 
Pathologies such as stroke and sepsis that lead to inflammation within the brain, either within that 
brain parenchyma itself or present peripherally leading to systemic effects, have been shown to 
significantly alter neuronal homeostasis and therefore function.  
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1.7. Vascular Cerebral inflammation 
Cerebral inflammation has been shown to underlie many neuropathologies; Alzheimer’s, Parkinson’s, 
MS, Stroke and endotoxaemia to name but a few. What differentiates the inflammation seen in both 
Stroke and endotoxaemia from other cerebral inflammatory pathologies is that the response is 
initiated and largely driven by peripheral immune cells and mural cells of vasculature. For this reason, 
the aim of this work was that by establishing a reliable model of brain inflammation using either stroke 
or endotoxaemia as an initiating stimuli, the effects of SFN on the inflammatory intravascular 
interactions could be investigated. As highlighted above, agents and syndromes the effect these 
interactions alter the inflammatory outcome and may therefore be of therapeutic benefit in patients 
at risk of cerebral intravascular inflammatory events.  
 
Both stroke and endotoxamia are associated with marked leukocyte, platelet and endothelial 
activation. In the case of Stroke, platelet activation is central to the ischaemic event which drives the 
tissue infarction and subsequent inflammatory response associated with tissue reperfusion. 
Therefore, stroke risk factors involve pathologies associated with platelet activation such as 
atherosclerosis, atrial fibrillation and hypertension. Hence, targeting the inhibition of platelet 
activation by either anti-platelet agents such as aspirin and clopidogeril; or via anti-coagulants, such 
as warfarin, represent effective therapies in order to reduce the risk of stroke onset. Once a stroke 
has occurred, tissue plasminogen activator (tPa), represents the gold standard in current acute stroke 
treatment (a significant downfall with this therapeutic agent is the necessity for patients to receive 
treatment no longer than 6hr post tissue infarction197). This, together with mechanical clot removal, 
allows recanalization of the blocked vessel and therefore reperfusion of the ischaemic tissue. Although 
these interventions are invaluable to restore blood flow in order to address the tissues oxygen deficit; 
it is also known that tissue reperfusion is associated with a significant inflammatory response which is 
concomitant with further tissue damage. This is not currently effectively targeted by therapeutic 
interventions. Therefore, an agent capable of effecting platelet responses, as well as immune cell 
activation represents a potential beneficial therapeutic avenue.  
 
Clinically, patients suffering from endotoxaemia represent a different patient cohort from Stroke 
patients in that there is prevalence for patients to already be on a high dependency ward or intensive 
care unit. The trigger for endotoxaemia is infection with bacteria, both gram positive and gram 
negative, although gram negative bacterial infection is more commonly the cause. Infection leads to 
rapid activation of several cell types within the vasculature (via aforementioned TLR4 dependent 
pathway), including platelet, leukocyte and endothelial cells.  Systemic inflammatory responses ensue 
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throughout the body; including the brain, which is affected by altered perfusion, cellular interactions 
at the blood brain barrier and release of inflammatory mediators.   
 
The vascular inflammatory component and increased activation of several cell types, as well as TLR4 
activation, is therefore common to both the pathology underlying stroke and endotoxaemia. The use 
of animal models and in vitro work offer an opportunity to study the effect of activation of these cells 
types, their subsequent interactions and also the ability of anti-inflammatory agent such as 
sulforaphane (SFN) to alter these responses. 
 
Although these clinical pathologies arise from distinct patient cohorts, it is apparent that they share 
some common pathophysiological hallmarks such as TLR activation62,65. On top of this, patients who 
have suffered from a bacterial infection are known to be at increased risk of subsequently having a 
stroke198-200. Furthermore, some findings suggest that patients with a prior infection have also been 
suggested to present with greater neurological deficit on entering the clinic200. These findings suggest 
interplay between previous activation of the immune system and a possible priming effect increasing 
vulnerability for subsequent ischaemic episodes.  
 
1.8. Models of cerebral inflammation 
1.8.1. Stroke models 
The ischaemic component of stroke is able to be modelled in animals via occlusion of arterial blood 
supply in order to enable investigators to study the whole body response to brain infarction. Models 
are categorised into global stroke; where all/the majority of the blood supply to the brain is occluded 
as would be the case following cessation of the heart beat or focal stroke; where a specific region or 
territory of the brain undergoes an ischaemic episode as would be the case following middle cerebral 
artery occlusion (MCAo). 
 
Global stroke models are generally conducted in small rodents (mice, rats and guinea pigs), and involve 
clipping of the carotid (and in some cases vertebral arteries) leading to an interruption in cerebral 
blood flow (See Figure 1.5). These clips are left in place for 5min up to 1hr, and pathology during 
reperfusion is studied on removal of the clips. Focal stroke models involve a more technically difficult 
surgery leading to a localised, focal ischaemia. These are also most commonly conducted in rodents 
and may involve insertion of a filament into the middle cerebral artery (MCAO (see Figure 1.5)), 
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injection of a thrombogenic agent into the cerebral microcirculation or exposure and ligation of the 
MCA via a cortical window.  
 
 
Figure 1.5: Surgical vessel isolation for global and focal stroke models 
Diagrammatic representation of the isolated carotid arteries in mice. Right; represents clipped 
vessels in order to perform global ischaemia (BCCAo), and left; representing the isolation of the 
common carotid artery in order to introduce a filament into the left middle cerebral artery for a 
focal stroke model (MCAo). (Gillespie, unpublished) 
 
MCAo is the most commonly used model, and can involve temporary or permanent filament 
placement. This model is thought to be the gold standard model due to its reproducibility, the ability 
to alter ischaemic times and reperfusion period to study the time course of damage onset and due to 
its ability to replicate some of the pathology seen in MCAo patients with in the clinic. Although this 
appears to be the model of choice for current stroke research considerable care must be taken in 
order to achieve reproducibility as variations in experimental protocol such as animal temperature 
and anaesthetic regimes can lead to significant alterations in research findings.       
1.8.2. Endotoxaemia models 
Models of endotoxaemia and the use of LPS have provided a valuable tool to study immune responses 
in both animal models and in vitro cell lines. Its addition to cultured cell lines has allowed carefully 
dissection of the cellular pathways activated downstream of TLR4 activation and the ability to study 
the effects of various potential therapeutic agents. Likewise, its use in animal models allows a whole 
body response to endotoxin to be studied enabling reactions throughout the vasculature and within 
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different vascular beds to be studied. Further, several groups have also reported data from human 
studies following the effects of ‘microinjection’ of LPS into healthy volunteers201. 
 
Specifically within the brain, inflammatory responses can be stimulated via direct injection of LPS into 
the brain parenchyma or following peripheral exposure to the bacterial product. Central injection 
leads to an inflammatory response primarily driven by activation of cells of the brain parenchyma, 
namely microglia. On the other hand, systemic exposure leads to a response driven by cells present 
within the vasculature and infected tissue. Effects of LPS injection in the periphery are dependent on 
treatment protocols such as dose and route of administration, but all lead to various alterations in 
haemodynamics, thermoregulation, immune cell activation, as well as altered physiology in many 
organs201. 
 
For the purposes of this project, a systemic challenge using i.p. injection was chosen in order to study 
the effect that activation of cells within the vascular component would have within the cerebral 
microcirculation.  
 
The specific effects of SFN on leukocyte-endothelial cells interactions has not been previously 
visualised within the cerebral microvasculature. Furthermore, the effects that SFN has on platelets is 
only just beginning to be appreciated36,202,203. How these alterations in platelet function may affect 
leukocyte-platelet interactions has also not been investigated. Owing to the aforementioned effects 
of platelet-leukocyte-endothelial interactions during inflammatory conditions, an agent that could 
affect the inflammatory profile of all of these cells may be highly beneficial in counteracting 
inappropriate inflammatory responses. Investigation into the ability of SFN to have these effects is 
therefore a major aim of the work herein.    
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1.9. Hypothesis 
The hypothesis to be tested throughout the work presented in this thesis is that owing to the 
previously published ability of SFN to induce anti-inflammatory effects in several cell types;  
 
Sulforaphane pre-treatment will induce protective, anti-inflammatory effects via Nrf2 leading to 
decreased intravascular cellular interactions and amelioration of the inflammatory profile 
associated with the inflammatory model established 
1.10. Aims 
In order to investigate this hypothesis the following aims will be addressed:  
1. Establish a suitable model to induce and visualise cellular interactions within the brain 
following an inflammatory stimulus (Chapter 3) 
 
Leukocyte-endothelial interactions are known to be induced following inflammation and are a key 
process during the recruitment of leukocytes into inflamed tissues. Animals will undergo either MCAo 
(as a model of ischaemia induced inflammation) or receive an i.p. LPS injection (as a model of 
peripheral induced inflammation) to allow visualisation of leukocyte-endothelial interactions using 
IVM as a measure of the induction of a vascular cerebral inflammatory response. 
 
2. Use the above model to investigate the ability of SFN to alter the leukocyte endothelial 
interactions during the vascular cerebral inflammatory response (Chapter 4) 
 
SFN has previously been found to have anti-inflammatory effects in several models. Following 
production and evaluation of a suitable cerebral inflammatory model, SFN pre-treatment will be used 
prior to inflammatory stimulation to examine whether this isothiocyanate is a suitable agent with 
which to alter leukocyte-endothelial interactions associated with cerebral inflammation. Peripheral 
cell counts will also be performed in order to observe whether total changes in cell numbers 
associated with the protocol could underlie any changes seen.  
 
3. Use molecular in vitro approaches to study how SFN alters protein expression in brain tissue 
and cytokine production in response to inflammatory challenges (Chapter 4) 
 
Tissues taken from animals undergoing LPS and SFN treatment will be collected in order investigate 
the molecular changes underlying any changes associated with SFN pre-treatment, and cytokine 
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measurement will be used as a marker of the ability of SFN to alter the inflammatory profile associated 
with the model. 
 
4. Investigate how SFN affects the functional response of specific isolated human immune cells 
in order to  define potential cell specific effects (Chapter 4 + 5) 
 
Stimulation of both leukocytes and platelets is known to contribute to the inflammatory response. 
Work with isolated cells types will aid understanding of the cell specific effects that are associated 
with any changes that may occur in the leukocyte-endothelial interactions seen in the animal model, 
and will also highlight how different cellular populations respond to SFN in isolation. 
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Chapter 2: 
MATERIALS AND METHODS 
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2.1. Materials  
Reagent Supplier Location 
1,3,5, Triphenyl-tetrazolium formazan Sigma Aldrich Poole, Dorset, UK 
Antisedan Orion Healthcare Berks, UK 
Bupivacaine Astra Zeneca Luton, UK 
Citrate dextrose solution Sigma Aldrich Poole, Dorset, UK 
Corn oil Sigma Aldrich Poole, Dorset, UK 
Fetal calf serum Sigma Aldrich Poole, Dorset, UK 
Formalin solution Sigma Aldrich Poole, Dorset, UK 
Fura 2-AM Sigma Aldrich Poole, Dorset, UK 
Hanks Solution Sigma Aldrich Poole, Dorset, UK 
Heparin, porcine sodium salt from 
intestinal mucosa 
Sigma Aldrich Poole, Dorset, UK 
Histopaques (1077+1119) Sigma Aldrich Poole, Dorset, UK 
Ketamine Fort Dodge Animal Health  Southampton, UK 
L-Glutamine–Penicillin–Streptomycin 
solution 
Sigma Aldrich Poole, Dorset, UK 
LDH Cytotoxicity Kit Roche Diagnostics Germany 
Lipopolysaccharide, 0111:B4 Sigma Aldrich Poole, Dorset, UK  
Pentobarbital Sodium  Merial Animal Health Harlow, Essex, UK 
Prostagladin E1 Sigma Aldrich Poole, Dorset, UK 
Rimadyl Pfizer Sandwich, Kent, UK 
Roswell Park Memorial Institute (RPMI) Sigma Aldrich Poole, Dorset, UK 
Saline Baxters Healthcare Thetford, Norfolk, UK  
SFN Sigma Aldrich Poole, Dorset, UK 
Turks Solution Merck, Millpore Darmstadt, Germany 
Trypan Blue Sigma Aldrich Poole, Dorset, UK 
Xylazine Bayer Newbury, Berkshire, UK 
 
Table 2.1 Reagents used during experimental protocols 
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2.2 In vivo work 
2.2.1. Animal work 
All mice used in this project were 21-30g, male, C57Bl6 and purchased from Charles River, UK (except 
for mice used in photo-thrombosis model; Jackson Laboratory, USA). They were kept under ambient 
conditions; 19-23oC, 12hr light/dark cycle, free access to ad libitum standard chow and water with 
environmental enrichment provide in cages of up to 5. All experiments were conducted with 
appropriate licensing as per the Animals (Scientific Procedures) Act 1986/ EU directive 201/63 
guidelines, and the revised Directive 2010/63/EU. 
2.2.2. General surgery used in all intravital microscopy (IVM) studies 
Mice were anaesthetised with Ketamine (150mg/kg) and Xylazine (7.5mg/kg), and placed on a heat 
mat with temperature maintained at 37oC ± 1oC. The skin overlying the right jugular vein was removed 
and the area surrounding the vein was blunt dissected clear. Surgical thread was looped under the 
vein and superior end was ligated to occlude the blood flow. A 27G needle tip was used to puncture 
the vein and a cannula was introduced for the later injection of Rhodamine 6G injection. 
2.2.3 IVM protocol 
Mice were then placed on a stereotactic board in a sphinx position with the head secured in a flat 
plane using ear bars. Skin covering the left parietal bone was removed, as was the underlying 
periosteum. Using a dental drill, a 5mm diameter cranial window was drilled and the bone was 
removed to expose the brain below. This was then bathed in saline and a coverslip was placed over 
the window. 100µl Rhodamine (0.02%) was injected through the cannula 5 min prior to visualisation 
using the intravital microscope with the CY3 filter in order to label circulating leukocytes.  
2.2.3. LPS studies 
Time response studies: Mice were treated with 0.5, 1 or 4mg/kg LPS and the cerebral microvasculature 
was visualised at 1, 2 or 4hr post LPS injection. 
Dose response: Mice were injected with LPS at doses from 0.1, 0.25, 0.5, 1, to 4 mg/kg followed by 
visualisation of the cerebral microvasculature at 4hr. 
At the end of all experiments blood was taken into heparinised syringes with a 25G needle and brains 
were collected following cervical dislocation for supporting in vitro work, snap frozen and stored at -
80oC. 
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2.2.4.1. Middle cerebral artery occlusion (MCAo) model 
Mice were anesthetised with Ketamine (150mg/kg) and Xylazine (7.5mg/kg), and placed on a heat 
mat. Local application of bupivacaine was injected subcutaneously, and an incision was made in the 
skin overlying the left common carotid artery. The common carotid, external and internal carotid 
arteries, as well as the occipital and pterygopalatine arteries were blunt dissected clear. Surgical 
thread was looped underneath the common artery and the inferior end of the common carotid artery 
was tied off. The superior end was clamped using a microvascular clip, and a small incision was made 
using micro-scissors into which the doccol was inserted. This was then guided up the internal carotid 
artery approximately 9-11mm in order to block the entrance to the middle cerebral artery. This was 
left in place for the entire ischaemic period, following which it was removed and silk around the 
superior end of the common carotid artery was occluded. The exposed area was then hydrated with 
saline, and the skin was sutured using a discontinuous stitch. The mice were injected with 500µl of 
saline for fluid rehydration and left to recover in a warm environment. 
2.2.4.2 TTC staining 
Following the specified reperfusion time period, animals were anaesthetised and blood was removed 
via cardiac puncture. The mice were then decapitated and the brain was removed, and placed  in ice 
cold PBS for 15min. Using a razor blade and brain slicer, the brain was cut into 2mm coronal sections 
and the immersed in 2% TTC at 37oC for 15 min, followed by fixation in 10% formalin. Sections were 
laid out and photographed in order to quantify the infarct volume. 
2.2.5. Photothrombosis model 
Prior to experiments the intravital microscope was configured daily in order to ensure that the FITC 
light channel would expose a 100μm2 area to 1.087 x 10-3 W/cm2 (± 2%) using a 175W Xenon light 
source. This intensity was set to following the photo-haemolysis of murine erythrocytes in a period of 
5-6mins conducted to ensure consistency between FITC dextran lots for ongoing work. 
Mice were then prepared as detailed above for the IVM experiments. Once the jugular had been 
cannulated and the mice had been placed on a stereotactic frame with the parietal cerebral cortex 
exposed, animals were injected with FITC-dextran (5% at 10ml/kg) via the cannula. This was allowed 
to circulate for 10min at which point mice were placed on the IVM. Appropriate vessels were selected 
(straight, non-branching, 30-45μm width for both arterioles and venules) on the bright field filter 
where possible. The filter was changed to the FITC channel. The timer was started and the thrombus 
formation was monitored. The point at which the platelets occluded the vessel lumen for a period of 
30sec was recorded as the vessel occlusion time.  
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2.3 In vitro work  
2.3.1. Cell fractionation 
Brains were collected immediately following cervical dislocation, and snap frozen. Cortical regions 
were removed, and place into a pre-chilled eppendorf. All samples were fractionated using the Actif 
Motif Nuclear extract kit (40010) as follows: Tissues were homogenised and incubated with 3ml/g 
tissue in hypotonic buffer supplemented (as per kit) with detergent (1%) and DTT(1%) on ice for 15min. 
Eppendorfs were transferred to a pre-chilled (4oC) centrifuge and spun at 850g for 10min. 
Supernatants were removed, and kept on ice for later pooling with a subsequent step. The pellet was 
then re-suspended in hypotonic buffer and incubated for 15min. 25µl detergent was added and 
samples were vortexed for 10 sec. Samples were spun down at 13000g for 10sec and pooled with the 
earlier fraction. These samples constituted the cytoplasmic fraction. For the nuclear fraction, the 
above pellet was resuspend in 50µl complete lysis buffer (as per kit), vortexed for 10sec and incubated 
on ice for 30min. Samples were re-vortexed and spun at 14000g for 10min. Supernatants were 
collected and saved as the nuclear cell fraction. 
2.3.2. Protein quantification 
All protein concentrations were quantified using Applichem Bradford Solution. 1µl of sample was 
added to 200µl of Bradford reagent. Samples were compared to a standard curve made using BSA (0-
10mg/ml) in appropriate buffer. Colourimetric wavelengths were read at 595nm and compared 
against the known BSA protein concentration standard curve. All samples and curves were run in 
duplicate and the average was taken.  
2.3.3. Western blots 
All protein samples were quantified as above and used to ensure equal loading. Precast 10-20% Tris 
Glycine NU-PAGE gels were used with an XCell SureLock® Mini cell power pack.  10µl of SeeBlue® Plus2 
prestained standard was used as a molecular ladder, followed by the quantified samples. Blots were 
run in Invitrogen Tris Glycine buffer for 2hr at 125V constant voltage. Gels were then removed from 
the cassette and transferred onto nitrocellulose membranes using an Invitrogen blotting module, with 
Invitrogen Running buffer (20% methanol) for 1hr at 25V. Blots were then blocked in 5% Milk TBSt for 
1hr at room temperature, washed with TBSt for 10min on the rocker followed by incubation with the 
primary antibody in skimmed milk overnight at 4oC on the rocker. Membranes were washed with TBSt 
for 10min and incubated with horse radish peroxidase conjugated secondary antibodies for 1hr at 
room temperature. Pierce ECL western blotting substrates were then incubated with the membrane 
for 2min. In a dark room, X-ray films were then exposed to the membrane and films were developed.  
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2.3.4. Bead array 
Blood samples from mice treated in the LPS studies were taken at the end of intravital microscope 
protocols using cardiac puncture into heparinised syringes with a 25G needle. Blood samples were 
spun down for 5min at 10,000RPM. Plasma was removed and snap frozen, then stored at -80oC. 
Plasma samples were then prepared as per BD Cytometric Bead Array kit protocol. The fluorescent 
intensities for each analyte (IL12p70, IL-6, TNFα, IL-10, IFNγ, MCP-1) in individual samples were then 
measured using a BDFACs Calibur Flow Cytometer. Cytokine expression was then quantified against a 
set of standards (0-5000pg/ml).  
2.3.5. Nrf2 ELISA 
Nuclear samples taken from the above cell fractionation studies were used in order to quantify nuclear 
Nrf2 expression across treatment groups. Samples were prepared as per Activ Motif Trans AM Nrf2 
kit manual, and 8.5µg of nuclear protein were added per well in triplicate. Relative Nrf2 expression 
was then quantified from the colorimetric readout taken at 450nm. 
2.4 Ex vivo work 
2.4.1. Human neutrophil isolation 
All reagents (Roswell Park Memorial Institute medium (RPMI), Fetal calf serum (FCS), Penicillin – L-
Glutamine – Streptomycin, Histopaque 1077 and 1119) were placed in a sterile hood and bought to 
room temperature. 3ml of histopaque 1077 was layered over histopaque 1119. Blood was collected 
from NSAID free, healthy volunteers into a 60ml pull back syringe with 10% Sodium Citrate. Blood is 
then diluted 1:1 in RPMI containing penicillin (100units), L-glutamine (2mM) and streptomycin 
(0.1mg/ml) and 6ml is layered gently onto the histopaque gradient. This was spun at 400g for 30min 
at room temperature. The polymorphonuclear cell layer is removed, resuspended in 12ml RPMI and 
spun down at 400g for 15min. Cell pellets were then briefly resuspended in ice cold ddH2O followed 
by addition of Hanks solution. Cells were spun down at 400g for 10min and then resuspended in RPMI 
(with penicillin (100units), L-glutamine (2mM), streptomycin (0.1mg/ml) and FCS (10%)). Cells are then 
washed in 12ml RPMI followed by spinning for 10min at 400g. Cell pellets were then resuspended, 
pooled and the cells are counted on a light microscope with Turks staining and a Neubauer Bright line 
haemocytometer. Cell numbers were calculated as follows: 
  Cells number counted x dilution factor x 104 = Cells/ml 
Cells were then resuspended at 1 x 106cells/ml in RPMI. 
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2.4.2. Human neutrophil stimulation 
Cells were isolated and resuspended in RPMI with penicillin (100units), L-glutamine (2mM) and 
streptomycin (0.1mg/ml) as documented above. Cell suspensions were then aliquoted out onto two 
24well plates at 5 x 105cells/ml. Cells were then exposed to increasing doses of SFN (0.1-25µM) for 
4hr followed by addition of LPS (0.1μg/ml) for 14h. Control wells contained untreated neutrophils. 
Plates were incubated at 37oC, 5% CO2. At the end of incubations, plates were spun at 400g for 10min 
supernatants were collected for IL-1β release analysis. Samples were snap frozen and stored at -20oC.  
2.4.3. Neutrophil IL-1β ELISA 
At the end of neutrophil stimulation experiments aliquots of culture medium were taken and snap 
frozen and stored at -20oC. Samples were then thawed on the day of running the ELISA. These samples 
and serial dilutions of the provided known standard were then run in duplicate as per the 
manufacturers’ instructions. The optical density of the unknown samples was plotted against a curve 
of best fit plotted from the known standards. 
2.4.4. Neutrophil lactate dehydrogenase (LDH) Assay 
Using the Roche cytotoxicity detection kit PLUS the following was conducted. Isolated neutrophils were 
suspended in RPMI with penicillin (100units), L-glutamine (2mM), streptomycin (0.1mg/ml) and 5% 
BSA, were pipetted across a 96 well plate, either with or without pre-incubation with SFN followed by 
LPS treatment. All samples were run in triplicate. Lysis buffer was added to the neutrophils marked 
for full lysis and untreated platelets were left for baseline LDH read outs. The plate was left on a shaker 
table at room temperature for 15min. Reaction mixture was added to each well, the plate was covered 
in foil and then left to incubate for a further 30 min. Stop solution was added to each well and the 
plate was then read at 490nm by a plate reader. Neutrophils treated with lysis buffer were taken as 
100% LDH release and untreated neutrophils were used for baseline LDH release. 
2.5 Platelet work 
All blood was collected immediately prior to experimentation using venepuncture within the cubital 
fossa. All volunteers were healthy, aged 18 – 65 and NSAID free 2 weeks prior to blood collection. 
Blood was collected into 50ml pull back syringe using a 23G needle. The anti-coagulatant used was 
acidified sodium dextrose (ACD, 1:9).  
2.5.1. Platelet Isolation and Aggregation  
Blood was aliquoted into 15ml falcon tubes, and spun down at 100g for 20min at room temperature. 
Plasma rich plasma (PRP) was then pooled in a 50ml falcon tube, and 5µg/ml PGE1 and 12µl/ml ACD 
was added. PRP was then spun at 1400g for 10min to pellet the platelets. The supernatant was 
Page | 54  
 
discarded and the platelets were re-suspended in tyrodes-HEPES buffer with 10mM glucose (THB+), 
with 5µg/ml PGE1 and 3ml ACD. Platelets were then centrifuged at 1400g for 10min. Platelets re-
suspended in THB+ at 250 x 103/µl. Platelets were then allowed to rest for 30min at 37oC. An 
appropriate volume of washed platelets were aliquoted into silicone coated cuvettes with stir bars, 
and placed in the light transmission aggregometer at 37oC under constant stirring conditions. Platelet 
reactivity was tested with 0.1U/ml thrombin to ensure reactivity before experiments were 
commenced. Aggregations were run for 3min following addition of various agonists. 
2.5.2. Ca2+ signalling 
Blood was spun down to the PRP stage, as above, then incubated at 37oC with CaCl2 (200µM) and the 
ionophore Fura2-AM (5µM) for 30min in the dark. PRP was then supplemented with 5µg/ml PGE1 and 
12µl/ml ACD, and spun down at 1400 RPM for 10min. The platelets were then resuspended at 
suspended in THB+ at 250 x 103/µl. Platelet reactivity was tested with 0.1U/ml thrombin to ensure 
reactivity before experiments were commenced. 
2.5.3. Platelet LDH Assay 
Blood was spun down to the PRP stage, and went through the first fast spin (1400g, 10min) then 
resuspended at in THB+ at 50 x 103/µl. Using the Roche cytotoxicity detection kit PLUS the following was 
conducted. 100µL of washed platelets were then aliquoted out, either with or without pre-incubated 
of SFN, onto a 96 well plate in triplicate. 5µL of lysis buffer was added to the platelets marked for full 
lysis, and plate was left on a shaker table at room temperature for 15min. 100µL of reaction mixture 
was added to each well, the plate was covered in foil and then left to incubate for a further 30min. 
50µL of stop solution was added to each well and the plate was then read at 490nm using a plate 
reader. 
2.6 Data Analysis 
2.6.1. Intravital microscopy videos 
Videos recorded from mice undergoing intravital microscopy procedures were all recorded in real time 
but saved for off line analysis. Three parameters were quantified in order to evaluate the inflammatory 
response within these vessels (Figure 2.1). These included; the number of rolling cells, the cell rolling 
velocity and the number of adherent cells.  The number of rolling cells was measured by counting the 
number of cells to pass a fixed point within the vessel (1.). The cell rolling velocity was measured via 
following a cells movement along the vessel wall and dividing the length it travelled by the time it took 
(2.). Finally, the number of adherent cells was counted as any cell that remained stationary within the 
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vessel for 30sec or longer (3.). All vessels chosen for analysis were straight and non-branching where 
possible.   
 
 
Figure 2.1: Diagrammatic representation of the parameters measured in order to quantify 
inflammatory responses within cerebral pial venules. (1. Number of rolling cell (mm3/min) 2. Cell 
rolling velocity (µm/sec) 3. Number of adherent cells (100µm)) 
 
2.6.2. Statistical Analysis 
All experiments were analysed using Prism Graph Pad statistical software. Experiments in Chapter 3 
and 4 were analysed with non-parametric ANOVA with Dunnetts post hoc tests on mean ± SEM and 
experiments in Chapter 5 used parametric ANOVA ± SD. Power calculations for Chapter 4’s in vivo 
experiments can be found in Appendix I.    
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Chapter 3: 
METHODOGICAL DEVELOPMENT OF AN 
APPROPRIATE CEREBRAL INFLAMMATORY 
MODEL 
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3.1. Results  
 
Outline 
Much of the early work investigating the effects of SFN on cellular physiology had done so with respect 
to oncology with the use of cancer models and cell lines; more recent work suggests that some of the 
beneficial findings may be attributable to the ability of SFN to cause anti-inflammatory effects204.  
Subsequent studies have found that SFN’s ability to induce Nrf2 within the vasculature promotes anti-
inflammatory effects and, this in turn, provides protection against the development of 
atherosclerosis25. Further work has shown that SFN crosses the BBB, a major hurdle for many 
therapeutics aimed at treating pathologies with the brain, and therefore, represented the possibility 
that SFN may be an attractive agent with which to target inflammatory pathologies within the brain24. 
 
The primary aim of this chapter of work was to set up an appropriate cerebral inflammatory model in 
order to investigate leukocyte-endothelial interactions within the brain: 
 
1. Establish a suitable model to induce and visualise cellular interactions within the brain 
following an inflammatory stimulus  
 
As highlighted in the introduction, stroke is a disease primarily driven by ischaemia caused by a 
blockage of the cerebral vasculature by a clot or embolus (approximately 85% of stroke patients suffer 
ischaemic stroke). The current dogma is that reperfusion of this ischaemic territory is vital in order to 
preserve the maximum amount of brain tissue, however, it is also associated with a significant 
inflammatory event – ischaemia-reperfusion injury (IRI). IRI is not currently effectively treated within 
the clinic. Through the use of the MCAo model of ischaemic stroke it was hoped we would recapitulate 
the pathology seen following ischaemic stroke in humans, enabling us to investigate the leukocyte-
endothelial interactions underlying IRI. Using this model in combination with IVM would allow 
visualisation and analysis of these leukocyte-endothelial interactions. IVM provides a sensitive, real 
time technology with which to visualise and quantify the cellular interactions that underlie 
inflammatory responses as depicted in Figure 1.3. Collecting information on further parameters such 
as infarct development, cytokine production and neurological scoring would be used to gain more 
information on the pathophysiology associated with the model, as well as providing markers to relate 
the model to outcomes seen in humans.   
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MCAo protocol optimisation 
The first protocol used involved insertion of a 210µM filament into the common carotid artery for a 
60min occlusion period, followed by a 24hr reperfusion time point as had been previously published 
(although longer time points and permanent ischaemia have also been used)205,206. This protocol was 
associated with unacceptable levels of mortality and therefore, with the aim of decreasing the 
mortality rate, the ischaemic period was decreased to a 30min ischaemic period. The effect of altering 
the body temperature was also tested alongside this new ischaemic period. 
 
Reducing the temperature during ischaemia did appear to alter the leukocyte-endothelial interactions 
that occurred (Figure 3.1). Sham treated animals (identical surgical interventions without insertion of 
the filament) had few cells rolling through the pial vessels, and a low number of cells becoming 
adherent. In comparison, all animals that had undergone MCAo had increased numbers of cells rolling 
through the microvasculature and were doing so at a relatively slowing rolling velocity (25-40µm/sec; 
Figure 3.1b). The number of adherent cells within the pial vessels was altered by the temperature 
during ischaemia. Animals that were maintained at 35oC had low levels of adherent cells that were 
comparable to those seen in sham operated mice (Figure 3.1c). However, mice that had their 
temperatures maintained at either 36 or 37oC had a greater number of adherent cells (Figure 3.1c). 
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Figure 3.1: Investigation into the effect of alteration of body temperature on leukocyte-
endothelial cell interactions in MCAo. Male, C57Bl6 mice (25-30g) underwent occlusion of the 
MCA via induction of a 210µM filament for 30min followed by withdrawal and a 24hr reperfusion time 
point. Leukocyte-endothelial interactions were then visualised using Rhodamine 6G and IVM. n=3-6 
mice/group.  
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Analysis of temperature dependent infarct development and mortality rates associated 
with the MCAo model  
Following the conduction of the IVM, the brains were removed at stained with TTC to study the 
development of the infarct in the ipsilateral hemisphere. Surprisingly, there appeared to be little 
difference in the size of the infarct that developed across the different temperature groups. Further, 
infarct development appeared to show a considerable amount of variability (Figure 3.2). Mortality 
rates associated with these altered temperatures remained high (≈60% at 35 + 36oC and ≈80% at 37oC) 
(Figure 3.3), and therefore it was investigated whether altering the ischaemia-reperfusion time points 
would improve survival and also data reproducibility (Figure 3.4).    


































Figure 3.2: Infarct development in the ipsilateral hemisphere using MCAo following a 
period of 30min ischaemia and 24hr reperfusion. Male, C57Bl6 mice (25-30g) underwent 
occlusion of the MCA via induction of a 210µM diameter filament for 30min followed by withdrawal 
and a 24hr reperfusion time point. Following IVM, brains were taken, sliced along the coronal axis and 























Figure 3.3: Mortality rate associated with MCAo following a period of 30min ischaemia and 
24hr reperfusion. Male, C57Bl6 mice (25-30g) underwent occlusion of the MCA via induction of a 
210µM diameter filament for 30min followed by withdrawal and a 24hr reperfusion time point. n=9-
31 mice/group.  
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Investigation into the effect of altering the MCAo model protocol on the consistency of data 
generation  
Reducing the time of reperfusion was shown to alter the leukocyte-endothelial interactions (Figure 
3.4). The number of rolling cells was seen to markedly decrease when the reperfusion was lowered 
(205 (20min ischaemia), 207 (30min ischaemia) cells/mm3/min 4hr reperfusion); vs. (512 (30min 
ischaemia) cells/mm3/min 24hr reperfusion), although it was similar between the 20min and 30min 
treatment groups. Cell rolling velocity remained comparable between all groups. Cell adhesion 
appeared to be markedly decreased in the 30min ischaemia groups when reperfusion was decreased 
from 24hr to 4hr. However, paradoxically, decreasing the ischaemia time to 20min appeared to 
increase the number of adherent cells that were present within the microvasculature when compared 
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Figure 3.4: Investigation into the effect of alteration of ischaemia and reperfusion time on 
leukocyte-endothelial cell interactions in MCAo. Male, C57Bl6 mice (25-30g) underwent 
occlusion of the MCA via induction of a 210µM diameter filament for 20 or 30min whilst body 
temperature was maintained at 36oC followed by withdrawal of the filament and a 4hr or 24hr 
reperfusion time point. Leukocyte-endothelial interactions were then visualised using Rhodamine 6G 
and IVM. R = reperfusion. *P<0.05 compared with sham treated animals using nonparametric ANOVA 
with Dunns post hoc test. n=2-4 mice/group.  
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Investigation into the effect of altering filament size on the MCAo model on the consistency 
of data generation  
It was also investigated whether alteration of the filament size would decrease the variability and 
improve the results gained. The number of rolling cells within the microvasculature following 30min 
ischaemia and 4hr reperfusion did appear to be altered in line with filament size (Figure 3.5). The 
smallest filament, 190µM diameter, was associated with the lowest number of cells rolling through 
the venules, which increased in line with increasing filament diameter (210µM and 230µM; Figure 
3.5a). The cell rolling velocity was again relatively constant and did not seem to be affected by 
alterations in the filaments diameter. Following removal of the large and medium sized filament there 
appeared to be a relatively low number of cells adhering to the venular walls at 4hr, however, 
following removal of the small filament there was an increased but also significantly varied number of 
adherent cells.  
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Figure 3.5: Investigation into the effect of alteration of filament size on leukocyte-
endothelial cell interactions in MCAo. Male, C57Bl6 mice (25-30g) underwent occlusion of the 
MCA via induction of a 190 (small), 210 (medium) or 230µM (big) diameter filament for 30min whilst 
body temperature was maintained at 36oC. The filament was withdrawn and 4hr reperfusion time 
point was allowed prior to leukocyte-endothelial interactions being visualised using Rhodamine 6G 
and IVM. Bars represent filament size. n=2-4 mice/group.  
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MCAo model development discussion 
The aim of using the MCAO model was to produce a reproducible model in order to investigate the 
leukocyte-endothelial interactions and other pathophysiological markers associated with 
inflammation in the post ischemic brain. As a model, MCAo represents the gold standard technique in 
order to investigate potential treatments in stroke therapy for several reasons. The majority of 
patients that enter the clinic following a stroke  have undergone an ischaemic episode (≈85%), and 
therefore the ability to recapitulate this in animal models allows investigation into: the activation of 
different cell types and the pathways associated with this cerebral ischaemia, the time frames 
necessary to improve outcome, as well as events subsequently occurring during reperfusion207. As the 
surgery involves insertion of a filament to occlude the MCA intraluminally, it does not require a 
craniotomy thereby minimising risk of direct damage to the brain. This means that any inflammation 
seen should be as a cause of vascular occlusion rather than damage that could be associated with 
externally clamping the MCA as may occur in other models. Mice are ideal to use for several reasons: 
knowledge of their genome means the availability of relevant genetically altered animals can aid 
hypothesis testing; the ability to compare like with like with other work on going in the group would 
be advantageous; smaller animals meaning lower doses and reduced reagent costs and the availability 
of data already published on the model in this species allows comparison of results gained with a 
current body of literature. However, the use of mice in this model does represent a significant surgical 
challenge, and due to the length of anaesthesia and post-operative immobility can be physiologically 
stressful to the animals. The small size of mice means that the surgery involved requires a delicate 
hand and significant precision. Isolation and occlusion of the vasculature involved in inserting the 
filament takes time to learn and requires precise and careful surgical ability.  
 
Here, insertion of the filament into the external and common carotid artery was tested in order to 
ensure minimal damage to the soft tissue surrounding the vessel. Due to the vessels proximity to 
trachea and the fact that it underlies the salivary glands, minimal tissue disruption is important since 
inflammation of the area could lead to breathing difficulties and unnecessary agitation of the salivary 
glands leads to secretions which can affect the area. Although both vessels provided accurate filament 
insertion, the common carotid artery route was thought to be associated with the least tissue damage, 
and was therefore less likely to affect the animals’ outcome (See Figure 3.6). Furthermore, through 
testing the optimal length of insertion advancement of the filament to 13mm from the bifurcation of 
the common carotid artery lead to optimal covering of the MCA (Taylor, unpublished). Also, when this 
position was reached slight resistance could be felt on the filament. Further advancement can lead to 
damage of the cerebral vasculature and surrounding tissue. 




Figure 3.6: Illustration highlighting route of filament insertion. Diagrammatic representation 
of filament insertion into either the common carotid (A) or external carotid artery (B). (Gillespie, 
unpublished) 
 
In line with this, and shown above, was the testing of various filament sizes and types in order to 
provide the optimal vessel occlusion. Several types of ‘homemade’ filament were tested. These 
included monofilaments which were cut and coated in silicone. However, the difficultly in creating 
uniform filaments with these methods and their durability made them unsuitable. For this reason, use 
of the doccol filaments provided the most suitable filament to cause the occlusion. From the results 
gained in Figure 3.5, as well as the mortality and infarct size associated with each filament, it was 
apparent that the medium filament (diameter of 210µM) was most suitable. The variability seen with 
the smaller filament (190µm diameter) appeared to be associated with incomplete occlusion in some 
animals since their TTC staining appeared to show no infarct. Both the 210µm and 230µm diameter 
filament were both associated with infarct development, so as the smaller filament appeared 
adequate this was used so as to limit damage to the vessels through insertion of a larger than 
necessary filament.  
 
Whilst trying to set up the model several different anaesthetic agents and regimes were also used. 
Several anaesthetic agents and regimes appear to interact with the pathology associated with cerebral 
ischaemia-reperfusion and therefore, the anaesthetic used and the doses administered represent 
another parameter that must be tightly regulated when performing MCAo208-210. Here, sodium 
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pentobarbital (100mg/kg) and isoflurane were tested. Sodium pentobarbital was inappropriate since 
its long recovery period prolonged the time the animals were immobile for and therefore presented 
a problem with temperature management. Isoflurane represented an attractive anaesthesia option 
due to its rapid recovery time and ability to control the depth of anaesthesia, however, the nature of 
the equipment association with the agents delivery complicated conducting the surgery and was 
therefore not taken forward. Furthermore, prolongation of exposure time to isoflurane has been 
shown to lead to significant experimental variation following ischaemic injury and was therefore not 
ideal for the purpose210.  
 
Another parameter which has been seen to affect pathophysiological outcomes following ischaemic 
stroke in mice is temperature. Without the correct equipment and constant monitoring temperature 
can be a difficult variable to accurately control. Not only do mice undergo rapid heat loss following 
induction of anaesthesia due to immobility and a high surface to volume ratio, their body temperature 
can also fluctuate markedly in the presence of external heat sources211. For these reasons, use of a 
homeothermic mat aimed to eliminate unwanted variation in body temperature. This also enabled 
investigation into the effect of altered body temperature on leukocyte-endothelial interactions, 
infarct development and mortality rates (Figures 3.1-3.3). Indeed, taking into account the mortality 
rates associated with MCAo for 30min followed by 24hr reperfusion temperature did appear to have 
an effect. Maintenance of the rectal temperature at 37oC appeared to be associated with a greater 
mortality level than that seen at either 35 or 36oC (Figure 3.1). For this reason, MCAo was no longer 
conducting with the rectal temperature of 37oC and 36oC was taken forward as an appropriate 
temperature to improve survival without decreasing temperature with a level that may be itself 
protective. Furthermore, the lower temperature of 35oC seemed to show a reduced level of cell 
adhesion compared to the other to temperature groups which could be indicative of an effect leading 
to altered leukocyte-endothelial cell interactions. Indeed, the use of hypothermia to dampen the 
inflammatory response and protect against cellular damage associated with various types of cerebral 
injury has received much attention212-214. The temperatures investigated are broad, ranging from as 
low as 17oC up to 35.5oC213. The effects of this thermo-reduction appears to be manifold, including 
decreasing cellular apoptosis, altering inflammatory cytokine levels both by reducing pro-
inflammatory cytokines (TNFα, IL1 and IL-6) and increasing anti-inflammatory cytokine (IL-10) levels, 
reducing cellular adhesion molecules and reducing ROS production212,215-217.  
 
It is also of note that there did not seem to be a correlation between increased leukocyte-endothelial 
interactions and the development of the infarct size (Figure 3.1-3.2). This seems somewhat surprising 
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since previous findings have indicated that the development of brain infarction is linked to the 
presence and recruitment of neutrophils to the damaged brain tissue, and that inhibiting the 
recruitment of these immune cells is associated with an amelioration infarct development and stroke 
outcome218-220. These variations in temporal dynamics of cell recruitment may in part be accounted 
for by differences in the MCAo protocol used, the techniques used to quantify the number of cells and 
whether techniques were looking at the presence of intravascular, parenchymal or total immune cell 
numbers220,221.   On the other hand, the size of the infarcts that developed, although similar between 
groups, did show a marked variability.   
 
Investigation into different ischaemia and reperfusion time points was explored to try and tighten the 
data been gained. Previously, alteration in ischaemia and reperfusion times has been shown to alter 
the associated presence of immune cell activation and hence, inflammatory profile present in the 
rodent brain222,223. Variation in the leukocyte-endothelial interactions however, remained marked 
with a standard error of between 30-45% in the level of cell adhesion seen in some groups. This 
highlighted the inconsistency of the data being gained from the model at this time and brought into 
question the validity of its use with the time pressures associated with the project.  
 
It was also found that when some mice had made it to the stage of drilling the cranial window in order 
to visualise the cerebral microvasculature, that they had increased intracranial pressure. This caused 
the tissue to distort at the site that the window was drilled and effect blood flow and therefore, caused 
difficulties in recording cellular interactions. This was potentially a combination of damage to the dura 
on removing the cranial window and manifestation of cerebral oedema that is known to be develop 
in the ipsilateral hemisphere of some mice. Breakdown of the BBB via loss of intercellular tight junction 
molecules such as claudin-5 and occludin, as well malfunctions in water transporters such as 
aquaporin 4 lead to an increase in parenchymal water content causing a subsequent elevation in 
intracranial pressure and potentially decreased blood flow224,225. This produced a confounding factor 
to subsequently conduct IVM on these animals since in intracranial pressure and altered blood blow 
to the area caused cellular damage and bleeding to the tissue trying to be visualised. 
 
Due to the inability to create reliable and reproducible data, and the difficulties outlined above with 
the MCAo model, it was decided that a model of endotoxaemia would be investigated for its 
applicability to visualise leukocyte-endothelial interactions within the cortical brain microvasculature. 
It was hoped that using this model would provide an alternative method with fewer confounding 
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factors in order to investigate and visualise leukocyte-endothelial interactions within the brain 
following an inflammatory stimulus as outlined in the aims.  
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Use of LPS as a model to investigate cerebral leukocyte-endothelial interactions 
The use of LPS to illicit an inflammatory response, both in in vitro and in vivo experiments, represents 
a useful tool to study many aspects of the host immune response. The ability to refer to a known body 
of data regarding the use of LPS to stimulate inflammation, the simplicity of the model itself and the 
robust and reproducible inflammatory response LPS generates made the use of i.p injection of LPS 
(0.5mg/kg), in conjunction with IVM, an appealing model to investigate to stimulate and visualise 
leukocyte-endothelial cell interactions within pial venules of the cerebral microvasculature. 
Development of this model also allowed investigation into dose and time dependent effects of LPS on 
cellular interactions.  
Investigation into the time dependent effects of LPS on leukocyte-endothelial interactions 
Throughout the time course studied neither the sham surgery associated with the protocol, nor the 
vehicle treatment of saline, was associated with the presence of any marked leukocyte-endothelial 
interactions. There were very few cells rolling along the vessel walls, and likewise, there was an 
absence of cells that were adherent to the vessel wall. This was seen to be the case at the 1, 2 and 4hr 
time points in sham and saline treated animals (Figure 3.7). At no time point were there any significant 
differences in the interactions seen following either sham or saline treatment.  
 
Similarly, following i.p. injection with LPS at both the 1-2hr time points there were seen to be very few 
cells present in the cerebral microvasculature that were either adherent or rolling along the vascular 
wall.  However, following a 4hr incubation period with LPS there was a notable increase in cellular 
interactions within the venules visualised. In animals treated with LPS, the number of leukocytes 
rolling within venules increased significantly. Furthermore, these leukocytes exhibited a slow rolling 
velocity. Furthermore, there was a concomitant and significant increase in the number of leukocytes 
that were adherent to the vessel wall (Figure 3.7). These observations were true when LPS treatment 
was compared to either sham or saline treatment.  
 
At this point it is worth noting that these effects were specific to venules. Interactions between 
leukocytes and endothelial cells within the arterial side of the vascular bed of the cortex were 
generally absent as can be seen in the still images taken from recorded videos presented in Figure 3.9. 
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Figure 3.7: Peripheral LPS induces leukocyte-endothelial interaction in cerebral pial 
venules in a time dependent manner. Male, C57Bl6 mice were injected with Saline or LPS 
(0.5mg/kg) or underwent sham surgery, followed by visualisation of cerebral pial vessels via 
craniotomy at 1, 2 and 4hr post injection. A) Cell flux (per mm3/min) B) rolling velocity (µm/sec) and 
C) no. of adherent cell (per mm3). Data expressed as mean ± SEM. *P<0.05 compared to sham and 
vehicle treated group; # P<0.05 compared vehicle treated group using ANOVA with Dunns post hoc 
test. n=4-8 mice/group 
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Investigation into the dose dependent effects of LPS on leukocyte-endothelial interactions 
To investigate the dose dependency of these cellular interactions, a range of i.p. LPS doses were 
studied at the 4hr time point (Figure 3.8). It was apparent across all doses tested that there was an 
increase in cellular interactions within the parietal cortical venules following peripheral LPS.  
 
All doses of LPS tested showed a trend towards increased numbers of cells rolling (with a significant 
difference seen in with doses of 0.1mg/kg and 0.5mg/kg LPS) along the venule walls in comparison to 
saline treated animals in which there were very few (Figure 3.8a). Similarly, the rolling velocity at 
which these cells were travelling in LPS treated mice was slow ranging from 5-25µm/sec (Figure 3.8b). 
Finally, all doses tested showed a marked increase in the number of cells that were adherent to the 
vessel wall of the venules within the parietal cortex, with doses of 0.1, 0.5 and 4mg/kg LPS showing 
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Figure 3.8: Peripheral LPS induces leukocyte-endothelial interaction in cerebral pial 
venules over various doses. Male, C57Bl6 mice were injected with LPS at varying doses 4hr prior 
to visualisation and compared to appropriate vehicles. A) Cell flux (per mm3/min) B) rolling velocity 
(µm/sec) and C) no. of adherent cell (per mm3). Data expressed as mean ± SEM. *P<0.05 compared 
with vehicle treated group using ANOVA with Dunns post hoc test. n=3-8/group  






Figure 3.9: Representative photographic image of the cortical parietal microvasculature 
taken from mice that have undergone saline or LPS treatment respectively, showing 
increased presence of leukocytes specifically within the pial venules. Male, C57Bl6 mice were 
injected with Saline (A) or LPS, 4mg/kg (B). Parietal pial vessels were visualised after 4hr exposure. 
(Gillespie, unpublished) 
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LPS model discussion 
The data gained using this model of endotoxaemia highlights the applicability of the endotoxaemia 
model as an appropriate inflammatory model which produce a consistent inflammatory response to 
stimulate leukocyte-endothelial interactions within the brain. Teaming this with IVM allows us to 
achieve one of the primary aims of the thesis. 
Use of IVM 
IVM used in combination with injection of fluorescent dye provides a power tool with which to study 
the cellular interactions induce within the brain by endotoxaemia in real time, in live anaesthetised 
animals. The ability to resolve individual cells means they can be tracked, and their behaviour studied, 
as they move along the vessel walls. Due to the depth and nature of the brain tissue, it is typically 
cortical vessels that are viewed, and therefore, the discussion here is in relation to cortical parietal 
pial vessels. Differences in flow between vessels of the arterial and venular sides of the capillary bed 
allow the two vessel types to be identified. Across all treatment groups there was a general absence 
in leukocyte-endothelial interactions within arterioles, and therefore, this data is not presented or 
discussed since no changes were observed. This is in support of previous data which has found that 
leukocyte adhesion is confined to venules except in cases of extreme vascular damage226.  
 
The parameters investigated here allow the effect of different stimuli and drug 
interventions/protocols to be tested and compared. The number of rolling cells within a vessel may 
be indicative of upregulation of adhesion molecules involved in the early stages of the inflammatory 
cascade, such a P-, E- and L-Selectin; either on the endothelium or leukocytes respectively1,130. When 
teamed with the rolling velocity this can be used as a marker for the strength of these interactions 
with slower rolling velocities potentially indicating the involvement of integrins and immunoglobulins 
which form stronger bonds, meaning they are associated with a slower rolling phenotype and 
therefore a decreased rolling velocity158,227. Finally, increased levels of cell adhesion suggest a more 
inflamed environment and the likelihood for a more activated vasculature and circulating leukocytes. 
For this reason, IVM provides an invaluable tool with which to study the inflammatory environment 
within the brain and the cellular interactions it induces. In tissues other than the brain, emigration of 
cells out of the vasculature can be followed however, due to the thickness of the tissue this is more 
difficult within the brain. Development of more powerful microscopes, such as spinning disc confocal 
and two photon IVM’s, are currently being used to aid this area of investigation. 
Model of endotoxaemia 
Preliminary data highlighted that peripheral injection with LPS was capable of altering leukocyte-
endothelial interactions within the brain. This ability of peripherally administered LPS to induce 
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leukocyte-endothelial interactions within the brain has previously been reported elsewhere228,229. One 
of the benefits of using this method of inducing a central inflammatory response in order to visualise 
cellular interactions is that the brain itself is not directly damaged in the procedure itself. This means 
that cellular interactions are a direct result of vascular and peripheral immune cell activation rather 
than a local immune cell activation within the brain as would be the case if intracerebroventricular 
injection were used. 
 
A general absence of cellular interactions in both sham and saline treated animals highlighted that the 
surgery itself did not stimulate cellular interactions; likewise, neither did vehicle treatment.  Firstly, 
these results in Figure 3.7 suggest that the surgery involved with preparing mice for use with IVM does 
not itself stimulate leukocyte-endothelial interactions within the cortical pial vessels, and neither does 
a peripheral injection per se (minimal interactions in saline treated animals). Secondly, the results 
highlight the ability of a peripheral stimulation of the immune system using LPS to induce immune cell 
interactions within venules of the brain microvasculature. Finally, it also highlights the temporal 
nature of this response in that the interactions seem to become apparent at the 4hr time point (Figure 
3.7). LPS injection led to an increase in the number of cells rolling through the cortical cerebral venules 
(Figure 3.7a), in line with leukocytes exhibiting a slow rolling velocity.  The behaviour of these cells is 
indicative of an increase in the expression of adhesion molecules which would support the greater 
interaction seen between the peripheral leukocytes and brain endothelial cells (Figure 3.7b). This is 
also in line with the significant increase in the number of adherent cells, which would also require an 
upregulation of adhesion molecules at the blood rain barrier in order from them to attach to the 
vascular wall (Figure 3.7c).  
 
Indeed, the ability of LPS to stimulate leukocyte-endothelial interactions has been attributed to 
upregulation adhesion molecule expression and the release of pro-inflammatory cytokines from 
various cell types including leukocytes, platelets, endothelial cells and cells of the brain 
parenchyma228,229. The effect of LPS on cytokine production within the plasma will be discussed further 
in the subsequent chapter. The adhesion molecules that have been suggested to cause these 
increased leukocyte-endothelial interactions are similar to those in the periphery and include 
molecules such as selectins, integrins and immunoglobulins (Also see Table 1.1)1,230. Upregulation of 
the selectins on both leukocytes and endothelial cells are associated with the rolling of cells along the 
vessel wall and are likely to explain the increased rolling seen here.130,231,232 
The ability of LPS (and Sepsis) to cause haemodynamic alteration within the brain could be suggested 
as a factor that may alter the number of leukocytes rolling through the microvasculature233; however, 
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other groups using a similar protocol to that used here, and studying blood flow in the periphery, 
found that at this dose and time point LPS injection did not appear to be associated with altered 
haemodynamics based on shear rate measurements234. Measurement of alterations in cerebral blood 
flow using technology such a laser Doppler flow would be beneficial to investigate this in order to 
confidently rule out this effect. This was not something available at the time these experiments were 
conducted; although, previous studies within the group found shear stress within the cerebral 
microvasculature was not affected at this dose of LPS (Gavins, unpublished). 
 
LPS  has previously been shown to release leukocyte haemopoetic bone marrow stores which could 
contribute to the increased cell flux235. Peripheral cell counts did suggest that LPS injection was 
associated with a significant increase in the number of circulating neutrophil and lymphocyte numbers 
(Table 4.1). Peripheral cell counts did highlight the presence of both neutrophils and lymphocytes in 
the peripheral blood, and interestingly, previous reports have suggested that 90% of the leukocytes 
interacting with the BBB following peripheral LPS injection were postulated to be neutrophils228.  
 
In addition, these effects of LPS to induce leukocyte-endothelial interactions have been suggested to 
occur due to activation of TLR4 on the endothelium236. Although this is not something to have been 
investigated here, it is an interesting phenomenon and may be of consequence later in the discussion 
of the effects seen with SFN. Furthermore, this complementary data suggests that, at least at the time 
point studied here, microglial activation does not appear to play a role in driving these interactions228. 
This finding potentially places the onus on a more peripheral immune cell and endothelial driven 
response to LPS in this model of endotoxaemia and would therefore be of interest to take into account 
when investigating SFN’s potential effects. 
 
The consistency in leukocyte-endothelial interactions seen across the doses of LPS tested here (Figure 
3.8) may be supported by the findings of Granger et al (unpublished) that the expression of E- and P-
selectin are upregulated within the brain across a broad range of LPS doses (3-50µg/mouse) at 3-4hr 
respectively. Knowing that the expression of these selectins aids the rolling of leukocytes along the 
endothelial surface supports the effects seen here. This group have also published work showing the 
upregulation of ICAM-1 expression in response to LPS within the brain, and further, highlight the 
sensitivity of the brain tissue in particular to the effects of LPS in this response232. This study did not 
report dose dependent effects of LPS on ICAM-1 expression but it does highlight the sensitivity of the 
brain tissue to respond to peripheral immune challenge. Equally, the ability of LPS to induce TNFα and 
IFNγ is likely to play a role in the upregulation of these adhesion molecules; marked increases in both 
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these cytokines within the plasma were seen here (Table 4.1) and the circulation of these would 
support and/or enhance the increased expression of adhesion molecules reported by these pro-
inflammatory mediators elsewhere231,232. 
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Discussion on appropriate use of model of cerebral inflammation 
The primary aim of this Chapter was to validate an appropriate model of cerebral inflammation in 
order to investigate the leukocyte-endothelial interactions that underlie this physiological response 
to immune stimulation within the brain microvasculature. 
 
Several obstacles were faced when investigating the use of the MCAo model. This model was initially 
chosen due to its ability to reproduce pathological pathways activated following ischaemic cerebral 
infarction in the human stroke condition. The aim was that use of this model would allow investigation 
into leukocyte-endothelial interactions over specific periods of tissue reperfusion, and link this to the 
development of cerebral tissue infarct development and other markers of inflammation such as 
cytokine release and alteration of protein expression. However, due to the high mortality rates 
experienced with the model and the inconsistency of the data gained continued use of this model was 
not appropriate. 
 
Therefore, the use of LPS as a stimulant of vascular inflammation was pursued. Although the 
mechanisms underlying the inflammatory response initiated through the use of this inflammogen are 
different to that associated with MCAo; for example, 
 The inflammation is driven primarily by immune cells of the periphery and vasculature 
 There is no direct cerebral ischaemia response 
 There has been no reported cerebral cell death and infarction 
 
However, the inflammatory pathways do overlap in some aspects, i.e. activation of TLR4 on immune 
cells leading to inflammatory cell signalling, immune cell activation and cytokine induction. 
Furthermore, there are benefits to the use of LPS as a model of inflammation in that  the technique 
used for its induction is much more simple, requires much less intervention and therefore is a lesser 
source of variation. Also, the ability to recapitulate aspects of the model in vitro on single cell 
populations is an attractive tool for dissecting mechanisms of actions and investigating cell specific 
functional effects.  
 
Most importantly, the aim of this Chapter was to generate a model that induced reproducible 
leukocyte-endothelial interactions within the cerebral parietal cortex that could be visualised using 
IVM technology in order to access leukocyte-endothelial interactions, and the data generated here 
highlight that use of LPS in order to do this and the suitability of IVM and Rhodamine to visualise these 
interactions via cranial window.   




ENDOTHELIAL INTERACTIONS IN THE CORTICAL 
BRAIN MICROVASCULATURE DURING 
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Outline 
Work in the previous Chapter highlighted the applicability of LPS to stimulate leukocyte-endothelial 
interactions with the brain. The work also highlighted the usefulness of IVM as a sensitive imaging 
modality with which to visualise these interactions. Together the use of LPS and IVM to generate an 
in vivo model to visualise cerebral inflammation provided the ability to study the effects of SFN on the 
leukocyte-endothelial interactions during a cerebrovasculature response. The rationale in visualising 
these effects being that, it is known that leukocyte-endothelial interactions (as depicted in Figure 1.3) 
are a hallmark of the evolving inflammatory response; therefore, an agent that could alter these 
interactions may have potential anti-inflammatory effects, and highlight its potential for use as a 
therapeutic agent in cerebrovascular pathologies. 
 
Aims: 
Therefore the preliminary aim of this Chapter was to: 
 
1. Use the LPS model outlined in the previous Chapter to investigate the ability of SFN to alter 
the leukocyte endothelial interactions during the vascular cerebral inflammatory response  
 
To gain further understanding into how SFN may affect the inflammatory response associated with 
LPS, collection of plasma through cardiac puncture blood sampling was used to investigate the 
systemic cytokine response associated with the LPS and SFN treatment protocol. Peripheral cell counts 
were also used to see how leukocyte and platelet cell numbers are affected by the treatment protocol, 
and see how these changes may be associated with any alterations in cellular interactions noted using 
IVM. 
 
The secondary aim of this Chapter which was to: 
 
1. Use molecular in vitro approaches to study how SFN alters protein expression in brain tissue 
and cytokine production in response to inflammatory challenges 
 
Collection of cortical brain tissue was used to investigate whether any effects associated with SFN 
treatment led to physiological alteration of Nrf2, owing to the previously published effects of SFN on 
Nrf2 previously noted and discussed in Chapter 1237,238. Use of an in vitro neutrophil assay allowed the 
specific effect of SFN on this leukocyte population to be studied to understand whether a specific 
effect on this cell type may be associated with outcomes from the in vivo model.    




Effect of SFN pre-treatment (saline vehicle) on leukocyte-endothelial interactions stimulated via LPS  
The first set of experiments in this Chapter investigated the use of pre-treatment with SFN (dissolved 
in saline) to alter leukocyte-endothelial cellular interactions. Saline vehicle was chosen, as previously 
studies investigating SFN’s anti-inflammatory effects had highlighted positive findings with this vehicle 
and the thought that this vehicle would not interfere with inflammatory effects being visualised in the 
model made it an attractive choice of vehicle40. 
 
Saline pre-treatment did seem to alter the number of cells rolling through the microvasculature, 
showing a significant increase in Sal/LPS treated mice when compared to LPS treatment alone or 
Sal/Sal treatment. The rolling velocity of these cells was not significantly altered in any treatment 
protocol (Figure 4.1a/b).  
 
When looking at the level of cell adhesion, all LPS treated mice were seen to have increased numbers 
of adherent cells within the pial vessels visualised. These increased levels of cell adhesion were only 
significant from the controls in mice treated with LPS alone (Figure 4.1c). SFN at the 3 doses tested in 
this treatment protocol (using saline as a vehicle) did not result in a significant alteration in either the 
number, or speed of cells rolling through the pial venules; neither did it significantly change the 
number of adherent cells counted within the vessels (Figure 4.1).  
  

















































































































































































Figure 4.1: SFN in saline vehicle alters LPS induces leukocyte-endothelial interaction in 
cerebral pial venules but does not decrease cell adherence. Male, C57Bl6 mice were injected 
treated with increasing doses of SFN at 5, 25 or 50mg/kg (or vehicle saline) for 24hr prior to treatment 
with LPS (0.5mg/kg) for 4hr. Cerebral pial vessels were visualised and compared to appropriate 
vehicles. A) Cell flux (per mm3/min) B) rolling velocity (µm/sec) and C) no. of adherent cell (per mm3). 
Data expressed as mean ± SEM. *P<0.05 compared with vehicle treated group using ANOVA with 
Dunns post hoc test. n=3-8/group 
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Investigation into the stability of SFN in various vehicles using mass spectrometry 
SFN has proven anti-inflammatory effects in a plethora of diseases, and therefore, these findings 
(Figure 4.1) appeared to contradict a large body of previously published work25,239,240.  For this reason, 
mass spectrometry was undertaken on samples of SFN that had been stored in various vehicles at -
20oC for one month in order to check their stability. Chemical ionisation with Cl+ was carried out and 
the resultant spectra are displayed. Figure 4.2 shows the mass spectra for samples that had been 
stored in saline, corn oil or a corn oil/PBS emulsion. Figure 4.2a shows SFN which had been dissolved 
in saline, with the expected peak representing SFN at 195m/z (SFN’s molecular weight (177.29) + Cl+ 
(18)). However, there also seems to be multiple other ionisation peaks suggestive of presence of 
several breakdown products. On the other hand, Figure 4.2b and c show much cleaner spectra with 
the main peak at 195m/z representative of ionised SFN conjugated to Cl+ with fewer surrounding 
peaks. 
 
For this reason, the protocol used in Figure 4.1 (SFN dissolved in saline) was repeated using a more 
suitable vehicle for SFN (corn oil/PBS) with the hope that this improved stability, and therefore, would 
allow a more conclusive investigation into whether SFN could affect leukocyte-endothelial 
interactions in the LPS model earlier validated. 
  








Figure 4.2: Mass spectra (chemical ionisation) showing the ionised SFN peaks [M+NH4]+m/z 
195 following dilution in various vehicles. SFN was diluted in saline (A), pure corn oil (B) or corn 
oil/PBS (C) as for the preparation for animal injections. Samples were then aliquoted out and sent for 
mass spectrometry analysis with chemical ionisation in order to observe compound stability. 
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Effect of SFN corn oil/PBS treatment on leukocyte-endothelial interactions stimulated via LPS  
Following on from the highlighted much improved stability of SFN in corn oil, SFN pre-treatments were 
re-run using corn oil and PBS as a vehicle. To ensure that the pre-treatment of corn oil would not affect 
subsequent LPS responses, this vehicle was tested against LPS alone (Figure 4.3). Corn oil treatment 
did not seem to affect the number of cells that were present within the microvasculature, or how they 
were interacting with the vessel wall. Responses to saline or LPS injection showed similar levels of cells 
rolling through the pial venules and the speed at which they were doing so regardless of whether 
animals had been pre-treated with corn oil and PBS or not (Figure 4.3a and b). Likewise, similar 
numbers of cells were adherent to the pial vessel wall following pre-treatment with corn oil/PBS as in 
those that had received not pre-treatment (Figure 4.3c). Importantly, there remained a significant 
difference in the amount of cells that were rolling and adherent following LPS treatment whether corn 
oil was present or not (Figure 4.3a and c). Therefore, corn oil represented a suitable vehicle for SFN 
dilution as it maintained the molecular stability and that it did not affect the subsequent leukocyte-
endothelial interactions induced by LPS within the cerebral parietal cortex. Therefore, this vehicle was 
used to investigate whether SFN could affect the cellular interactions downstream of LPS injection.  
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Figure 4.3: Corn oil vehicle does not alter LPS induced leukocyte rolling and adherence in 
cerebral pial venules. Male, C57Bl6 mice were injected with saline or LPS (0.5mg/kg), with 
subsequent groups receiving a prior administration of corn oil/PBS 24hr prior to treatment with LPS 
(0.5mg/kg) for 4hr. Cerebral pial vessels were visualised and leukocyte-endothelial cell interactions 
quantified. A) Cell flux (per mm3/min) B) rolling velocity (µm/sec) and C) no. of adherent cell (per mm3). 
Data expressed as mean ± SEM. *P<0.05 when compared to indicated group using ANOVA with Dunns 
post hoc test. n=6-8/group 
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Effect of SFN pre-treatment (corn oil/PBS vehicle) on leukocyte-endothelial interactions stimulated 
via LPS  
As mentioned previously, the cellular interactions stimulated by LPS injection were not significantly 
altered in the presence of corn oil pre-treatment, and there continued to be an increase in cell rolling 
and adhesion associated with LPS injection as previously shown and discussed (Figure 4.3). 
 
SFN treatment at 5mg/kg did not appear to be effective at decreasing leukocyte-endothelial 
interactions. There was no apparent difference between mice that had received corn oil pre-treatment 
or SFN treatment (5mg/kg) on the number of rolling cells (Figure 4.4a). Likewise, there was no 
significant alteration in the cell rolling velocity or in the number of adherent cells in SFN 5mg/kg 
treated mice in comparison to those pre-treated with corn oil (Figure 4.4b and c).  
 
When the dose of SFN was increased to 50mg/kg, however, SFN treatment was associated with 
alterations in leukocyte-endothelial interactions with in the cerebral microvasculature. Firstly, SFN 
(50mg/kg) was associated with a marked increase in the number of cells rolling through the 
microvasculature. This increase in the number of cells rolling through the pial venules was not 
however significant when compared to mice that had received either corn oil/LPS or SFN at 5mg/kg 
with LPS treatment (Figure 4.4a). The speed at which these cells were rolling in SFN(50mg/kg)/LPS 
treated mice was significantly increased when compared to mice that had received corn oil pre-
treatment and LPS.  
 
Treatment with SFN (50mg/kg) was also associated with a marked decrease in the number of cells that 
were adherent within the cerebral microvasculature with numbers decreasing to more than half that 
seen in animals treated with corn oil and LPS (711 vs. 334 cells per mm3). These changes were not 
significant, however, mice receiving this dose of SFN no longer showed a significant difference in the 
number of adherent cells when compared to animals treated with corn oil and saline or SFN (50mg/kg) 
and saline (Figure 4.4c).  
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Figure 4.4: SFN in corn oil vehicle alters LPS induces leukocyte rolling and adherence in 
cerebral pial venules. Male, C57Bl6 mice were injected with saline or LPS (0.5mg/kg), with 
subsequent groups receiving a prior administration of corn oil/PBS or SFN(mg/kg) at indicated doses 
24hr prior to treatment with LPS (0.5mg/kg) for 4hr. Cerebral pial vessels were visualised and 
leukocyte-endothelial cell interactions quantified. A) Cell flux (per mm3/min) B) rolling velocity 
(µm/sec) and C) no. of adherent cell (per mm3). Data expressed as mean ± SEM. *P<0.05 when 
compared to indicated group using ANOVA with Dunns post hoc test. n=6-8mice/group 
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Effect of SFN pre-treatment (corn oil/PBS vehicle) on peripheral immune cell counts 
Peripheral cell counts taken via blood sampled via cardiac puncture were somewhat variable (Table 
4.1). There was a trend towards increased neutrophils following treatment with LPS in naïve animals, 
as well as those receiving corn oil or SFN. Differences between neutrophil counts following corn oil or 
SFN were absent and less marked respectively. Monocyte levels appeared to be effected to a lesser 
level by the treatment regimen and no significant decrease across the groups were seen. Circulating 
numbers of these cell were much lower than any other leukocyte population. Lymphocyte levels 
appeared to be lower in all LPS treated animals when compared to their saline pre-treated 
counterpart. Both corn oil and SFN appeared to further enhance this difference by appearing to 
increase peripheral lymphocyte counts, with a significant difference between the lymphocyte levels 
of saline and LPS treated animals being apparent following SFN treatment. Platelet levels were 
relatively comparable across groups with no significant alterations seen, yet, elevated platelet counts 
did appear to be present in mice receiving SFN (50mg/kg) and saline. 
 







Corn Oil SFN (50mg/kg) 
Saline LPS Saline LPS 
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Table 4.1: Differential peripheral cell counts. Blood was collected, 4hr post LPS treatment with 
or without prior SFN treatment (-24hr, 50mg/kg), via cardiac puncture. Leukocytes counts were 
performed using Turks solution (1:20), and platelet counts were performed in buffered ammonium 
oxide (1:100 dilution). Values represent mean cell count (x104) per ml ± SD. *P<0.05 when comparing 
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Analysis of Nrf2 subcellular localisation following LPS/SFN treatment protocol  
Nuclear fractions from cortical brain samples were isolated using dissection of the cortex and cell 
fractionation. Nuclear subcellular fractions were then quantified using an ELISA. There appeared to be 
no significant difference in the nuclear localisation of Nrf2 in any treatment group regardless of 
whether mice had received treatment with LPS or SFN (Figure 4.5). 
 




























Figure 4.5: Nuclear Nrf2 Expression does not vary across treatment groups. Brains were 
collected from mice receiving Saline or LPS (+4hr, 0.5mg/kg) with or without subsequent corn oil or 
SFN(-24hr; 50mg/kg) pre-treatment, and the cortices were dissected for Nrf2 expression 
quantification via ELISA, Values represent mean optical density ± SD. n = 3 mice/treatment group 
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Effect of LPS/SFN treatment protocol on peripheral cytokine profile 
Blood collected from mice that had been treated with the LPS/SFN treatment protocol was used in 
order to quantify the effects of SFN on peripheral cytokine expression (Figure 4.9 and 4.10). IL12-p70 
appeared to be present at low levels across all treatment groups with detection in the plasma not 
reaching above 10pg/ml in any treatment group; there need not appear to a significant changes 
between any treatment group at the time point tested ((SFN -24hr, LPS +4hr) Figure 4.6a). Across all 
other cytokines tested, there appeared to be undetectable circulating cytokines in the saline treated 
animal, regardless of the pre-treatment they received. Circulating TNFα levels was increased in all 
animals receiving LPS, and these effects were not altered significantly by either corn oil or SFN pre-
treatment (Figure 4.6b). Likewise, MCP-1 and IL-6 were both evidently increased following LPS 
treatment (with nearly all of the animals MCP-1 levels exceeding the maximum detectable level of the 
kit), and from appeared to be largely unaffected by prior corn oil or SFN pre-treatment (Figure 4.7a 
and c respectively).  IFN γ was again increased following administration of LPS in groups tested, and 
there did appear to be a trend towards decreased levels in animals receiving SFN pre-treatment 
(Figure 4.6c). IL-10 levels were also increased by LPS treatment, and although there appeared to be 
some variability between the groups, levels did not appear to correlate with any particular pre-
treatment protocol (Figure 4.7b). 
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Figure 4.6: Plasma expression of IL12-p70, TNFα and IFN γ following SFN and LPS 
treatment protocol. Plasma was collected via cardiac puncture from mice receiving Saline or LPS 
(+4hr, 0.5mg/kg) with or without pre-treatment with corn oil or SFN(-24hr; 50mg/kg) via FACS 
cytometric BEAD array. Values represent means ± SD. n = 3 murine plasma samples/treatment group 
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Figure 4.7: Plasma expression of MCP-1, IL-10 and IL-6 following SFN and LPS treatment 
protocol. Plasma was collected via cardiac puncture from mice receiving Saline or LPS (+4hr, 
0.5mg/kg) with or without pre-treatment with corn oil or SFN(-24hr; 50mg/kg) via FACS cytometric 
BEAD array. Values represent means ± SD. <5000 indicates animals within this group had MCP-1 levels 
beyond the maximum detectable range. n = 3 murine plasma samples/treatment group 
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LPS stimulated IL-1β production as a marker of functional neutrophil alteration following SFN and 
associated LDH release 
To further support the work in this Chapter, a functional assay using isolated human neutrophils was 
conducted in order to study the effects of LPS and SFN on this cell type specifically (Figure 4.8). It was 
found that neither the protocol itself, nor any of the doses of SFN tested were associated with any 
detectable induction of IL-1β release. However, treatment with LPS (1µg/ml) was associated with an 
increased level of IL-1β release (≈20pg/ml). Treatment with the doses of SFN tested here no did seem 
to affect this IL-1β release at this time point. Equally, none of the treatment groups tested in this assay 
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Figure 4.8: SFN administration is not associated with alterations in release of IL-1β 
following treatment with LPS. Isolated neutrophils were resuspended in RPMI with glutamine 
(2mM), streptomycin (100Units) and FCS (10%) at 5.5x104cells/ml, and incubated with SFN over 
various doses for 4hr prior to 14hr treatment with LPS (1µg/ml) min. Data expressed as mean IL-1β 
release ± SEM. n=4 donors/group 
 


















Figure 4.9: SFN treatment is not associated with increases in LDH release associated with 
the neutrophil stimulation assay. Isolated neutrophils were resuspended in RPMI with glutamine 
(2mM), streptomycin (100Units) and BSA (5%) at 5x104/ml, and incubated with SFN over various doses 
for 4hr prior to 14hr treatment with LPS (1µg/ml) min. Data expressed as a mean percentage of LDH 
released stimulated by complete cell lysis ± SEM. n=3 donors/group  
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4.2. Discussion 
Finding the right vehicle for SFN 
Following on from the characterisation of the leukocyte-endothelial interactions stimulated by LPS, 
the aim of this Chapter was to investigate whether SFN could alter these cellular interactions, and if 
so, whether this would be associated with any alteration of the function of inflammatory cells. Existing 
literature had shown that SFN dissolved in saline was a suitable vehicle; SFN in saline was able to 
induce Nrf2 and induce anti-inflammatory effects and therefore, saline was chosen due to its 
suitability for use as an in vivo vehicle40. Other groups previously published in vitro studies had shown 
that key enzymes upregulated by SFN induced Nrf2 peaked around 12-48hr post administration and 
for this reason, a pre-treatment timing of 24hr was deemed appropriate to induce anti-inflammatory 
enzymes prior to the LPS challenge and coincide this with their peak upregulation. Additionally, effects 
of SFN appeared to be apparent in several other animal models, both peripherally and within the 
brain, at a starting dose of 5mg/kg. For this reason an initial protocol using i.p. injection with SFN pre-
treatment at 5mg/kg dissolved in saline was used to investigate the effects of SFN in the model of 
cerebral inflammation was established in Chapter 4.25,41,42,241. 
 
Initial experiments conducted in this project using SFN dissolved in a saline vehicle did not appear to 
support the anti-inflammatory effects of SFN previously shown40. The dose was increased to both 25 
and 50mg/kg and the effects of leukocyte-endothelial interactions were visualised. Barring some 
alterations in the number of cells rolling through the microvasculature, there appeared to be little 
effect; and certainly no inhibitory effects of the visualised cellular inflammatory response within the 
brain (Figure 4.1). Potential reasons for these differences in the response to SFN seen here compared 
to other previously reported work may be due to differences in protocol for making up SFN, but it was 
apparent that in our protocol, SFN did not appear to altering leukocyte-endothelial interactions in the 
manner we had anticipated owing to the published anti-inflammatory effects within the literature 40.  
 
Due to this disparity seen with respect to published work supporting anti-inflammatory effects 
associated with SFN and the lack of effect in the model used here, it was questioned whether SFN was 
stable in a saline vehicle. This led to the conduction of the liquid chromatography mass spectra to be 
performed on SFN that had been dissolved in saline, a corn oil and PBS mix or corn oil alone (Figure 
4.2). Corn oil was selected as a vehicle due to its previously published used, and also the fact that it 
was less reactive with the isothiocyanate than saline or water25. The outcome of these spectra 
suggested that SFN was indeed unstable in a saline vehicle, as demonstrated by the multiple small 
ionization peaks present (Figure 4.2a). However, when SFN was dissolved in either a corn oil and PBS 
Page | 99  
 
mix vehicle or corn oil alone much cleaner spectra were produced suggesting a cleaner product and 
therefore, much improved stability (Figure 4.2b and c). For this reason, experimentation with SFN in 
saline was no longer pursued and all further experiments were conducted with SFN in a corn oil and 
PBS vehicle.  
Effects of SFN on leukocyte-endothelial interactions 
Following on from these findings indicating the instability of SFN in saline, pre-treatment with corn oil 
and PBS was tested to ensure that this protocol would not interfere with the leukocyte-endothelial 
interactions we had previously seen with LPS (Figure 4.2/3). Data indicated that similar leukocyte-
endothelial interactions occurred in the presence of this pre-treatment with a significant increase in 
the number of rolling and adherent cells when LPS treated animal were compared to their saline 
controls (Figure 4.3). Due to this finding it was concluded that pre-treatment with SFN did not alter 
the inflammatory cell interactions stimulated by LPS, and therefore suggested that corn oil/PBS was a 
suitable vehicle for in vivo SFN administration. 
 
Pre-treatment with SFN at dose of 5 and 50mg/kg were then tested. It appeared that SFN at 5mg/kg 
was not able to alter leukocyte endothelial interactions. The number of rolling cells were comparable 
to those seen in vehicle treated animals, as was the rolling velocity and the number of leukocytes that 
were adherent to the vessel wall (Figure 4.4). However, when the dose of SFN was increased to 
50mg/kg there did appear to be alterations in the leukocyte-endothelial interactions associated with 
LPS injection. Firstly, there was a marked elevation in the number of cells seen to be rolling through 
the microvasculature when compared to all other LPS treated groups (Figure 4.4a). These cells also 
appeared to be travelling at an increased rolling cell velocity when compared to animals treated with 
corn and LPS (Figure 4.4b). There was also a marked reduction in the number of adherent cells within 
the pial venules, meaning the number of adherent cells in SFN(50mg/kg)/LPS treated animals was no 
longer significantly different from those being treated with saline(Figure 4.4c). This suggested that 
SFN pre-treatment was capable of altering LPS induced leukocyte-endothelial interactions and may 
provide potential anti-inflammatory effects within the cerebral microvasculature. Taken together, 
these altered cellular interactions suggest that SFN (50mg/kg) pre-treatment is affecting the way 
leukocytes interact with the LPS stimulated cerebral endothelium, and could therefore, potentially 
produced anti-inflammatory effects.   
 
These alterations seen in the experiments of Figure 4.4 could be suggestive of the ability of SFN to 
alter the expression of the adhesion molecules underlying the leukocyte-endothelial interactions 
induced via LPS injection. As mentioned earlier, these include adhesion molecules covering all phases 
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of the leukocyte adhesion cascade discussed at length by Ley et al1. The expression of selectins 
regulates the primary interactions that occur between leukocytes and endothelial cells, and it has 
previously been shown that it is this adhesion molecule that mediates the increased number of rolling 
cells associated with LPS injection that were visualised in this project170-173. In order for leukocytes to 
progress on to develop firm adhesions to the vessel wall it is thought that both the endothelial cell 
and the leukocyte must both be express fully functional and activated integrin molecules. Alteration 
of the ability of integrin molecules to undergo the conformational changes that support this firm 
adhesion would could therefore subsequently effect interactions associated with the leukocyte 
adhesion cascade175,180. The fact that this reduction in leukocyte adhesion seen in Figure 4.4c 
(following SFN (50mg/kg) treatment compared to corn oil/LPS treatment) is concomitant with an 
increased in the number of rolling cells (Figure 4.4a) suggest that there may have been a shift in these 
late stage adhesion molecules such as ICAM1 and/or β2 integrins that support firm adhesion, but that 
the presence of earlier stage adhesion molecules involved in cell rolling such as the selectins and 
mucins remain potentially unaltered (see Table 1.1). Indeed, although not previously reported in 
neutrophils per se, the ability of SFN to alter the expression of cell adhesion molecules downstream 
of LPS challenge has been highlighted before. Both in endothelial cells and monocytes pre-treatment 
with SFN decreased the expression of late stage adhesion molecules following an inflammatory 
challenge38,242. Interestingly, the level of ICAM1 expression specifically has not been shown to be 
altered via SFN treatment38. Indeed, it may be that SFN is altering the β2 integrin family that interact 
with ICAM1. This could be via interference with the intracellular signalling that mediates integrin 
activation following engagement of chemokines with their receptors; or via inhibiting the elongation, 
unravelling or stabilisation of the integrins that is needed to exposed their high affinity β propeller 
head to engage ICAM1 and cause firm adhesion152-156.  
 
Equally, SFN has been shown to alter the ability of TLR4 to respond to the presence of LPS through 
alteration of the MD2 accessory protein’s LPS binding pocket243,244 which could potentially alter 
cellular interactions induced by LPS, however, this may be an unlikely explanation for the interactions 
seen here due to the remaining high levels of rolling cells and lack of SFN treatment to alter LPS 
induced cytokine production in blood samples taken and following the LPS challenge of human 
neutrophils (Figure 4.5 and 4.8).  
Effects of LPS and SFN on peripheral cytokine production 
In order to investigate the effects of SFN on cytokine production cytokine levels within the plasma 
were analysed. Since cytokines are released from a plethora of cell types, and are in turn capable of 
acting in an autocrine and paracrine manner, their presence within the plasma helps to give a snapshot 
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of the systemic effects of LPS and SFN on the underlying inflammatory response. A peripheral sample 
was deemed the most appropriate as it is known that LPS has systemic effects following i.p. injection 
as was used here, and therefore this sampling technique may better reflect any effects that SFN may 
have on alteration of the cytokine profile present82,130,245. Furthermore, sampling by cardiac puncture 
allows a large, consistent sample to be taken and therefore allowed multiple cytokine analyses to be 
ran; thus generating a more rounded picture of any potential effects of SFN.  
 
A cytometric BEAD array was used as this kit allowed sensitive quantification of a range of cytokines 
that are known to be involved in the inflammatory response to LPS such as TNFα, MCP-1 and IL-6. Due 
the systemic sampling method the production of these cytokines could be owing to release from 
several cell types including neutrophils, monocytes, platelets and endothelial cells which are all 
thought to play a key role in the responses seen within this model228,246.  
 
TNFα and IL-6 are prototypic pro-inflammatory cytokines that have been widely shown to be rapidly 
released, in large amounts following the onset of inflammation in several pathologies247,248. The rapid 
and marked increase in TNFα seen here is similar to that previously published in papers using similar 
protocols with peripheral sampling236,249.  Indeed, injection of TNFα alone can been seen to mirror 
many of the pathological effects that occur downstream of LPS injection highlighting the seminal role 
of TNFα in orchestrating the cellular response to LPS130. Along with IL-1β, TNFα and IL-6 act at their 
cognate cell surface receptors to induce intracellular signalling cascades that lead to the activation of 
various transcription factors (e.g. NFκB, p38) leading to the upregulation of cell adhesion molecules 
(e.g. ICAM1) and production of other pro-inflammatory mediators such as ROS, COX-2 and iNOS (see 
Figure 1.1)130,250. The ability of these aforementioned cytokines to stimulate neutrophil and 
endothelial cells; as well as playing a role in platelet activation, supports the findings here. Data 
generated in this project indicated that SFN pre-treatment did not affect the systemic levels of these 
two pivotal pro-inflammatory cytokines at this time point (TNFα and IL-6; Figure 4.6-7). Some in vitro 
work has previously shown that SFN treatment is capable of reducing TNFα mRNA, effects on actual 
protein levels appear to vary and therefore maybe dependent on time of sampling and the treatment 
protocol used40,251. Interestingly, SFN has been shown to be able to induce IL-6 production in vitro, a 
finding that was abolished in the absence of Nrf2252. Increased IL-6 in SFN treated groups was not seen 
here but whether this occurred at an earlier stage and may have potential priming actions could be of 
interest to investigate. 
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MCP-1 (CCL-2) was also found to be upregulated following injection with LPS (Figure 4.7). Contrary to 
earlier work suggesting a purely inflammatory role, it is now thought that MCP-1 plays an important 
role in the controlling the inflammatory response associated with LPS. Removal of this chemokine 
leads to an increase in endotoxemia induced mortality253. It has also been suggested that MCP-1 may 
induce its protective effects via inhibition of IL-12 release from T cells and stimulating the release of 
IL-10253. Although very low levels IL12-p70 were seen in the samples taken here, there were seen to 
be considerable levels of IL-10 within plasma samples (Figures 4.9-10), specifically in LPS treated 
animals. The release of this cytokine in association with LPS highlights the multifaceted response of 
the immune system and TLR4 activation in response to LPS challenge. On top of this suggested 
immunomodulatory role of MCP-1, it has been suggested to play a role in the increased adhesion 
molecule expression and release of other pro-inflammatory cytokines such as TNFα 253,254. This brings 
to light the dichotomous role for MCP-1, whilst supporting the findings presented here whereby high 
levels were seen in LPS treated animals that were seen to have increased leukocyte-endothelial 
interactions (Figures 4.4 and 4.6-7). It is of interest that MCP-1 acts in this dual modal manner to play 
potentially both pro-inflammatory and immunosuppressive roles since one of its primary actions has 
been suggested to be induction of monocyte chemo-attraction255. This monocytic recruitment may be 
involved the initiation of wound healing and present an aspect of the resolution phase of the 
inflammatory response.  Therefore, it is interesting that at this time point, MCP-1 is already elevated 
to this level. This could suggest a potential induction of the resolution phase, or an attempt of the 
immune system to regulate the inflammatory response, may have already begun in order to counter 
the pro-inflammatory effects of TNFα and IL-6 amongst other inflammatory mediators. 
 
Equally, IL-6 has also been described to harbour these bimodal pro- and anti-inflammatory effects. 
Several papers have indicated the elevation of IL-6 following LPS challenge, often at a slight delay to 
TNFαand IL-1β, likely indicating an inductive effect of one or both of these cytokine forerunners on 
release of IL-6248. The pro-resolution/anti-inflammatory effects of IL-6 may involve effects on 
leukocyte trafficking via alteration of chemokine expression, alongside subsequent effects of these 
cells once within the tissue256,257. 
 
Previously published data also suggests that production of IFNγ by T cells plays a corroborative role 
alongside IL-6 to reduce leukocyte trafficking256. This seems somewhat at odds with the trend towards 
a potential reduction in IFNγ induced by SFN here, when considered alongside the reduced leukocyte-
endothelial interactions seen in the IVM studies. One explanation for this could be that SFN alters IFNγ 
at an earlier time point and this snapshot is simply showing the cytokine in a refractory phase. A more 
Page | 103  
 
detailed sampling protocol and examination of the cytokines across a boarder time frame would help 
to elucidate a clearer picture of the effects SFN may play on the temporal cytokine profiles. 
  
This BEAD array kit also included analysis of IL-10, a cytokine whose release has received much interest 
in its role as a mediator of inflammatory resolution258. Interestingly, this cytokine was also upregulated 
in every LPS treatment group highlighting the complex nature of the cytokine response to an 
inflammatory challenge. Again, the data collected here does not suggest that SFN pre-treatment 
modifies the production of IL-10. Whether this is the case over the time period prior to sampling would 
require further investigation. 
 
Although none of these cytokines are statistically altered following SFN treatment, they are all 
markedly increased in LPS treatment groups highlighting the potent and reactive systemic response 
of the host immune system to LPS challenge inflammatory nature of the host response to LPS. 
Whether the effects were mirrored in a more local cerebral environment or at the level of specific cell 
types (e.g. leukocyte subsets, endothelial cells, platelets) cannot be determined from this sampling 
technique but would potentially reveal specific drivers of this cytokine response.  
Modulation of Nrf2 via SFN 
Since it is the current dogma that the mainstay of SFN’s effects are via modulation of the Nrf2-KEAP1 
system, it was investigated whether at the time point used to visualise the cellular interactions 
administration of SFN was associated with altered nuclear Nrf2 expression. Cortical brain tissues were 
analysed since this corresponded to the tissue visualised during the IVM procedure. At this time point, 
there appeared to be no alteration in the nuclear expression of Nrf2 across any treatment group 
(Figure 4.8). Owing to the length of time that SFN had been administered to animals this finding is not 
necessarily unexpected. It is likely that SFN may have already induced Nrf2 translocation closer to the 
time of administration and its nuclear levels has subsequently decreased. Indeed, this finding is in 
agreement with others who have reported similar levels of total and nuclear Nrf2 levels following SFN 
pre-treatment at similar time points to those used here259. Previous groups have shown that SFN 
metabolites are detected within the brain over a rather acute time frame, as rapidly as ≈10min and in 
other cases between 2-6hr with apparent clearance by 24hr24,40. This suggests that peripheral 
administration with SFN rapidly reaches the brain and could, therefore represent the possibility for 
rapid alterations of Nrf2-KEAP1 interactions, leading to acutely increased levels of nuclear Nrf2 that 
would be missed at this time point.  
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Effect of SFN on peripheral leukocyte cell counts 
The trends towards increased peripheral leukocytes counts seen here following LPS challenge is in 
agreement with previous data investigating the effects off LPS on peripheral blood cell counts. It has 
been shown that LPS induces both neutrophil and lymphocyte egression from the bone marrow, as 
well as causing a refractory drop in bone marrow leukocyte reserves235. Conversely, other groups have 
also reported a decrease in circulating leukocyte counts and attribute this to the sequestration in 
organ vascular beds228. These paradoxical findings may be explained by differences in sampling times, 
where cells may show an early increase in circulating numbers before dropping following recruitment 
and/or trapping within the microvascular beds of various organs. Why SFN would be associated with 
a significant increase in peripheral lymphocyte counts in saline treated animals compared with those 
being challenge with SFN is unclear. Whether these increased lymphocytes are involved in the altered 
cellular interactions seen with SFN is also not known. Previous work by the Kubes group has suggested 
that the percentage of cells interacting with the inflamed vasculature that are lymphocytes is 
remarkably low at four hours following LPS challenge, however, whether this is affected by SFN cannot 
be deduced from this work228. This could be further clarified by the use of specifically tagging different 
leukocyte subsets with different fluorescent markers.    
Functional effects of SFN on human neutrophil cytokine production 
The aim of the in vitro work using the human neutrophils was to investigate whether SFN could 
specifically alter neutrophil functional responses to SFN. Although the assay did show that LPS 
stimulated the release of IL-1β when present in the cell culture medium, pre-exposure of SFN across 
a range of doses did not seem to affect this IL-1β release (Figure 4.8). This indicated that SFN was not 
capable of affecting the functional response of neutrophils to LPS in this given protocol. 
 
Possible reasons for this lack of effect may be due an insufficient pre exposure to SFN prior to 
treatment with LPS meaning an inability to upregulate sufficient anti-inflammatory mechanisms. 
Previously, it has been shown in other cell types that maximal phase II detoxification enzyme mRNA 
was upregulated at 12-24hr, with peak protein expression ranging from 24-48hr post exposure to 
SFN29. Therefore, if these enzymes need to be present and upregulated before the neutrophils are 
exposed to an inflammatory stimulus this may be a reason for the lack of effect of SFN seen in this 
study.  
 
Conversely, other research have found that SFN afforded protection against LPS in other cell types 
when co-applied with an LPS challenge when measuring a range of inflammatory cytokine mRNA and 
transcription factor expression30. Differences may be due to time at which the samples were taken or 
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potentially that particular cell population’s exhibit different responses or time courses in their 
response to SFN or LPS. 
 
This treatment protocol was chosen as it was found that with longer periods of ex vivo cell culturing 
leukocytes appeared to develop an apoptotic phenotype71. Therefore, in order to minimise activation 
caused purely by keeping the neutrophils ex vivo for a prolonged time frame, a treatment protocol of 
4hr pre-exposure to SFN followed by 14hr LPS treatment was chosen. It was thought that this provided 
the optimal experimental design to pre expose the neutrophils to SFN and then induce an adequate 
inflammatory stimulus with LPS (as taken from previous work within the group). 
 
Another potential reason for the lack of effect may be due to use of corn oil in the SFN vehicle, and 
the fact that this did not adequately mix within the cell culture medium. This may have led to 
inadequate exposure of the cells to SFN, and therefore, a lack of subsequent Nrf2 induction. This 
vehicle was used to avoid the necessity of exposing the cells to DMSO following the negative effect 
we saw when this was used in platelet experiments. Modification of this aspect of the protocol may 
shed further light of potential effects of SFN. 
 
Summary 
The work in this section highlights the ability of SFN to alter leukocyte-endothelial interactions 
following a systemic inflammatory response (initiated by LPS administration). LPS induced significant 
leukocyte-endothelial interactions which were concomitant with increased circulation neutrophils 
following exposure to LPS. Peripheral cytokine sampling highlighted the marked released of several 
pro-inflammatory cytokines associated with LPS which further supports the inflammatory response 
seen in the cortical microvasculature. A dose dependent effect of SFN treatment highlighted its ability 
to alter these leukocyte-endothelial interactions within the brain, with a potentially explanation being  
alteration in expression of adhesion molecules such as ICAM1 or the β2 integrins; this suggestion 
would support the trend towards fewer adhesive cells following SFN (50mg/kg) and LPS treatment but 
a maintenance of elevated numbers of cells rolling through the microvasculature and no significant 
alteration in the number of cells circulating within the blood, with the exception of the lymphocyte 
difference seen between the SFN (50mg/kg) treated animals. 
 
Further investigation into the underlying cell signalling events mediating these effects are needed to 
delineate how SFN is modulating these interactions. In particular, gaining a more detailed time course 
of Nrf2 translocation would aid understanding of the temporal dynamics of this transcription factor 
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induced by SFN and alongside this, a more detailed temporal cytokine profile would highlight the 
kinetics of cytokine production and the effect of SFN on these. The effect of SFN on cytokine receptors 
may also be of interest in defining how SFN alters cellular responses to inflammatory stimuli.  
 
Additional experiments will also enable clarification of how SFN is mediating the shift seen in Figure 
4.4 (adhesive to rolling phenotype). The use of monoclonal antibodies to ICAM1 or knockout mice 
would elucidate whether these effects of SFN on the number of adherent cells was ICAM1 dependent, 
and whether removing this adhesion molecule abolishes any effects of SFN. It would also be of interest 
to investigate whether this LPS response is associated with migration of leukocytes into the brain 
parenchyma and whether SFN alters this. A simple MPO assay could highlight the presence of reactive 
neutrophils across the treatment groups and highlight where this shift from cell adhesion to rolling 
was supported by decreased neutrophil reactivity within the brain. The use of specific fluorescently 
labelled antibodies to different leukocyte cell populations would also be of interest to delineate 
whether any of the alterations in cellular interactions following SFN treatment was driven by particular 
leukocyte subsets.  
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Chapter 5: 
INVESTIGATION INTO THE EFFECT OF SFN ON 
PLATELET FUNCTION 
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5.1. Outline 
Owing to the increasing knowledge of the role that platelets play during inflammation including:  
- the  ability to promote both homo- and heterotypic interaction of leukocytes and endothelial cells 
- the fact that these cellular interactions support inflammatory function and migration of leukocytes 
and platelets into inflamed tissues   
- the finding that the presence of both of these cell types with in tissues both cell types can promote 
inflammation through the release of inflammatory mediators, 
made investigation into the effects of SFN specifically on platelets an interesting and novel area of 
investigation.  
 
Furthermore, at the outset of these experiments the specific effects of SFN on platelet function was 
not something that had been previously reported. Since it had been highlighted in the previous 
Chapter that SFN altered leukocyte-endothelial interactions stimulated in the LPS model, but that at 
the time points investigated there was no associated effect on cytokine production, Nrf2 expression 
or a functional effect on neutrophil using in vitro protocol, there was potential that SFN’s effects may 
in part be explained by a platelet dependent function providing an exciting experimental question.  
 
In support of conducting experiments to investigate the effect of SFN on platelet physiology in these 
experiments, it is the current dogma that the mainstay of SFN’s effects involves the binding to key 
cysteine residues within its protein targets. It has previously been found that compounds capable of 
interacting with these groups are able to alter platelet physiology260.  Hence, the aim of the work in 
this Chapter was to investigate what effect the presence of SFN would have on platelet responses. 
 
Light transmission aggregometry was used to investigate how the presence of SFN altered platelet 
aggregatory responses to several physiological platelet agonists, and provide evidence as to whether 
SFN could specifically alter platelet functional. Fura-2 loaded platelets were used to investigate 
whether these effects were associated with intraplatelet calcium movement. Lactate dehydrogenase 
(LDH) release was measured as a marker of cell membrane integrity and the potential of cytotoxicity 
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5.2. Results 
Investigation into dose related effects of SFN on isolated platelets 
As a preliminary study, it was of interest to investigate whether SFN alone had any effect on platelet 
function. In order to do this, platelets were isolated, washed and resuspended in THB. The effects of 
the addition of SFN were then compared to that of a known classic platelet agonist, thrombin. 
Thrombin is a serine protease that acts to on both PAR1 and PAR4 to cleave the receptor leading to 
activation of platelet aggregation116,261. This experiment allowed the aggregatory ability of the platelet 
isolates to be checked and subsequently visualise the effect of SFN to stimulate any aggregatory 
response. As Figure 5.1 highlights, addition of thrombin (0.1U/ml) was associated with a robust 
aggregatory response. A dose of 0.1U/ml Thrombin was chosen from previous work showing its 
consistent ability to induce a robust platelet aggregatory response across a sample of donors262.  
Furthermore, addition of SFN over a range of doses so not associated with stimulation of platelet 
aggregation, suggesting that SFN does not act as a platelet aggregation agonist within these 
parameters.  
































Figure 5.1: Treatment with a range of doses of SFN does not induce platelet aggregation. 
Isolated platelets were washed and resuspended in THB at 250x103/µl. Platelets were added to 
cuvettes under constant stirring conditions (12000rpm) and the effects of SFN addition were 
compared to aggregation induced by thrombin (0.1U/ml) using area under the curve. All 
aggregations were run for 3min following addition of test compound. Data expressed as mean area 
under the curve ± SEM. *P<0.05 compared with thrombin treated group using ANOVA with Dunnets 
post hoc test. n=3-5 donors/group 
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Investigation into dose related effects of pre-incubations with SFN on isolated platelets to classic 
platelet agonists – thrombin, ADP and collagen 
Next, investigation into whether the presence of SFN would either potentiate or inhibit the effect of 
subsequent agonist addition was undertaken. In these experiments platelets were incubated with SFN 
for either 2 or 30min followed by addition of a submaximal dose of agonist addition. Firstly, the effect 
of SFN pre-treatment on platelet responses to thrombin was investigated. Platelet aggregatory 
responses following a 2min incubation period with SFN prior to thrombin addition showed no effect, 
either potentiation or inhibition, on aggregatory responses to thrombin (Figure 5.2a). However, 
following a 30min incubation period with SFN, 100µM inhibited platelet aggregation (Figure 5.2b).  
 
Two further platelet agonist (ADP and collagen) responses were also compared in the presence of SFN 
pre-incubation. Both ADP and collagen are weaker platelet aggregation agonists compared to 
thrombin, and therefore, may allow further effects of SFN to be seen. Collagen is present within the 
damaged vasculature as observed in atherosclerosis, and ADP is released by damaged cells and 
platelet dense granules105,137. Using both these agonists, it was clear that there were trends present 
towards an inhibition of platelet aggregation (Figure 6.3-4). Using ADP in PRP, SFN pre-incubations at 
both 2 and 30min showed a dose dependent trend towards inhibition of platelet aggregation, with 
significance seen at 100µM SFN with 2min preincubation (Figure 5.3a).  
 
Aggregations carried out with collagen highlighted the most potent inhibition of platelet aggregation 
following SFN pre-incubations. Both 2 and 30min incubations with SFN caused a dose dependent 
inhibition of platelet aggregation (Figure 5.4). Inhibition was most marked following 30min incubation 
periods with 40-100µM SFN significantly inhibiting aggregations. Significant inhibition was also seen 
at 60-100µM SFN following 2min incubation periods. 
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Figure 5.2: Pre-treatment with SFN induces dose and time dependent changes in the 
aggregation stimulated by thrombin. Isolated platelets were washed and resuspended in THB at 
250x103/µl. Platelets were added to cuvettes under constant stirring conditions (12000rpm) and 
aggregation stimulated by thrombin (0.1U/ml) were compared to that stimulated by thrombin 
induced aggregations in platelets pre-incubated with SFN/THB (30min). A) 2min vs. B) 30min 
incubations. All aggregations were run for 3min following addition of test compound Data expressed 
as mean area under the curve ± SEM. *P<0.05 compared with thrombin treated group using  ANOVA 
with Dunnets post hoc test. n=5 donors/group 
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Figure 5.3: Pre-treatment with SFN induces dose and time dependent changes in the 
aggregation stimulated by ADP. PRP was isolated from whole blood. PRP was added to cuvettes 
under constant stirring conditions (12000rpm) and aggregation stimulated by ADP (1.56µM) were 
compared to that stimulated by ADP induced aggregations in platelets pre-incubated with SFN/THB 
(30min). A) 2min vs. B) 30min incubations. All aggregations were run for 3min following addition of 
test compound Data expressed as mean area under the curve ± SEM. *P<0.05 compared with ADP 
treated group using  ANOVA with Dunnets post hoc test. n=3-5 donors/group 
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Figure 5.4: Pre-treatment with SFN induces dose and time dependent changes in the 
aggregation stimulated by collagen. Isolated platelets were washed and resuspended in THB at 
250x103/µl. Platelets were added to cuvettes under constant stirring conditions (12000rpm) and 
aggregation stimulated by collagen (2.5µg/ml) were compared to that stimulated by collagen induced 
aggregations in platelets pre-incubated with SFN/THB (30min). A) 2min vs. B) 30min incubations. All 
aggregations were run for 3min following addition of test compound Data expressed as mean area 
under the curve ± SEM. *P<0.05 compared with collagen treated group using  ANOVA with Dunnets 
post hoc test. n=3-5 donors/group 
 
Page | 115  
 
Investigation into intraplatelet calcium movement following platelet exposure to SFN and 
associated LDH release 
To investigate whether these anti-aggregatory effects are associated with any intracellular cell 
signalling events, platelets were loaded with Fura-AM fluorescent dye and fluorescence was measured 
(Figure 5.5). Thrombin (0.1U/ml) induced a rapid and marked increase in fluorescence, suggesting 
activation of intracellular cell signalling pathways and therefore, release of Ca2+ stores. However, 
neither addition of SFN or its vehicle THB, induced any alteration in fluorescence indicating that there 
was no release of intracellular Ca2+ stores indicative of a lack of intracellular signalling stimulation via 
SFN.  
 
In order to examine whether SFN incubation is associated with any alterations in cell viability, a lactate 
dehydrogenase (LDH) assay was performed in order to measure any alterations in cell membrane 
viability (Figure 5.6). Following a 30min incubation period with SFN, LDH release was measured and 
compared to platelets that had been fully lysed in order to release their total LDH. Neither agonist 
addition; thrombin and ADP, nor a wide range of SFN doses were associated with LDH release when 
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Figure 5.5: SFN treatment is not associated with alterations in resting intracellular Ca2+ 
release. Isolated platelets were washed and resuspended in THB at 250x103/µl, loaded with Fura2AM 
and allowed to equilibrate for 30min in the dark at 37oC. Platelet Ca2+ movement was measured as an 
alteration in light emission (340/380nm) in response to addition of classic agonist thrombin (0.1U/ml), 
SFN at (100µM) or vehicle treatment. Cuvettes were under constant stirring conditions (12000rpm). 
Graph shows representative trace from n=3 donors 





































Figure 5.6: SFN treatment is not associated with alterations in LDH release following a 
30min incubation period. Isolated platelets were washed and resuspended in THB at 50x103/µl, 
and incubated with SFN over various doses for 30min. Data expressed as a mean percentage of LDH 
released stimulated by complete cell lysis ± SEM. *P<0.05 compared with collagen treated group using 
ANOVA with Dunnets post hoc test. n=3 donors/group 
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Investigation into the effects of SFN like ABPs on isolated platelets and following pre-incubation 
periods prior to thrombin induced platelet aggregation 
Following the inhibition of platelet aggregation seen following SFN pre-incubations above, we went 
on to conduct the aggregations with several activity based probes (ABP) (Figure 5.7). These 
compounds are SFN ‘like’ molecules that have undergone functional alterations to their 
isothiocyanate group. These modifications mean that unlike SFN, the ABP’s have a higher binding 
affinity than SFN and therefore bind targets in a more permanent manner. The aim of using these 
molecules was to dissect the target molecules within the platelets that SFN was binding to. In order 
to test whether these compounds had similar effects to SFN on the ability to inhibit platelet 
aggregation, they were also run through the light transmission aggregometry protocol as described in 
Section 2.5. As was seen with SFN, addition of all ABP compounds and their vehicle to aliquoted 
platelet cuvettes did not stimulate platelet aggregation when monitored over a 3min period (Figure 
5.8). Following a 30min incubation period at 100µM all of the compounds showed a trend to inhibition 
of platelet aggregation stimulated by thrombin (0.1U/ml) which was significant in both ABP1 and 
ABP2. When the dose of SFN was lowered to 10µM this inhibition of platelet aggregation to thrombin 
(0.1U/ml) was no longer present (Figure 5.9).   
  




Figure 5.7: Chemical structure of SFN and SFN like ABP compounds. SFN and SFN like ABP 
compounds showing various additional alkyne groups in pink to allow subsequent use of Click 
chemistry to isolate protein targets that the compounds have bound. (Clulow et al, unpublished) 
  






































Figure 5.8: Treatment with a range of ABP compounds does not stimulate aggregation. 
Isolated platelets were washed and resuspended in THB at 250x103/µl. Platelets were added to 
cuvettes under constant stirring conditions (12000rpm) and the effects of ABP (100µM) compound 
addition were compared to aggregation induced by thrombin (0.1U/ml) using area under the curve. 
ABP vehicle contained (0.4% DMSO; final in cuvette). All aggregations were run for 3min following 
addition of test compound. Data expressed as aggregation as a percentage of that stimulated by 
thrombin control ± SEM. *P<0.05 compared with thrombin treated group using ANOVA with Dunnets 
post hoc test. n=3-5 donors/group 
 
  






































































Figure 5.9: Treatment with a range of ABP compounds inhibits platelet aggregation 
induced by thrombin. Isolated platelets were washed and resuspended in THB at 250x103/µl. 
Platelets were incubated with ABP compounds A) 100µM or B)10µM for 30min, then added to 
cuvettes under constant stirring conditions (12000rpm) and stimulated with thrombin (0.1U/ml). ABP 
vehicle contained (0.4% DMSO; final in cuvette). All aggregations were run for 3min following addition 
of test compound. Data expressed as aggregation as a percentage of that stimulated by thrombin 
control ± SEM. *P<0.05 compared with thrombin treated group using ANOVA with Dunnets post hoc 
test. A (n=2-3 donors/group) B (3-5 donors/group) 
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5.3. Discussion 
The aim of the work in this chapter sought to investigate the effects of SFN on platelet function. Since 
the IVM work using the model of endotoxaemia presented in chapter 4 had highlighted the ability of 
SFN to alter leukocyte-endothelial interactions, there was a possibility that this could also involve 
modulation of platelet function. Previous work in several inflammatory models has shown a 
contributory role of platelets in the development and progression of inflammatory pathology, and the 
effect of SFN on platelet function was not something that had been specifically reported124,128. 
Furthermore, it is known that platelet activation underlies the pathology associated with sepsis 
whereby patients are seen to have disseminated intravascular coagulation (DIC) and altered 
haemostatic factors263. Additionally, it is known that platelets express TLR4, and that presence of LPS 
can thereby alter their aggregatory and thrombotic platelet function246,249,264,265.  As a result, the work 
in this Chapter represented an exciting novel avenue of research into SFN’s physiological effects. 
 
Light transmission aggregometry provided an ideal starting point to study SFN’s effects on isolated 
platelets. Use of this technique allowed investigation into whether the presence of SFN could directly 
affect platelet function in response to various aggregatory stimuli. Thrombin, collagen and ADP were 
used as platelet agonists; use of these three different agonists allowed investigation into the effects 
of SFN following platelet stimulation at distinct receptors (which in turn activate diverse platelet 
signalling pathways) to be explored. Furthermore, each of these agonists may be encountered 
physiologically in either stroke or sepsis making them relevant to this body of work.  
 
Thrombin is a classic platelet agonist known to act via cleavage of the PAR1 and PAR4 receptors. 
Signalling through these receptors activates the platelets to undergo shape change and subsequently 
aggregate together. Under normal wound healing physiology, a local increase in the presence of 
thrombin activates platelets that are adhering to exposed collagen at the vessel wall. Release of 
platelet intracellular granules amplifies platelet recruitment, and thrombin is further involved in the 
stabilisation of the platelet plug via its role in fibrinolysis and consequent thrombus stabilisation. 
Aggregations to thrombin conducted here showed that a pre-incubation period of 30min, but not 
2min, was associated with a modest inhibition of platelet aggregation. This suggested that SFN must 
in some way be altering the way in which platelets were able to respond to the presence of thrombin, 
either potentially at the receptor level, or via alteration of the intracellular downstream signalling 
cascades associated with PAR1 and/or PAR4. This will be discussed subsequently. These experiments 
were then conducted in response to addition of collagen and ADP. 
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Collagen is of particular pertinence to thrombotic risk since it is exposed following damage to the 
vascular wall as may be seen following injury or via rupture of an atherosclerotic plaque, and is non to 
be a risk for subsequent onset of ischaemic stroke266,267. It activates platelet responses via the GPVI 
receptor and also via interactions with the integrin α2β1. Collagen aggregations appeared to be most 
sensitive to exposure to SFN following both 2 and 30 min pre-incubation periods. Aggregation curves 
appeared to show that SFN delayed the onset and time taken for platelet shape change to occur and 
also slowed the onset of the overall aggregatory response. The working hypothesis is that this may be 
via SFN’s ability to interact with and adduct to cysteine residues in protein key to the signalling cascade 
associated with collagen induced platelet aggregation. These ideas are expanded below.   
 
Finally, ADP activates platelet responses via the purinergic receptors, P2Y12 and P2Y1. It is though that 
P2Y1 is predominantly involved in the initial shape change associated with platelet activation, whereas, 
P2Y12 receptor underlies the subsequent onset of the aggregatory response 268. ADP as a platelet 
agonist is of interest since it is known to be released via damaged cells and could therefore affect 
platelet activity within their vicinity, and furthermore, it is also released by activated platelets 
following exposure to other agonists such as thrombin and collagen. ADP induced aggregations 
showed a trend towards inhibition by SFN exposure following both 2 and 30min pre-incubations with 
100µM SFN reaching statistical significance at 2min. Again, the presence of cysteines within the 
purinergic receptors may provide a rationale for these inhibitory effects, and is discussed below269.  
 
After seeing these inhibitory effects associated with SFN pre-incubation to all of the agonists tested, 
lactate dehydrogenase release (LDH) in platelets incubated with a range of SFN concentrations was 
tested. LDH release as a measure of cell membrane integrity was used as it provided a rapid and 
sensitive indicator which could be reproducibly performed, and did not necessitate prolonged 
incubation periods with the platelets which may have itself affected results. The doses of SFN used in 
these platelet aggregations caused no greater LDH release than that associated with either vehicle 
treatment or platelets incubated alone. This suggested that the effects were unlikely to be due to 
disruption of cell membrane integrity causing a reduction in the platelets ability to respond to stimuli. 
 
It was then of interest to investigate whether during this pre-incubation period with SFN there was an 
induction of platelet signalling pathways that were causing these protective effects. Using Fura-2 
loaded platelets, it was apparent that addition of SFN to the platelet suspensions did not release 
intracellular Ca2+ stores following addition of SFN, and was therefore unlikely to be having its effects 
via activating signalling pathways. For this reason, the current hypothesis is that the effects observed 
Page | 123  
 
here are likely to be associated with alteration of platelet thiols that are involved in the initiation of 
platelet signalling cascades to various agonists. 
 
This hypothesis is postulated based on the known evidence both of how SFN effects the interactions 
between KEAP1 and Nrf2, and previous thiol modulating agents have affected platelet function.  
 
The current dogma is that SFN binds key cysteine residues within KEAP1, leading to a change in its 
confirmation and subsequent release of Nrf2. KEAP1 is known to harbour an unusually high level of 
cysteines within its structure, highlighting its role as a cellular oxidative sensor and ability to be rapidly 
reduced13. SFN has been shown to bind many of these cysteines located throughout its structure270. It 
is still to be clarified how binding to different cysteines is physiologically relevant and may specifically 
alter interactions. In any case, the promiscuous binding of SFN to thiols therefore represents a 
plausible hypothesis for SFN’s effects seen here. Furthermore, binding to these residues would also 
occur in the absence of cell signalling induction.   
 
The role of surface thiols on platelets is also beginning to become better understood and of functional 
relevance.  Vicinal thiols are free sulfhydryl groups which are found in close proximity to one another 
under normal physiological conditions. Their ability to interchange between dithiols and disulphide 
bonds appears to represents a form of functional control. Inhibiting these molecular conversions has 
been shown to affect platelet activation214,215. Likewise, alterations in free thiols have been shown to 
be important to several integrins (α1β2, α5β1, αIIbβ3) involved in platelet adhesion and that enzymes 
involved in this exchange are important for platelet function271-273. This theory also supports the 
marked inhibited demonstrated in aggregations to collagen following incubation with SFN, since the 
main collagen receptor GPVI has been shown to contain a free –SH group in its cytoplasmic tail which 
is necessary for the homodimerisation of the two immunoglobulin domains in order to create a 
functional GPVI receptor274. If SFN was capable of binding to this thiol group, it may be able to inhibit 
successful GPVI dimerization and therefore inhibiting signal transduction at this receptor supporting 
the inhibition of collagen induced platelet aggregation seen here. 
 
Therefore, if SFN were to be binding or interacting with some of these key cysteine containing 
proteins, it could support the inhibitory effects that are seen herein. It was for this reason that the 
work involving the ABP compounds was initiated. Firstly, similar aggregometry studies using pre-
incubations were conducted to investigate whether the ABP compounds would have a similar effect 
on the platelets ability to aggregate. In all instances, results showed that the ABP compounds caused 
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an inhibition of the platelet aggregation. It is also clear that these inhibitions appeared to be different 
both between the ABP compounds and SFN, and also between the individual ABP compounds tested.  
This result was in part expected since the primary purpose of using this compounds was their ability 
to bind their protein targets in a permanent manner through their ability to form ‘relatively stable’ 
thiocarbamate bonds, whereas, SFN is known to bind in a reversible manner forming dithiocarbamate 
bonds which are kinetically labile275. The fact that there appeared to be marked differences between 
the ABP compounds’ ability to inhibit the platelet aggregation to thrombin may be due to their 
differences in the strength of the bonds they form and proteins targeted. Indeed, taking into account 
previous work investigating ABP1, the data supports the finding that ABP1 causes the greatest 
inhibition since it has previously been shown to have the greatest potency in a cancer cell line, 
potentially indicating it as the compound with the greatest ability to bind its targets (Clulow, 
unpublished work). 
 
Ongoing work with platelets and these compounds aims to further decipher the proteins targeted by 
these compounds to shed further light on the potential protein targets of SFN within platelets. 
Furthermore, previous studies looking into the effects of compounds that inhibit platelet activation 
through interactions with protein thiols have shown the reversibility of these effects through 
incubation periods followed by removal of these agents; this protocol reversed the inhibitory effects 
seen272. Conducting experiments such as these may also shed further light on the potential of SFN 
having these effects through thiol interactions. 
 
Inhibition of receptor function occurring downstream of SFN binding key extracellular cysteine has 
been indicated at other receptors in different cell types. TLR4 receptors isolated from monocytic cells 
exposed to SFN prior to LPS challenge had SFN adducts at specific extracellular receptor cysteine 
residues243. Further, effects of SFN extended to a decrease in key downstream signalling effectors, 
such as NFκB and COX2243. Furthermore, this effect was reversed when either dithiolthreitol or N-
acetyl-L-cysteine, two thiol donors, were present indicating the reversible and thiol dependent nature 
of the inhibition243. This could support the effects seen here, especially since the most marked effects 
were seen in the collagen induced aggregations and the α2β1 integrin involved in collagen activation 
of platelets has been seen to contain several free thiols which may provide the potential sites for SFN 
adduction. Indeed, it has been speculated that these thiol residues are necessary for the adhesion 
stimulated by the presence of collagen276. Molecular alterations in these sulfhydryl groups occur when 
platelets interact with collagen via the α2β1 integrin, and therefore, it is possible that compounds that 
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effect the ability of this receptor to alter its binding affinity will therefore effect its ability to 
subsequently respond to the presence of collagen273.  
 
The role of thiol interactions has also been indicated to be of significance in the P2Y12 receptor, indeed 
it has been highlighted as a potential mode of action associated with the inhibition of platelet activity 
associated with clopidogrel. These effects seem to be specific to the P2Y12 receptor and are dependent 
of the expression of two cysteine residues that form a disulphide bond269. 
 
Other avenues of interest to explore with this work would be investigation into intracellular effects 
that SFN may be having on platelets. Several recent papers have highlighted the potential of SFN to 
alter thrombotic responses and several key intracellular signalling proteins using both animal models 
and in vitro experiments. As shown in work within this project Jayakumar et al, found that SFN pre-
incubations were associated with a decrease in aggregatory reactivity of platelets in response to 
collagen, which also resulted in a decrease in Ca2+ release202. Similarly, Oh et al, found responses in 
line with work conducted here in that SFN pre-incubations inhibited responses to collagen, ADP and 
thrombin aggregations, and that these inhibitory effects were most marked in collagen stimulated 
aggregations203. Likewise, Chuang et al, found dose dependent inhibitory effects following SFN pre-
incubations following stimulation of platelet aggregation following stimulation at various receptors36. 
However, some discrepancy has been shown in that Jayakumar et al, did not find inhibitory effects of 
SFN using thrombin as a platelet aggregation agonist; ADP induced aggregations were not 
investigated. This may be due to differences in vehicle or agonist doses used. Preliminary work for this 
project using DMSO as a vehicle appeared to mask the more subtle responses seen in ADP and 
thrombin induced responses, and other work in the group has previously found the solvent to be 
associated with cytotoxicity. Investigation into key cellular signalling pathways showed that the 
presence of SFN altered phosphorylation of PLC, PKC, MAP kinases and Akt, as well as decreasing OH• 
formation and increasing cAMP202. Other effects of SFN downstream of inhibiting collagen induced 
aggregation include decreased thromboxane synthesis, reduced ROS production and decreased ATP 
release36,202. 
 
To investigate whether the in vitro effects presented here are relevant at a whole system level 
preliminary work using a light/dye model of thrombosis is being used in some preliminary experiments 
order to investigate the effects of SFN on thrombotic responses within the cerebral microcirculation. 
This work is on-going nevertheless, the early results are presented in appendix I. 
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5.4.Summary 
Taken as a whole the work presented in this Chapter 5, alongside that recently published in the cited 
papers within, highlights the anti-aggregatory effects following pre-treatment with SFN. SFN did not 
directly stimulate any platelet aggregatory responses but was able to alter platelet responses to three 
key biological platelet agonists. The exact mode of action is unclear, but from the work presented it 
does not appear to be associated with an active cell signalling response. Additional studies are 
required to determine the exact molecular interactions by which SFN is inducing these changes. Work 
with the ABP compounds found that they too were able to alter platelet aggregatory responses. 
Further work with these ABP compounds will help to expose potential protein targets to which SFN 
may be binding within the platelets, with the hope being that this may shed light on the in vitro 
inhibition associated with SFN seen here. Equally, conducting some of the above aggregations in the 
presence of thiol donors such as N-acetylcysteine and dithiothreitol would be beneficial in order to 
elucidate if the anti-aggregatory effects seen here occur in a thiol dependent manner.  
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Chapter 6 
CONCLUDING SUMMARY AND FUTURE WORK 
  
Page | 128  
 
6.1. Overall summary 
As research into cerebrovascular diseases continues, the presence of inflammation underlying these 
pathologies appears increasingly apparent, both within the CNS and the peripheral circulation137,277. 
Central to this ongoing inflammation is the presence of leukocyte-endothelial interactions via 
adhesion molecule expression, and release of bioactive molecules such as cytokines and ROS from the 
cells involved1. At the outset of this project, the aim of this body of work was to investigate how SFN 
would alter cellular interactions induced by inflammation within the cerebral microvasculature.  
 
In order to study these cellular interactions an appropriate model with which to induced leukocyte-
endothelial interactions within the brain was required, along with a suitable technology with which to 
visualise these interactions. At the outset of this project the hope was that this model would be based 
around the cerebral inflammation induced my ischaemia-reperfusion injury downstream of middle 
cerebral artery occlusion. This would have provided an ideal pre-clinical model with which to 
investigate the ability of SFN to alter the leukocyte-endothelial interactions induced by IRI and as well 
as other pathological markers associated with ischaemic stroke. However, owing to the difficulties 
outlined in Chapter 3, the use of this model was not ethically just or scientifically satisfactory. 
Therefore, a second model was investigated. This model involved peripheral injection of LPS and was 
found to induce robust and reproducible leukocyte-endothelial interactions. One of the strengths of 
this model was that it provide reproducible data in order to study the leukocyte-endothelial 
interactions induced in the brain following an inflammatory stimulus as outlined in the initial aims.  
 
As presented in Chapter 3, these interactions appeared to be time, but not dose, dependent. 
Therefore, to allow comparison to be made between results gained here, and a body of work 
published in the literature, it was decided that LPS injection at 0.5mg/kg at a 4hr time point 
represented the most useful experimental data with which to gain novel findings on the effects of SFN 
on inflammatory cell interactions and compare these with current knowledge of these inflammatory 
interactions with in the brain. 
 
Using this experimental protocol, it was found that a peripheral challenge with LPS caused an increase 
in the amount of leukocytes interacting with the blood brain barrier within cortical pial venules. 
Following treatment with LPS, leukocytes were seen to slowly roll along the venular endothelium with 
a concomitant increase in the number of cells that were becoming adherent. This leukocyte behaviour 
was specific to animals treated with LPS suggesting that peripheral stimulation of leukocytes via an 
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LPS challenge was sufficient to alter the way in which these cells acted within the microvasculature of 
the brain.  
 
IVM provided a sensitive imaging modality with which to be able to observe these individual cellular 
interactions and subsequently allow offline analysis of the number of rolling cells, their velocity and 
the number of cells that were adherent to the vessel wall. Hence, this model provided the ability to 
study how SFN could alter the intravascular interactions of leukocytes and endothelial associated with 
inflammation. One downfall of this analysis was that it did not allow leukocytes to be followed 
extravascularly. The ability to do this with more power IVM technology could help to present a further 
parameter of the inflammatory response, and also, more information on whether SFN effects these 
later stages of inflammatory cell migration should any be seen.     
 
In order to study any effects SFN may have it was necessary to find a suitable dosing regime and vehicle 
for the i.p. administration of SFN. Following a literature review it was deemed that an appropriate 
starting treatment protocol with SFN would involve 24hr pre-treatment with SFN prior to LPS, in order 
to elevate several phase II detoxification enzymes that had previously been associated with the anti-
inflammatory effects of SFN prior to LPS challenge22,25,28. Due to the fact that the effects to be studied 
were of an inflammatory nature, it was attractive to use saline as a vehicle for SFN as this had 
previously been used for SFN with positive anti-inflammatory effects shown and is widely considered 
not to affect normal physiological responses40. However, in the early experiments that were 
conducted there appeared to be little indication of an anti-inflammatory effect associated with SFN 
(in saline) pre-treatment across a range of doses. As this appeared at odds with a body of published 
literature, mass spectrometry was used to investigate whether SFN was stable in a saline vehicle. 
Spectra produced indicated the presence of several breakdown products with SFN in a saline vehicle 
and therefore, spectra where repeated in corn oil and corn oil/PBS (10%) as alternative vehicles that 
had also been previously published25,259. Spectra produced with SFN in either corn oil or SFN produced 
indicated much cleaner products indicating fewer breakdown products and greater stability. For this 
reason, corn oil/PBS was taken forward in order to provide greater stability but minimal corn oil 
administration due to the potential for it to interfere with potential inflammatory outcomes278,279. It 
was reasonable to expect that the lack of effect seen with SFN dissolved in a saline vehicle may have 
been owing to its breakdown, and therefore, experiments were re-run using SFN dissolved in corn 
oil/PBS. A more in-depth understanding of the chemistry of SFN’s isothiocyanate may have helped to 
avoid this downfall, but as previous groups had shown positive effects with SFN in a saline vehicle, the 
use of SFN in this vehicle was appealing.  
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Firstly, visualisation of the effect of pre-treatment with this new vehicle was tested to ensure that it 
did not affect the parameters being measured (as there are many groups investigating the effect of 
dietary oils and their constituent omega fatty acids on physiological responses278,280,281). As leukocyte-
endothelial interactions did not appear to be effected via the presence of corn oil, the ability of SFN 
pre-treatment in this vehicle was investigated. The current data suggests that SFN was able to alter 
the leukocyte-endothelial interactions associated with peripheral LPS exposure. Put in the most 
simplistic terms, when using IVM to investigate a potential anti-inflammatory agent, one may expect 
an agent to decrease all parameters of the leukocyte-endothelial interactions highlighted in Figure 1.3  
- the thought being that decreasing these interactions would highlight a decreased inflammatory 
environment and therefore protect the visualised tissue from damage associated with the noxious 
inflammatory environment.  
 
The hypothesis for Chapter 4 was that pre-treatment with SFN would induce Nrf2 regulated anti-
inflammatory enzymes, protect the vasculature from inflammatory challenges thereby leading to a 
decreased in the leukocyte-endothelial interactions that were visualised. Indeed, the data presented 
in Chapter 4 suggests that SFN decreases the number of adherent cells; however, this was not 
associated with a concomitant decrease in the number of rolling cells. This is intriguing as it could 
suggest that SFN has altered the phenotype of the BBB endothelium, the leukocyte, an intermediary 
cell (such as platelet) or a combination of all of these to change the interactions that were visualised 
using IVM. One explanation could be that SFN has altered the ability of either leukocytes or endothelial 
cells to upregulate or increase the affinity of their adhesion molecules associated with firm adhesion, 
such as the β2 integrins or ICAM1 respectively. Previous work has shown that SFN and other 
phytochemical pre-treatment of monocytes was able to alter their inflammatory adhesion molecule 
expression, and therefore adhesion; hence the potential for a similar effect in vivo on other leukocyte 
cell types may be possible242,282. This would support the finding of decreased adhesion, and mean that 
these previously adherent cells could still present but only be supported by the weaker interaction 
associated with the selectins consequently, leading to the increase in the number of cells rolling 
through the pial vessels. In future work, it would be interesting to investigate how these interactions 
and the effects of SFN would be affected in the absence of the β2 integrins or ICAM-1 to further 
elucidate whether these adhesions molecules were indeed a mechanism of action for the altered 
leukocyte-endothelial interactions seen here. This would help to elucidate whether this decrease in 
adhesion and shift towards increased numbers of rolling cells following SFN treatment was due to 
altered adhesion molecule physiology.  
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It would also be of interest to see whether this decrease in adhesion was teamed with a decrease in 
neutrophil presence within the brain parenchymal tissue. As investigation into leukocyte emigration 
was not possible here, the potential to use a simple MPO assay as a marker of the presence of 
activated neutrophils may be interesting, as well as the use of immunohistochemistry to detect and 
compare the presence of intracerebral leukocytes between treatment groups. 
 
This effect seen on the leukocyte-endothelial interactions using IVM were not associated with 
alterations in cytokine profiles or Nrf2 nuclear expression taken from terminal samples. The data 
presented in Figure 4.5 failed to show any difference between cellular localisation of Nrf2 in any 
treatment, investigation into Nrf2 localisation at further time points would help to clarify whether 
alterations in this transcription factor varied over a broader temporal profile. This would help to 
determine whether the effects seen here where dependent or independent of Nrf2 transcription 
factor. This could also be supported by investigation into the expression of proteins of the glutathione 
system and HO-1 as a marker of phase II detoxification enzyme stimulation. In combination, these 
experiments may help to delineate a mechanism of action associated with the altered leukocyte-
endothelial interactions presented here; as the cellular pathways underlying the effects presented in 
this thesis are not currently known. 
 
Neither using blood samples from animals or LPS challenge of human neutrophils suggested that SFN 
was capable of functionally altering cytokine production downstream of SFN and LPS treatment. Again 
this could due to the time point chosen and would benefit from further sampling at multiple time 
points. Also, the use of a vehicle with greater solubility would help to resolve potential issues faced 
with the in vitro corn oil treatment of human neutrophils. In the animal model however, it is possible 
that even though the cells in SFN treated animals seem to have shifted from an adherent to a rolling 
phenotype they still maintain the same functional capacity to produce cytokines.; ex vivo testing of 
isolated cells may shed further light on this.  
 
To draw on the work presented in Chapter 5 highlighting the ability of SFN to alter platelet 
physiological responses, there is potential that SFN may alter leukocyte-platelet interactions thereby 
having a downstream effect on the ability of leukocytes to adhere to the inflamed BBB. Indeed, using 
several platelet agonists, pre-treatment with SFN decreased the ability of the platelets to respond to 
stimuli highlighting the ability of SFN to alter the platelets function. This work was of real interest since 
little work investigating the effect of SFN on platelet physiology had previously been published. The 
fact that SFN affected platelet responses could point to a possibility that SFN was capable of effected 
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platelet-leukocyte interactions. To take this work forward, and tie it into the leukocyte-endothelial 
interactions it would be interesting to investigate further cellular interactions using FACS to study 
whether isolated platelet-leukocyte interactions were affected following exposure to SFN. In vitro 
work investigating the ability of SFN to affect platelet binding, for example to endothelial monolayers, 
could also aid to develop a broader picture of how SFN may alter various intercellular interactions. In 
doing these further studies, light may be shed on how SFN altered the platelet-leukocyte-endothelial 
interactions presented in Chapter 4; something that is currently lacking and would help to bring 
together the work in chapter 4 and 5.  Further, along this vein of thought, it could be informative to 
conduct the LPS/SFN in vivo studies in mice lacking platelets. This would highlight both; differences in 
leukocyte response in the absence of platelets, and secondly, how SFN affects leukocytes downstream 
of LPS challenge may change in the absence of platelet – to highlight whether the platelet is a factor 
in the altered leukocyte-endothelial interactions following SFN treatment.  
 
Work in Chapter 5 would also benefit from further investigation in to the specific mode of action by 
which SFN is affected platelet activation. To this end, I think it would be of interest to perform the 
studies using a similar protocol with the addition of a washing step or use of a thiol donor chemical 
such as DTT. This would highlight whether the effects of SFN where reversible (suggesting the potential 
presence of reversible underlying covalent bonds formed between the platelet and SFN), and also, 
whether there where via interactions with thiol groups as suggested in the discussion of Chapter 5. 
This would shed further light on the effects of SFN on platelet physiological and may also provide 
further mechanistic possibilities for Nrf2 independent cellular responses. Likewise, further work with 
the ABP compounds in both platelets and neutrophils would also help to elucidate cellular targets of 
SFN helping to clarify the mechanisms underlying SFN’s alteration of platelet and leukocyte responses. 
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6.2. Concluding remarks 
To this end, the work presented in this thesis has shown the ability of SFN to alter inflammatory 
leukocyte-endothelial interactions in vivo and platelet aggregatory responses in vitro. The aim to 
establish a suitable model with which to induce and visualise cellular interactions within the brain was 
met and this allowed the effects of SFN to be studied as outlined in the second aim. The cellular and 
molecular approaches used to study the underlying cellular changes were inconclusive in providing 
the mechanism of action by which SFN altered leukocyte-endothelial interactions and platelet 
aggregatory responses. For this reason the hypothesis outlined in the introduction cannot be fully 
accepted by the work presented here. Work did show for the first time that SFN treatment was 
associated with decreased cell adhesion following LPS challenge. In line with this was an unexpected 
associated increased numbers of rolling cells. Induction of Nrf2 or amelioration of the inflammatory 
profile was not found at the time points presented here. This poses the need for further research into 
the effect that SFN may have on platelet-leukocyte interactions to tie this work together. It also leaves 
open the mechanism of actions that underlie these leukocyte and platelet effects, whereby additional 
investigation is needed to shed light onto the pathways that SFN is interacting with to cause the end 
effects presented in chapter 4 and 5. The extra studies mentioned in this summary would help to 
validate the work shown in this thesis, and conclusively address whether the effects of SFN could 
indeed represent a therapeutically useful intervention for the treatment of inflammatory pathologies 
within the brain.  
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Appendix 1 
As much as in vitro aggregometry experiments provide a fantastic opportunity to investigate the effect 
of various platelet agonists and potential anti-aggregatory agents on isolated platelets, this system 
also has its down falls. Due to the inherent nature of the isolated platelets, the system creates a 
somewhat pro-aggregatory environment devoiding the platelet of physiological interactions which in 
vivo act to counter platelet stimulatory signals. For this reason it is important to take findings 
generated with light transmission aggregometry into more complex models to investigate whether 
compounds display similarly inhibitory effects in the presence of these various external influences and 
cell types. Several in vivo thrombosis models have aided further understanding of pathways involved 
in thrombus initiation and formation, and provide a useful tool to investigate potential therapeutic 
targets. The light-dye model used herein involves venous injection of a light sensitive dye, fluorescein 
isothiocyanate (FITC), in combination with epi-illumination via a xenon light source. This subjects a 
specific 100µm2 area to photo-activation leading to subsequent platelet activation and thrombus 
formation. This thrombus formation can then be followed temporally in order to monitor 
development of vascular occlusion. Vascular occlusion occurs in both arterial and venous vessels 
depending on the vessel exposed to the xenon light source, although time of onset and occlusion has 
been shown to vary depending on the vascular bed used, underlying pathologies present and the 
vessels chosen249,283. The light dye model produces thrombus formation in the absence of endothelial 
denudation; it is postulated that endothelial ROS production underlies the thrombus formation it 
induces265. Other models include the use of lasers or ligatures to physically damage the endothelium, 
injection of other photoactive dyes such as Rose Bengal and direct application of Ferric Chloride to 
exposed areas of the vasculature surface284. 
 
Benefits of the use of the light dye model include; several vessels in one animal to be recorded due to 
the small area of the brain exposed to the light source at any one time allowing both arteriolar and 
venular thrombus formation to be visualised in one animal, minimal interference with the tissue is 
required reducing the likelihood of any tissue damage effecting the onset of platelet formation and 
the lack of complex surgery needed to expose specific vessels decreases surgical stress to the animal 
used.  
 
As a side project to support the in vitro work presented in Chapter 5, thrombus formation in the 
cerebral microvessels used to investigate the effect of SFN on in vivo platelet responses to try and 
broaden the picture of SFN’s effects on platelet cell function. Rather than solely being an initiator of 
pathology in cerebral infarction, vascular occlusion is being appreciated as event that occurs as part 
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of a multi-stage and –cellular process involving driven by underlying inflammatory processes285.  Use 
of the light dye model allowed the study of intravascular thrombus formation following endothelial 
cell injury.  
Results 
Figure A.1 shows the findings from the light/dye thrombosis model. This was used to investigate 
whether an underlying inflammatory response would affect the onset of thrombosis in the cerebral 
microvasculature. Furthermore, it allowed visualisation of any effects afforded by pre-treatment with 
SFN. The data collected showed that complete occlusion of the cerebral microvasculature did not 
appear to be significantly altered when comparing mice that had received either saline or LPS i.p. 
injections. This was the case in both the arterial and venous side of the microvasculature that was 
analysed. However, when comparing the mean onset time of blood flow cessation, mice treated with 
LPS do appear to show an accelerated venule occlusion time when compared to saline treated mice 
(34.81 ± 10.40min vs. 41.75 ± 18.75min to blood flow cessation respectively; Figure A.1b). This same 
trend was not seen in the arterioles of saline or LPS treated mice were values were much more 
comparable (37.49 ± 12.21min vs. 38.30 ± 11.06min to blood flow cessation respectively; Figure A.1a).  
 
Trends across the venules of mice treated with LPS, and receiving prior corn oil or SFN treatment were 
more difficult to deduce since corn oil alone seemed to delay the onset of blood flow cessation, albeit 
not statistically significantly, and this was not increased by SFN (34.81 ± 10.40min (LPS), 58.94 ± 
21.99min (Corn Oil/LPS) and 55.54 ± 14.78 (SFN/LPS); Figure A.1a). In saline treated animal, corn oil 
pre-treatment seemed to affect the blood flow cessation in venules to a lesser degree and therefore 
in did highlight a trend towards an increase in the time to blood flow cessation by SFN (41.75 ± 
18.95min (Sal), 44.90 ± 21.99min (Corn Oil/Sal) and 67.89 ± 10.05min to blood flow cessation 
(SFN/LPS) respectively; Figure A.1a).  
 
Similar trends were noted when looking at the arterioles of mice receiving corn oil injections in that 
there appeared to be little effect of corn oil pre-treatment when mice received a saline injection (37.49 
± 12.21min (sal) vs. 36.43 ± 9.177 to blood flow cessation respectively (corn oil/sal); Figure A.1b), 
however, in mice receiving an LPS injection corn oil did seem to show some interaction in effecting 
the flow cessation of the arterioles (38.30 ± 11.06min (sal) vs. 47.96 ± 19.37 (corn oil/sal); Figure A.1b). 
SFN pre-treatment did not markedly alter arteriole occlusion time above any effects seen by corn oil 
whether followed by saline or LPS injection. 
 
 




































































































Figure A1: Cerebral vessel occlusion caused by light/dye induced thrombosis is unaltered 
following LPS administration or pre-treatment with SFN. Male, C57Bl6 mice were treated with 
SFN or vehicle corn oil (1hr, 5mg/kg, i.p.) prior to injection with LPS or vehicle saline (2hr, 1.5 x 106 
EU/kg). Blood flow cessation time was measured A) cerebral venules and B) cerebral arterioles in 
straight and non-branching vessels with a diameter of 30-45µm. Bars represent the mean ± SD. n =3-
6 mice/group 
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Discussion 
This model involves injection of a FITC dextran, a photo-excitable dye, into the venous circulation via 
a jugular cannula. Exposure of a 100µM2 area of the cortex to epi-illumination by a Xenon light source 
then leads photo-activation of FITC dextran and subsequent localised thrombus formation. This mode 
of thrombus formation is thought to be via production of superoxide molecules following activation 
of the FITC; this occurs in the absence of endothelial denudation264. Thrombi formed appear to be 
platelet rich, fibrin poor and display a general absence of leukocytes264,286.  Use of this model was 
advantageous as it allowed data to be gained on thrombus formation in arterioles and venules within 
one animal. It also allowed similar vessels to be visualised as were used within the endotoxemia study, 
and allowed temporal development of the thrombus formation to be visualised. Furthermore, the 
light/dye model has advantages over other models, such as topical FeCl3 application, in that the former 
produces an intravascular insult leading to platelet activation, whereas, the later leads to outside-in 
damage of the vessel causing endothelial denudation and subsequent collagen exposure287. 
 
The in vivo findings presented form part of an ongoing project and require further validation. At 
present, conclusions on whether pre-treatment of animals with SFN is capable of inhibiting 
subsequent thrombotic responses are difficult to draw.  
 
In order to discuss the data as it stands, the arteriole findings across treatments groups will be 
compared, followed by effects within the venule treatment groups and then discussion about effects 
seen between these two groups. Potential factors causing these effects will then be postulated with 
relation to work previously published. 
 
Time to blood flow cessation in cerebral arterioles was not affected by the presence of LPS. This is in 
opposition to previous work showing that exposure of mice to LPS leads to a reduction in the time to 
thrombus formation in several vascular beds283. It appears that pre-treatment with both corn oil and 
SFN appear to induce increased variability in the time to vessel occlusion, particularly in mice that are 
then subsequently exposed to LPS. Reasons for this are unclear since this variability was not seen when 
the corn oil vehicle was administered in the endotoxaemia model, however, the treatment protocol 
was different and may therefore cause different effects within the vasculature or at the vessel wall. 
This variability could be via an effect of the corn oil on the platelet, the endothelium or both. Taking 
this in account, the results are slightly ambiguous. There are slight trends towards a delay in onset to 
blood flow cessation with SFN, however, the variability seen makes conclusions uncertain. Larger ‘n’ 
numbers are needed to better power the study and hopefully remove some of the variability seen in 
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order to shed more light on potential SFN induced alterations in thrombosis. Indeed several groups’ 
report ‘n’ numbers of up to 12 animals per group, suggesting these larger ‘n’ numbers are required 
for work with this model249,264. 
 
Lack of difference seen between saline and LPS treated animals may be associated with difference in 
biological activity of the LPS used. Several papers have reported alterations in findings between LPS 
lots; one paper reported having to give over three times the same dose of endotoxin in order to 
achieve similar thrombotic findings between subsequent doses of LPS264. Furthermore, different 
mouse strains have shown a difference in thrombotic responses associated with LPS, whether this can 
be extrapolated to potential differences in mouse colonies that would contribute to these effects is 
unknown264. It seems unlikely that this would be the case as these mice are routinely used for studies 
within this laboratory. Potentially, increasing the dose of endotoxin given in the experiments here 
would increase the difference in thrombosis induced vessel occlusion between saline and LPS treated 
animals to a level comparable to that reported elsewhere264,283. Likewise, increasing the lamp power 
applied during vessel epi-illumination would be likely to increase thrombosis onset and may highlight 
greater differences between thrombosis kinetics in arterioles vs. venules. 
 
Within the venules measured there also appears to be rather large variability in results seen 
supporting the need for further experimentation. However, taking the data as it stands there was a 
slight, although non-significant, reduction in blood flow cessation time following treatment with LPS 
versus saline alone. This is in agreement with previous findings which is thought to involve platelet 
derived TLR4 and not be associated with the increase in neutrophil adhesion associated with LPS 
treatment which we and others have seen within the cerebral microvasculature246,249,264,283. Again, 
corn oil pre-treatment appears to alter thrombotic response, particularly in LPS treated animals, 
suggesting that this is potentially a real effect and not an artefact of small group sizes. Why this should 
occur in LPS treated animals remains unclear, but as mentioned above, with the level of variation seen 
in this group making conclusions seems somewhat futile. However, purely taking into account saline 
treated groups in the venules that were subjected to a thrombotic challenge, there does appear to be 
more of a discernible trend. Responses in both saline and corn oil pre-treatment followed by saline 
treatment are comparable, and furthermore mice receiving SFN pre-treatment followed by saline 
appear to show markedly delayed thrombus formation. This suggests that there is a possibility that 
SFN could modulate platelet position in vivo, and this is an effect that others have shown in several in 
vivo models. SFN pre-treatment was been found to decrease mortality associated with two different 
pulmonary thrombosis and also delay blood flow cessation in a light-dye thrombosis model with the 
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mesentery202,203. Further support taken from ex vivo work conducted under flow conditions has also 
highlighted the ability of SFN to decrease thrombus formation36. 
 
Lack of difference between time to blood flow cessation in arterioles and venules is also in opposition 
to previous data, as well as the rather marked time to the thrombus vessel occlusion. Here, the lamp 
power that was used is considerably less than that previously published (1.4-8W/cm2 vs. 1x10-3W/cm2) 
which would be the likely explanation for the slow thrombus formation seen here287. Indeed, 
thrombus formation using the light dye model has been shown to be a function of the light power and 
dye concentration and must therefore by closely monitored246. Therefore, it is highly probably that 
the lower light power used here explains this finding. Whether this decreased lamp power explains 
the lack of difference between arterial and venule thrombotic vessel occlusion is not certain. It may 
be that due to the lower power used, the increased time to thrombus formation causes the forming 
aggregates to be less stable due to the lower stimulus and therefore, more susceptible to being 
sloughed away. In fact, whilst recording the vessel occlusion it was often seen that occlusion occurred 
following accumulation of platelets downstream of the site of the light source which ultimately 
‘backed up’ to clog the vessel. This may obscure the differences seen in arterioles vs. venules reported 
elsewhere. Furthermore, this slow onset time may be somewhat perpetuated by the need for 
prolonged use of anaesthesia, as anaesthesia has previously been shown to effect thrombosis 
formation286. 
Summary 
Validation of this cerebral thrombosis model will allow clarification of the effects of SFN on in vivo 
platelet activation. This model is a useful tool to study the effects of SFN in the whole organism with 
the multiple cell interactions that occur during platelet activation and thrombosis response. Increasing 
the power used with the lamp should help to be vessel occlusion times in line with those previously 
published and may aid differences between the arteriolar and venular sides of the cerebral circulation 











The power calculations below where performed for the studies conducted in Chapter 4. They highlight 
the variability in the group sizes needed for the in vivo work conducted. Significance of graphs was 
only reported when the necessary number of animals was used as per the conducted power 
calculations. Power calculations for experimental data, especially in vivo work, are necessary to ensure 
that appropriate group sizes are used experimentally to warrant statistical significance is adequately 
reached. As can be seen below, the different parameters measured during the IVM experiments 
should different levels of variability. This is in part an inherent problem with IVM, as lower numbers 
of rolling cells seen consequently give a smaller sample size with which to calculate a mean rolling 
velocity. For this reason, when interpreting the IVM data gained from the rolling cell velocity it is 
important to bear in mind the number of rolling cells present within the same treatment groups.  
 
All power calculations were calculated using the formula: 
Standardised difference (d) = Target difference/Standard deviation 
2/d2 x cp, power 




Sal vs LPS 
2/(136.7/143.5)2 x 7.9 = 17.4 
 
LPS vs Corn Oil/LPS 




Sal vs LPS 
2/(4.4/5.6)2 x 7.9 = 25.3 
 
LPS vs Corn Oil/LPS 
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Sal vs LPS 
2/(721.9/312.4)2 x 7.9 = 3.1 
 
LPS vs Corn Oil/LPS 





Corn Oil/LPS vs SFN(50)/LPS 
2/(149.7/71.2)2 x 7.9 = 0.003 
 
SFN(50)/Sal vs SFN(50)/LPS 
2/(259.4/71.2)2 x 7.9 = 1.2 
 
B) 
Corn Oil/LPS vs SFN(50)/LPS 
2/(11.7/3.1)2 x 7.9 = 1.1 
 
SFN(50)/Sal vs SFN(50)/LPS 
2/(9.5/3.1)2 x 7.9 = 1.7 
 
C) 
Corn Oil/LPS vs SFN(50)/LPS 
2/(376.5/155.3)2 x 7.9 = 2.7 
 
SFN(50)/Sal vs SFN(50)/LPS 
2/(697.2/155.3)2 x 7.9 = 0.8 
 
Table 4.1 




Sal vs LPS 
36.7-9.9/15.7 = 1.7 
1.7/15.7 = 0.1 
2/(0.1 )2 x 7.9 = 1336.6 
 
LPS vs Corn Oil LPS 
33.7-32.7/17.7  
1/17.7 = 0.06 
2/(0.06 )2 x 7.9 = 4950 
 
Corn/Sal vs SFN/Sal 
42.7-33.7=9 
9/21.2= 0.425 
2/(0.425) 2x7.9 = 87.7  
 
SFN/Sal vs SFN/LPS 
42.7-35.7 = 7 
7/27.7 = 0.253 
2/(0.2532) = 247.412  
 
Lymphocytes 
Sal vs LPS 
133.6-65.5 = 68.1 
68.1/29.5 = 2.308 
2/(2.3)2 x 7.9 = 3 
 
LPS vs Corn Oil LPS 
241.7-61.7 = 179.4  
179.4/9.3 = 19.3 
2/(19.3 )2 x 7.9 = 0.042 
 
Corn/Sal vs SFN/Sal 
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438.3-241.7 = 196.6 
196.6/142.9= 1.4 
2/(1.4) 2x7.9 = 8.347  
 
SFN/Sal vs SFN/LPS 
438.3-67.5 = 370.8 
370.8/142.9= 2.6 
2/(2.6)2x7.9 = 2.3  
 
Monocytes 
Sal vs LPS 
7.5-5.7/6.1  
1.8/6.1 = 0.295 
2/(0.295 )2 x 7.9 = 181.557 
 
LPS vs Corn Oil LPS 
7.5-3.3/4.1  
4.2/4.1 = 1.024 
2/(1.024 )2 x 7.9 = 15.068 
 
Corn oil/LPS vs SFN/LPS 
3.3-2.5 = 0.8 
0.8/4.2 = 0.19 
2/(0.192) = 437 
 
Corn Sal vs SFN/Sal 
8.3-3.3 = 5 
5/4.1 = 1.220 
2/(1.2202) = 10.624 
 
Platelets 
Sal vs LPS 
107900-93133 = 14767 
14767/5446 = 2.712 
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2/(2.2712)2 x 7.9 = 2.149 
 
LPS vs Corn Oil LPS 
93133-89750 = 3383 
3383/20349 =  
2/(0.166)2 x 7.9 = 571.662 
 
Corn oil/LPS vs SFN/LPS 
98517-89750 = 8767 
8767/30085 = 0.291 
2/(0.2912) x 7.9 = 186.061  
 
Corn Sal vs SFN/Sal 
232233-100500 = 131733 
131733/303128= 0.435 
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